Here’s what you get:

1. Research Reports for more than 1000 companies!

2. Sector Intelligence Briefs

3. Detailed Valuation Models for companies

4. Industry Dashboards: Live RS ratings, dominant market stages, and sentiment across every industry.

5. Growth triggers, management consistency checks, walk the talk, thesis maps

6. and much more. Check out the landing page for an interactive demo.

Investorstack

Now onto today’s piece.

Azad Engineering is a Hyderabad based manufacturer of precision forged and machined components that go inside some of the most demanding machines on earth: gas turbines, aircraft engines, nuclear turbines, and oil and gas drilling rigs. What this means in plain terms is that Azad makes the individual rotating and stationary blades, airfoils, nozzle vanes, and critical sub components that sit inside these machines, spinning at extreme speeds, under extreme temperatures, where any dimensional error or material flaw would be catastrophic. These are not standard off-the-shelf parts. They are one-of-a-kind, customer-specific, made to tolerances measured in micrometers.

What Azad Engineering Does

The company was started in 2008 by Rakesh Chopdar, a high school dropout who had spent 12 years working in his father’s small nuts and bolts factory in Hyderabad. He began with a single second hand CNC machine in a rented shed, and his first significant customer was a government owned power equipment manufacturer that needed turbine airfoils. From there, he progressively moved into harder, more technically demanding parts - first for energy turbines, then for aerospace, then for defense. The company has been incorporated since 1983 (as Azad Engineering Private Limited) but the current precision engineering business was effectively built from 2008 onwards when Chopdar set up the CNC machining operation.

Azad operates at a point in the global supply chain where the product is too technically complex for low-cost manufacturers to produce and too cost sensitive for OEMs to make in house. Turbine blades are manufactured through a multi step process that involves precision forging of difficult alloys like nickel superalloys and titanium, followed by complex 5-axis CNC machining, heat treatment, and specialized coatings - all to sub-millimeter tolerances. The customer then runs these parts through a qualification process lasting anywhere from 18 to 48 months before they are approved for production. Once qualified, Azad becomes the single source or dual-source supplier for that part for the duration of a long-term contract, typically 5 to 8 years.

The sticky point is not just technical skill - it is the qualification itself. A turbine blade used in a GE Vernova gas turbine that powers a data center cannot be switched to a different supplier without re-running the entire qualification, re-certifying every process, and spending 2-4 years doing it again. This means that once Azad wins a part qualification, it essentially owns that part number for the life of the contract. With over 1,700 qualified parts and 45+ manufacturing processes, the cumulative barrier Azad has built is the reason why it calls itself the only Indian company qualified to make these products to global OEM standards.

Exports account for approximately 92% of revenue (Q1 FY26). Customers span the USA, Europe, Japan, and the Middle East. Azad describes its relationship as “trusted Tier 1 supplier” to global OEMs - meaning it supplies directly to the OEM, not through a Tier 2 intermediary.

Business Segments

Energy

Energy is Azad’s largest and most established segment, contributing approximately 81% of quarterly revenue as of Q2 FY26. The energy segment covers gas turbines, steam turbines, thermal turbines, and nuclear turbines. Within this segment, Azad manufactures the hot section rotating and stationary airfoils - specifically the blades, vanes, and nozzle segments that direct and accelerate high temperature combustion gases through the turbine stages.

The core capability is the ability to machine nickel based superalloys to aerospace-grade tolerances under conditions that simulate the thermal and mechanical stress the part will experience in operation. A gas turbine blade operates at temperatures that can exceed the melting point of the base metal - which is only possible because of sophisticated cooling channel designs drilled inside the blade and thermal barrier coatings applied to the surface. Azad makes the blade itself; the precision of the cooling holes and the geometry of the airfoil profile are what make or break turbine efficiency.

Azad’s energy customers read like a who’s who of global turbine manufacturing: Mitsubishi Heavy Industries (MHI), Siemens Energy, GE Vernova, Baker Hughes (through subsidiary Nuovo Pignone), Arabelle Solutions, and BHEL. The company has dedicated lean manufacturing facilities for both MHI (inaugurated March 2025, 7,200 sq m at Tunikibollaram, Hyderabad) and GE Vernova (inaugurated April 2025, 7,600 sq m). These customer dedicated plants are a notable feature - rather than running a general-purpose job shop, Azad builds a manufacturing cell specifically optimized for a single customer’s parts, with workflow, tooling, and processes designed around that customer’s specifications.

Azad signed Phase 1 of a long-term contract and price agreement (LTCPA) with MHI in November 2024 for supply of rotating and stationary airfoils for gas and thermal power turbines. Phase 2 followed in September 2025. The combined contract value across both phases is USD 156.36 million (approximately Rs 1,387 crore). In addition to this, Azad signed an 8-year LTCPA with MHI in March 2026 as a single source supplier for hot-section nozzle vane segments. MHI also awarded Azad the “2024 Partner of the Year” award, selected from over 1,000 global partners.

With GE Vernova, Azad signed a 6-year supply agreement in January 2025 for USD 112 million (Rs 960 crore) for gas turbine airfoils, and a separate 6-year agreement in May 2025 with GE Vernova’s steam power services for USD 53.5 million (Rs 458 crore) covering nuclear and thermal power airfoils.

The market dynamics for energy are driven by two forces: the global gas turbine backlog, and nuclear’s revival. GE Vernova alone has 55 GW of turbines under construction globally as of the 2025 annual report. Gas turbines are the swing capacity in grids transitioning to renewables - they can ramp up and down fast, which intermittent solar and wind cannot do. Global electricity demand is projected at 3.3% growth in 2025 and 3.7% in 2026, and gas turbines remain indispensable for dispatchable power. This creates a sustained demand pull for Azad’s turbine components.

On nuclear, India targets 22,000 MW of nuclear capacity by 2050. Globally, nuclear generation is set to grow by nearly 2% annually in 2025-26. Azad has qualified for nuclear turbine airfoils and was recently certified to supply nuclear turbine components to EDF France.

Aerospace and Defense

Aerospace and defense is the faster growing, higher margin segment, contributing approximately 19% of revenue as of Q2 FY26, but growing at 30.3% YOY in H1 FY26 versus 35.7% for energy - the aerospace ramp is progressing and management describes it as “the next wave.”

In aerospace, Azad makes rotating airfoils for aircraft engines (3D blades and vanes used in jet engines), as well as hydraulic system components, actuators, and fluid distribution parts for aircraft. The company’s aerospace portfolio supports platforms including the Boeing 737 and 747 families, Airbus A320, A350, Boeing 777, and Gulfstream G550. These are not low complexity stampings - they are the blades inside CFM56 and similar engines, and the structural hydraulic components that move the flight control surfaces.

The defense side includes components for military aircraft, missiles, and defense platforms. Azad manufactures components for Russian origin platforms (the Sukhoi Su-30MKI fighter used by the Indian Air Force has some Azad components) as well as for BrahMos (the supersonic cruise missile). The company has also secured a contract from India’s Ministry of Defence to serve as a production agency for the Gas Turbine Research Establishment’s (GTRE) Advanced Gas Turbine Engine (AGTE) - a long term contract to manufacture and assemble complete turbine engines for the Kaveri program, marine gas turbines, and army gas turbines.

The OEM relationships in aerospace are the deepest moat Azad has in this segment. Rolls Royce signed a 7 year agreement with Azad in January 2024 for components for defense aircraft engines - this was the first time an Indian company was approved by Rolls-Royce for complex engine components, and it opened the entire Rolls-Royce supply chain for Azad. Safran Aircraft Engines signed an MOU with Azad in Q2 FY26 for critical rotating engine components for defense platforms - the first step in what Azad describes as the same progression it went through with Rolls-Royce: MOU, technical assessment, qualification, contract. Pratt & Whitney Canada signed a long-term Master Terms and Purchase Agreement with Azad in November 2025 for aircraft engine components. Honeywell Aerospace and GE Aerospace are also in the customer list.

Azad VTC Private Limited, the subsidiary, received NADCAP accreditation for coatings in Q2 FY26 - this is a critical aerospace quality certification that validates Azad’s thermal barrier and other coating capabilities to international standards.

Oil and Gas

Oil and gas is the smallest segment but has stable, recurring demand. Azad manufactures components for drilling rigs - drill bits, slips used in wellhead and downhole equipment, reamers, and other precision parts used in exploration and production. Customers include Baker Hughes, and Azad has signed a 5-year strategic supply contract amendment with Nuovo Pignone (a Baker Hughes subsidiary) in May 2025, extending an existing agreement.

The oil and gas segment benefits from the same precision machining infrastructure as energy and aerospace. The parts are less technically demanding than hot section turbine airfoils, but require tight tolerances and materials that withstand downhole pressures and corrosive environments.

Azad also has a presence in the standalone power supply (SPS) segment, which covers small, portable power generation units used in military and remote applications - these require compact gas turbines, and Azad supplies components to these OEMs as well.

Products and Business Detail

Azad’s product catalogue is organized around three types of parts across four end markets:

Rotating airfoils - these are the 3D blades in both compressor and turbine stages of gas, steam, and aircraft engines. Compressor blades are made from titanium and high-strength steel alloys; turbine blades are made from nickel superalloys with complex internal cooling geometries. The turbine blades are the highest value, most demanding products Azad makes. A single gas turbine can have hundreds of blades across multiple stages, each made to different specifications.

Stationary airfoils (nozzles and vanes) - these are the fixed components that direct gas flow onto the rotating blades. They operate at even higher temperatures than rotating blades because the combustion gases hit them first. The hot section nozzle vane segments in Azad’s March 2026 MHI contract are among the most technically demanding components they make.

Hydraulic and fluid distribution components - for aerospace, these are the manifolds, fittings, and structural parts that carry hydraulic fluid through the aircraft’s flight control and actuation systems. Azad makes these from forgings (aluminum, titanium, stainless steel) to tight dimensional tolerances with internally machined passages.

Drill bits and downhole tools - For oil and gas, polycrystalline diamond compact (PDC) drill bits and other cutting tools used in oil and gas exploration drilling.

Manufacturing process: A typical blade starts as a raw investment casting or forging blank sourced from specialized suppliers (this is where the qualification pain begins - Azad must pre-qualify these input suppliers with the OEM, which adds to qualification lead time and working capital). The blank is then fixtured on a 5-axis CNC machining center and machined to final dimensional specifications. This involves removing material from complex curved 3D surfaces while holding tolerances of +/- 0.02mm or tighter. After machining, the part goes through heat treatment, non-destructive testing (fluorescent penetrant inspection, X-ray, ultrasound depending on the part), and final dimensional inspection. Some parts receive thermal barrier coatings applied by plasma spray or air plasma spray processes in Azad’s coatings subsidiary.

Facilities: Azad currently operates four manufacturing blocks at its legacy facility in Jeedimetla, Hyderabad, covering approximately 20,000-25,000 sq m. Since the IPO, it has commenced a 10x capacity expansion at Tunikibollaram, Hyderabad. Phase 1 covers 94,899 sq m and Phase 2 covers 67,267 sq m - together this new campus is approximately 7-9x the existing footprint. Within the new campus, Azad is building customer-dedicated lean manufacturing cells: the MHI lean factory (7,200 sq m, inaugurated March 2025), the GE Vernova lean factory (7,600 sq m, inaugurated April 2025), with plans for 8 such dedicated facilities total including a state-of-the-art forging plant.

Azad also acquired the assets of VTC Surface Technologies in May 2024 - a company specializing in advanced wear, corrosion, and heat resistant coatings. This brings critical coating capability in-house. The subsidiary (Azad VTC Private Limited) has since achieved NADCAP accreditation for aerospace coatings.

Certifications held: ISO 9001:2015, AS 9100:2016 (aerospace quality management), NADCAP (special processes, coatings), and various OEM-specific approvals from GE, Siemens, MHI, Rolls-Royce, and others. Each OEM has its own supplier qualification process that runs separately from the standard certifications.

Geographies: over 92% export revenue. Customer countries include the USA, Japan, Germany, France, and the UK. Azad also has an MOU to establish a manufacturing presence in Saudi Arabia, explored through its relationship with Baker Hughes - the Saudi energy market (Saudi Aramco and others) presents a potential geographic expansion opportunity.

Customers

The buying relationship at Azad is unusual because the customer is not just buying a part - they are qualifying a supplier. When GE Vernova decides to source turbine blades from Azad, it is making a multi-year commitment. The process starts with a technical assessment of Azad’s manufacturing capabilities, quality systems, and process control. It then moves to a First Article Inspection (FAI) where Azad produces sample parts that are measured and tested against every requirement. Only after FAI approval does the OEM place a production order. The entire process can take 18 to 48 months. For aerospace, add another layer: the FAA or EASA (European Aviation Safety Agency) may also need to approve the part design change before Azad’s production parts can fly.

Once this qualification is complete, switching to a different supplier requires starting the entire process again. This is why Azad’s attrition in the customer base is effectively zero - no OEM voluntarily goes through a 2-4 year requalification to switch suppliers, especially for life-critical parts. Rakesh Chopdar described it in the Q2 FY25 concall: “We are the only one in the country for certain product line. There is no one else.”

The customer base is concentrated but the concentration is by design. Azad targets the top 5-6 global OEMs in each end market and aims to grow wallet share within those relationships. As of Q2 FY26, management noted that their wallet share across customers in energy, aerospace, defense, and oil and gas is approximately 1-1.5% - which means there is substantial room to grow revenue within existing customers without winning a single new OEM relationship. Every time Azad qualifies a new part within a customer relationship, it adds to the locked-in revenue base.

Key customers as disclosed or confirmed: Mitsubishi Heavy Industries (largest disclosed relationship - combined contracts worth USD 156 million+), GE Vernova (gas turbine and steam power divisions - combined contracts USD 165 million+), Siemens Energy, Rolls-Royce (7-year defense engine deal), Safran Aircraft Engines (MOU stage), Pratt & Whitney Canada, Baker Hughes/Nuovo Pignone, Honeywell Aerospace, Arabelle Solutions (a subsidiary of GE), BHEL, and GTRE/DRDO for the Indian defense segment.

Average customer relationship is over 10 years for key accounts. The MHI relationship began in 2012. The GE relationship has been in place since the early days. This longevity matters because the OEM’s engineering team has already embedded Azad’s part drawings into their product lifecycle documentation - any change requires a formal engineering change order.

Azad primarily operates on long-term contract and price agreements (LTCPAs), typically 5-8 years in duration with fixed pricing (often with annual escalation clauses for raw material and labor indices). This provides revenue visibility but also means Azad bears the raw material price risk in the intervening period if contracts don’t have adequate pass through provisions.

Competitive Landscape

The global market for high-precision turbine airfoils and aerospace components is not a crowded one. Azad competes in two different competitive arenas.

Global competition: In the energy turbine components segment, Azad’s global competitors are primarily in China (Baoji Titanium Industry, Deyang Heavy Industry), Eastern Europe (Czech, Slovak, and Polish precision component companies), and Southeast Asia (Singapore and Thailand-based shops). The company’s annual report explicitly notes “growing competition from China and Eastern Europe.” Chinese competitors in particular can offer lower prices for simpler components. However, for hot-section components - the rotating airfoils in the highest-temperature stages of a gas turbine - Chinese suppliers have struggled to achieve OEM qualifications from GE, Siemens, and MHI because the process knowledge and metallurgical expertise required are extremely hard to replicate quickly. Azad’s 15+ years of building this knowledge base is the core competitive advantage.

In aerospace, global competitors include Tier 2 precision component suppliers from the USA (Honeywell Aerospace has in-house manufacturing, GE has some self-manufacture, but the Tier 2 supply chain includes companies like Heico, Transdigm subsidiaries, and Europe-based specialists), UK (Rolls-Royce’s own supply chain), France (Safran’s supply chain), and increasingly India.

Indian competition: Within India, the closest comparables in the precision components space are MTAR Technologies (makes critical components for nuclear, space, defense, and clean energy - FY26 Q3 revenue of Rs 278 crore), Paras Defense (primarily defense-focused, order book of Rs 1,100 crore), PTC Industries (aerospace castings), and Dynamatic Technologies (hydraulics and aerospace). The key differentiator is Azad’s margin profile - it has the highest operating margins among Indian peers because it targets the most technically demanding, highest-value products. Where MTAR and Paras make components for the Indian defense ecosystem (ISRO, DRDO, HAL), Azad makes components that go directly into commercial global OEM products - which means its revenue is dollar-denominated, pricing is set by global market dynamics, and the customer base is far more commercially rigorous.

Unimech Aerospace is another Indian peer in precision tooling for aerospace, but operates in a different niche (tooling vs. actual flight components).

Barriers to entry: the qualification process is the single most powerful barrier. Building the physical manufacturing capability (CNC machines, forge shop, heat treatment, inspection labs) requires Rs 500 crore+ in capital. Beyond the physical capability, earning the first OEM qualification takes 2-4 years. And the first qualification only unlocks one part number - building a 1,700-part portfolio takes decades. An entrant starting today would not be a credible alternative to Azad for existing OEM contracts for at least 7-10 years.

There is also a process knowledge barrier that money cannot easily replicate. Knowing how to machine a nickel superalloy at high metal removal rates without introducing residual stresses that cause fatigue cracking in operation - this is learned through years of trial, failure, and refinement on real production programs. Azad has built this tacit knowledge base over 15 years.

Why Azad wins: (1) It is already qualified - the entry barrier is behind it, not ahead of it; (2) it operates from India, giving it a structural cost advantage of 20-30% versus western competitors who make similar components; (3) its quality record (4+ million zero-defect components delivered since inception) gives OEMs confidence that the cost advantage doesn’t come with quality risk; (4) single-source positioning on most part numbers means price competition is limited once a relationship is established; (5) the “China+1” supply chain shift is structurally benefiting India as a manufacturing destination, and Azad is positioned directly in the path of that shift.

Where Azad could lose: (1) If Chinese suppliers accelerate OEM qualifications in western markets, particularly in the energy segment; (2) if Azad misexecutes on its 10x capacity expansion - delivering late or with quality issues during ramp-up could damage relationships; (3) if key customer relationships are concentrated and one large OEM reduces its sourcing from Azad.

Industry

Gas turbines: the global gas turbine market is driven by the insatiable demand for dispatchable power. Despite the growth of solar and wind, electricity grids need backup capacity that can switch on in minutes when the sun stops shining or the wind drops. Gas turbines fulfill this role. GE Vernova alone has 55 GW of turbines under construction globally - a backlog that will take several years to deliver, and each of those turbines needs thousands of precisely manufactured blades and vanes. The global steam turbine market was valued at USD 17-19 billion in 2024 and is expected to grow at approximately 2.4-2.5% CAGR through 2030.

Beyond new builds, the installed base of gas turbines requires regular maintenance and component replacement. Turbine blades have finite lifespans and must be replaced at maintenance intervals (typically every 25,000-50,000 operating hours). This creates a large, recurring aftermarket demand on top of the new build market. Azad participates in both new build and aftermarket supply.

Nuclear: global nuclear generation is growing at nearly 2% annually in 2025-26, supported by reactor restarts in Japan, new builds in China and India, and the revival of nuclear as a policy tool for decarbonization in Europe and the USA. India has committed to 22,000 MW of nuclear capacity by 2050 - which requires a vast supply of turbine components for the steam turbines that convert reactor heat into electricity. Azad’s qualification for nuclear turbine airfoils, including its certification by EDF France, positions it in a segment that has very few approved suppliers globally.

Aerospace: Commercial aviation is recovering from the COVID collapse. Airbus and Boeing have backlogs of thousands of aircraft, and both are trying to accelerate delivery rates. The CFM International LEAP engine (which powers the A320neo and 737 MAX) and Pratt & Whitney’s geared turbofan are the dominant new-generation engines, and the supply chains for these engines need to scale up. Azad’s qualifications on Rolls-Royce, Pratt & Whitney, and Safran programs position it directly in the path of this ramp-up.

Defense aerospace globally is in an expansion phase driven by the Russia-Ukraine conflict reshaping European defense spending, increasing India’s defense budget, and NATO partners re-arming. This creates demand for military aircraft engines, missiles, and naval gas turbines.

Oil and gas: oil and gas exploration CAPEX remains elevated as energy security concerns drive investment in domestic production. Baker Hughes, Schlumberger, and Halliburton continue to manufacture drilling equipment that requires precision components. This is a stable, lower-growth segment for Azad.

India’s aerospace ecosystem: the Indian government’s Make in India and Aatmanirbhar Bharat policies are creating a policy tailwind for domestic aerospace manufacturers. The Ministry of Defence has issued “positive indigenization lists” requiring domestic procurement for specified defense systems. The GTRE contract to manufacture the Kaveri-derived AGTE engine is a direct result of this policy. The India-USA defense technology cooperation framework and India’s engagement with France (on Rafale follow-ons and Sukhoi upgrades) are also creating opportunities for Indian precision component makers in global defense supply chains.

Growth Triggers

• MHI Phase 1 and Phase 2 contracts ramp-up: The combined USD 156 million MHI contract is in the early stages of production. The dedicated 7,200 sq m facility inaugurated in March 2025 is currently employing 200 workers and is expected to scale. Management on the Q2 FY26 call: “With the combined contract value with MHI now stands at INR 1,387 crores, a strong testament to our technical excellence.”

• GE Vernova ramp-up across two contracts: the USD 112 million gas turbine contract and the USD 53.5 million steam/nuclear power services contract run for 6 years each, with revenue building as production capacity ramps in the dedicated GE Vernova factory inaugurated April 2025. “The facility was inaugurated in the presence of Siemens Energy”s senior global leadership team” (BSE filing, Sep 2025, describing the Siemens lean factory).

• 10x capacity expansion commissioning: “In the next 12 to 18 months, we plan to have a total 8 dedicated lean manufacturing facilities, including 1 state of art, world-class forging plant at Tunikibollaram, Hyderabad.” The new facility will be approximately 5-6 lakh square feet, versus the current ~25,000 sq m. As this capacity comes online, Azad can fulfill orders it currently has capacity constraints on.

• Wallet share expansion within existing OEMs: Rakesh Chopdar: “Our wallet share as it... which is what products Azad is related to is around 30 billion plus. This is just a start.” Azad currently captures approximately 1-1.5% of its addressable wallet share across customers. As new qualifications complete and capacity comes online, this percentage grows.

• Pratt & Whitney Canada long-term agreement: the long-term Master Terms and Purchase Agreement signed in November 2025 opens the Pratt & Whitney Canada supply chain - a significant new relationship in aircraft engines. “The partnership sets the stage for a deeper strategic collaboration, giving Azad a stronger foothold in the global aerospace supply chain.”

• Safran MOU - aerospace qualification pipeline: the Safran MOU signed in Q2 FY26 for critical rotating engine components for defense platforms. Murali Krishna (Managing Director) on the call: “This agreement sets the framework for cooperation in developing critical rotating engine components for strategic defence platforms. This is an important step forward in strengthening India’s aerospace ecosystem.” Per the pattern with Rolls-Royce (MOU, then technical assessment, then 7-year contract), the Safran MOU could convert to a long-term supply agreement within 2-4 years.

• DRDO AGTE engine production: Azad secured a contract from India’s Ministry of Defence to be the production agency for the Advanced Gas Turbine Engine designed by GTRE. This is a qualitatively different kind of contract - it is not a component supply agreement but a production agency contract for complete engines. First deliveries were targeted for early 2026.

• Saudi Arabia facility: “We are now planning to set up a shop in Saudi Arabia... When we met the Ministry of Energy, we met their clients, they took us to their clients, which is Saudi Aramco and many more companies.” A manufacturing presence in Saudi Arabia, enabled through the Baker Hughes relationship, would open the Middle East market for Azad and reduce logistics costs for a large energy market.

• MHI 8-year single-source nozzle vane contract: Azad signed an 8-year LTCPA with MHI as the single-source supplier for hot-section nozzle vane segments - one of the most technically demanding components in a gas turbine. This adds a new, long-duration revenue stream on top of the existing MHI airfoil contracts.

• Coatings capability and NADCAP accreditation: Vishnu Malpani (Whole-time Director): “Azad VTC Private Limited, our subsidiary has achieved NADCAP accreditation for coatings.” This unlocks the ability to apply aerospace-grade coatings in-house for aerospace customers, a critical step toward capturing more of the value chain on each part.

Key Risks

• Capacity ramp-up execution risk: the 10x expansion is Azad’s defining bet. Building 5-6 lakh sq ft of manufacturing space, equipping it with specialized CNC machinery that takes 6-18 months to deliver from German and Japanese machine tool manufacturers, hiring and training specialized machinists, and running OEM qualification audits on the new facility - all simultaneously - is operationally complex. Management acknowledged in the Q1 FY26 concall (August 2025): “It has been challenging to match the growing demand with our facility to ramp up. We anticipate to similarly address these challenges to continue for a couple of upcoming quarters.” A delay in commissioning translates directly to revenue deferral.

• Working capital intensity: Azad requires high inventory to support the qualification process. Before a part is approved, Azad must run a full qualification batch - which requires purchasing the minimum order quantity of raw castings or forgings from the OEM-approved sub-supplier (e.g., 500 castings to qualify 5 pieces). This inventory sits until qualifications are complete. Rakesh Chopdar in the Q2 FY25 concall: “As the qualification is done, then that is done... The taper off is coming... That is just coming out of this phase.” The business had 179 days of debtors as of recent data, and the working capital cycle was a consistent point of analyst focus. As the company scales, the absolute working capital required grows. The QIP proceeds (Rs 700 crore raised in Feb/March 2025) provide a buffer, but sustained growth will require continued working capital funding.

• Raw material price risk: Azad uses nickel superalloys, titanium, and specialized steel alloys whose prices are globally determined and volatile. The company operates on long-term fixed-price contracts with OEMs (with some escalation clauses), meaning sharp moves in nickel or titanium prices compress margins unless fully hedged or passed through. This is exactly what happened in Q3 FY26: management noted on the Q3 FY26 concall that margins were impacted because the company was buying raw materials at spot rates (no long-term contracts in place) as it transitioned to self-sourcing through newly commissioned backward integration assets.

• Customer concentration: while the OEM relationships are deep and sticky, the revenue base is likely concentrated among 2-3 major customers. Any slowdown in CAPEX at MHI or GE Vernova, any shift in their sourcing strategy, or any quality issue that triggers a supplier review, would have an outsized impact on Azad’s revenue.

• Qualification failure or delay risk: Azad’s growth depends on completing new part qualifications that unlock production contracts. The qualification process is not within Azad’s full control - the OEM’s engineering and quality team must sign off. Delays in OEM qualification timelines (OEMs reducing their own engineering bandwidth, changing product designs mid-qualification) can push revenue out by quarters.

• Currency risk: with over 90% of revenue in foreign currency (USD, EUR, JPY) and cost base in Indian Rupees, the company benefits from Rupee depreciation and is hurt by Rupee appreciation. Management mentioned FX as a margin variable in multiple concalls.

• Single-promoter risk: Rakesh Chopdar is the founder, chairman, and CEO simultaneously. The business’s deep OEM relationships, technical knowledge navigation, and strategic decisions are concentrated in one individual. Succession and key-person risk is a legitimate concern for a company with this degree of founder-dependence.

Scenarios & Valuations

Bull Case

The new manufacturing campus at Tunikibollaram commissions fully by end of FY27 and reaches peak utilization by FY28 as guided. The eight dedicated lean factories become fully operational, each running at high utilization for a specific OEM customer. The Safran MOU converts to a long-term supply agreement within 2-3 years, adding a major French aerospace engine maker to the customer base - this is particularly significant because Safran’s CFM International joint venture (with GE) makes the LEAP engine that powers every Airbus A320neo, the best-selling commercial aircraft in history. The Pratt & Whitney Canada relationship deepens from the initial master agreement into substantial production volumes. The DRDO AGTE engine production begins generating meaningful revenue as Indian defense modernization accelerates. The Saudi Arabia facility opens, reducing logistics friction for Middle Eastern customers and adding a new manufacturing hub.

In this scenario, the combination of existing OEM relationships growing wallet share, new OEM relationships converting from MOU to contract, and the 10x manufacturing capacity coming online creates a flywheel: more capacity enables more qualifications, more qualifications create more locked-in revenue, more locked-in revenue enables more investment. The “China+1” supply chain shift and India’s defense indigenization policy continue to provide favorable winds. The company grows at 30%+ annually for several years and the EBITDA margin expands beyond 35% as operating leverage kicks in on the expanded facility base.

Base Case

The capacity expansion executes broadly on track but faces the normal delays and teething issues of building a complex precision manufacturing facility from scratch. The MHI and GE Vernova facilities ramp up through FY26-27, reaching steady-state by FY28 as management has guided. The Safran relationship progresses through technical assessment but the first production contract is 3-4 years away. Pratt & Whitney Canada generates modest initial volumes as the qualification process completes. The DRDO engine program delivers its first batch on schedule but remains small as a revenue contributor. The Saudi Arabia facility discussions continue but a physical facility is still 2-3 years away.

Revenue growth sustains at 25-30% annually as guided, driven by the existing OEM relationships growing and the new capacity absorbing the backlog. EBITDA margins stay in the 33-35% guided range with some quarterly volatility as new facilities carry startup costs before reaching utilization. Working capital remains elevated during the expansion phase. The order book of Rs 6,500+ crore provides multi-year visibility.

Bear Case

The capacity expansion faces significant delays - machine delivery timelines extend, OEM qualification audits of the new facility identify gaps that require remediation, and key technical staff are difficult to hire in the volumes needed. The new facilities take until FY29-30 to reach meaningful utilization. In the interim, Azad is carrying the CAPEX cost and depreciation of a large, underutilized facility against a revenue base that is growing slowly.

Simultaneously, the raw material cost issue experienced in Q3 FY26 persists - backward integration into self-sourcing is harder than expected, and the company continues buying at spot rates longer than anticipated, compressing margins. One or two large OEM customers slow their own production programs (e.g., GE Vernova faces order cancellations if gas turbine demand softens due to faster-than-expected grid-scale battery storage adoption), reducing the pull on Azad’s capacity. Chinese precision component makers accelerate their OEM qualifications in the energy segment, particularly for less technically demanding turbine stages, putting pressure on Azad’s pricing.

In this scenario, revenue growth slows to 15-20% and margins compress to 28-30% as the fixed cost base from the new facilities creates operating deleverage. The working capital situation worsens as inventory for new qualifications builds while offtake is slower than expected. The 179-day debtor days stretches further, creating cash flow pressure. The company remains fundamentally sound - its existing contracts and qualifications ensure baseline revenue - but the growth story takes several years longer than priced in.

Thanks for reading! Do check out Investorstack.

Here’s what you get:

1. Research Reports for more than 1000 companies!

2. Sector Intelligence Briefs

3. Industry Dashboards: Live RS ratings, dominant market stages, and sentiment across every industry.

4. Growth triggers, management consistency checks, walk the talk, thesis maps

5. and much more. Check out the landing page for an interactive demo.

Investorstack

Inox india is a vadodara based manufacturer of cryogenic equipment - tanks, systems, and turnkey installations that keep gases in their liquid form at temperatures ranging from -73°C all the way down to -271°C. If you have ever wondered how a steel plant gets its liquid oxygen, or how a hospital in rural india stores liquid nitrogen, or how an ISRO rocket fuels up with liquid hydrogen - the answer, in india and increasingly across the world, often involves a tank built by inox india.

The company was incorporated in 1976 as baroda oxygen limited, a subsidiary of the inox group - the same gujarati conglomerate that owns inox air products, inox wind, and (until recently) pvr inox cinemas. The original impulse was backward integration: the inox group was importing cryogenic tanks from the us, europe, and japan, and the lead times stretched beyond a year. Rather than depend on foreign suppliers for equipment that was foundational to their own industrial gas business, the promoters decided to build it themselves. That factory in vadodara opened in 1992, and the current company is the result of three decades of accumulated engineering experience in a field where the learning curve is steep and certifications are demanding.

The pivotal strategic move came in 2009, when inox india acquired a majority stake in cryogenic vessel alternatives (cva), a us-based manufacturer with a european presence. The combined entity operates under the brand inoxcva and now has manufacturing and service operations in india (vadodara and kalol, gujarat; silvassa), brazil (indaiatuba, são paulo), and europe (alblasserdam, netherlands). The brazil unit opened in 2016, specifically to serve south american customers with locally produced products and repair services.

What inox india actually makes is equipment for storing, transporting, and distributing cryogenic liquids - gases that have been cooled below their boiling points until they liquefy. Liquefying a gas compresses it to roughly 1/600th of its gaseous volume, which makes large-scale storage and long-distance transport economically viable. the core technology is vacuum insulation: a double-walled stainless steel vessel with a vacuum jacket between the walls, sometimes supplemented with perlite insulation, that slows heat ingress enough to keep the contents liquid for extended periods. Building this reliably - especially for large tanks, dangerous gases, and extreme applications like space propulsion or nuclear fusion - requires metallurgical expertise, precision fabrication, certified welding, and strict quality management.

The company serves customers across more than 100 countries, with after-sales support associates in 25 countries. as of the most recent data, it employs approximately 1,230 people. promoter holding stands at 75%, steady and unchanged.

Business Segments

Inox india operates across four business divisions. Three are disclosed as segments: industrial gas solutions, lng, and cryo scientific division (csd). beverage kegs / sustainable industrial packaging sits as a fourth product category within the same manufacturing infrastructure.

Industrial gas solutions

This is the backbone of the business. For the full year fy25, this segment contributed approximately 65% of revenue and 56% of order inflows. It makes, installs, and services cryogenic tanks and systems used to store and distribute industrial gases - liquid oxygen, liquid nitrogen, liquid argon, carbon dioxide, ethylene oxide, and increasingly, green hydrogen.

The core product here is the storage tank - a vertical or horizontal double-walled vacuum-insulated vessel ranging from small “microbulk” units of a few hundred liters (used by hospitals, labs, and small manufacturers) up to large flat-bottom tanks holding tens of thousands of cubic meters (used by steel plants and gas terminals). The company also makes transport tanks (iso containers and tankers) and vaporizers that convert liquid back to gas for end-use.

The customers are primarily the large industrial gas companies - air liquide, linde, air products, messer, taiyo nippon sanso, gulf cryo. These companies own and operate the air separation units that produce oxygen and nitrogen, then use inox india’s tanks to store and deliver the gases to end customers. this creates a specific commercial dynamic: inox india is a supplier to the gas companies, not to the end-use industries directly. The gas companies care intensely about reliability and certifications, because a tank failure in a hospital oxygen supply or a steel plant has severe consequences. they are not buying on price alone.

Inox india’s newest growth product within this segment is ultra-high purity ammonia iso containers for the semiconductor and solar industries - a product the company described in its q1 fy26 concall as india’s first of its kind, targeting the expanding semiconductor fabs being built across india and globally. The company also recently introduced co2 battery storage solutions, securing a pilot order from italy in q1 fy26, with management describing “global potential.” The segment is also supplying liquid helium containers and specialized tanks for semiconductor applications in the us - nine such tanks were delivered to a us semiconductor customer in q4 fy25.

LNG division

the LNG division designs, manufactures, and installs equipment for liquefied natural gas storage, distribution, transportation, and infrastructure. LNG sits at -162°C, requiring specialized insulation and safety engineering beyond standard industrial gas equipment.

there are three distinct sub-markets within this division:

LNG vehicle fuel tanks. Inox india supplies cryogenic fuel tanks to heavy-duty truck oems - tata motors, ashok leyland, and others. The tanks are mounted on lng-powered trucks and buses. In q1 fy26, the company supplied approximately 145 such fuel tanks in a single quarter. The kalol facility (in panchmahal, gujarat) is dedicated to this product and is being expanded - management described in the q2 fy26 concall plans to “scale our lng drill tank production up by 10x over the next few years.” In february 2025, inox india became india’s first cryogenic equipment manufacturer to receive the iatf 16949 certification from bureau veritas for this product category, which is a mandatory requirement for direct supply to automotive oems. This certification removes a previously real barrier to entry into the oem supply chain.

Management has consistently described lng as a “winner fuel” for heavy trucks over the next 8-10 years. The argument: lng cuts co2 by 20-30% versus diesel, extends range, and costs less per kilometer. The regulatory environment is shifting - the small and medium pressure vessel (smpv) rules were amended to approve lng as a vehicle fuel, which unlocked broader adoption. The company holds over 85% market share in lng semitrailers operating on indian roads.

LNG infrastructure. Inox india builds small-scale lng terminals - satellite stations, dispensing stations, and mini-terminals for islands and remote industrial users who cannot access the main gas pipeline network. It commissioned 6 lng dispensing stations in fy24, completed the antigua mini-lng terminal (4 x 1,000 m3 tanks), and in november 2024, won a major order from island power producer ltd. In the bahamas for 10 x 1,500 m3 lng storage tanks and a regasification system for a power plant. This was followed in q2 fy26 by two additional satellite lng power station projects from small island nations near the bahamas.

In fy25, the company commissioned a 33 m3 LNG semi-trailer in Taiwan. In q3 fy26, it secured orders for LNG storage tanks for an LNG terminal project in Africa (2 tanks of 500 m3 each) and LNG marine fuel tanks from a European customer for two tanks of 150 m3 each.

LNG regasification and station infrastructure within india. The government has long-term ambitions to build 1,000+ LNG dispensing stations along indian highways for truck fueling. Actual rollout has been slower than targeted. As of q2 fy26, only around 50 stations were operational or imminent. management acknowledged on the q2 fy26 concall: “LNG station somehow is not picking up that fast to our expectation. but definitely, some private [players are coming].” this slower-than-expected pace is the single most visible execution gap in the LNG story.

Cryo scientific division (CSD)

This is the highest-margin, most technically complex, and most prestigious segment. it works on large bespoke projects for global scientific and research institutions. The products are not commercial catalog items - they are one-of-a-kind systems engineered for specific experiments involving temperatures near absolute zero.

The most prominent project is ITER, the international thermonuclear experimental reactor being built in cadarache, france. ITER is a multinational fusion energy project - effectively a machine designed to demonstrate that nuclear fusion can produce more energy than it consumes. It requires some of the most demanding cryogenic engineering in existence: superconducting magnets that must be cooled to near absolute zero using liquid helium, and inox india has been manufacturing multi-process vacuum-jacketed transfer lines for the iter site. In q2 fy26, the company received two major refurbishment contracts for ITER - a vacuum vessel thermal shield repair for sector f and a cryostat thermal shield repair. The q2 fy26 transcript stated: “these projects underscore our ongoing partnership with global scientific research institutions and reaffirm our execution excellence at a complex cryogenic facility.”

The division is also bidding for projects at fair (the facility for antiproton and ion research in germany), and has been working closely with ISRO on cryogenic systems for the indian space program. The company was the first indian manufacturer to build a trailer-mounted hydrogen transport tank, designed jointly with isro. On the q1 fy26 concall, management mentioned a large isro tender (described as worth approximately rs 4,000 crore) and noted they were working closely with isro and expected an rfq by december 2025.

The csd contributed approximately 23% of q1 fy26 revenue. it is lumpy by nature - revenue depends on milestone billings from multi-year projects. order inflows can be volatile because single orders are large (the iter cryostat thermal shield order alone was rs 145 crore per q1 fy26 concall data).

Beverage kegs and sustainable industrial packaging

Inox india leverages its stainless steel fabrication and container expertise to manufacture stainless steel beverage kegs for the global brewing industry. The company had approvals from certain breweries and was awaiting approvals from heineken and ab inbev as of q2 fy26. Management confirmed on the q3 fy26 concall that both approvals had been secured, and that the company held approximately 40% exposure in that market segment.

The keg business is seasonal - peak demand runs january through july, aligned with summer brewing cycles in europe and north america. It is a lower-complexity product than cryogenic vessels but uses the same manufacturing infrastructure, providing incremental utilization.

The company also makes cryobio containers (liquid nitrogen containers for livestock semen preservation and pharmaceutical biosamples), disposable refrigerant cylinders, and helium balloon cylinders. The disposable cylinder segment has been growing - management guided for 2 to 2.5 million cylinders annually in the q2 fy26 concall, with approximately 500,000 manufactured in h1 fy26. A us customer placed an order for over 700,000 disposable cylinders in q3 fy26 alone.

Customers

The customer base divides neatly into three tiers by end market.

Large industrial gas companies are the dominant buyer segment for the industrial gas division. air liquide, linde, air products, messer, taiyo nippon sanso, gulf cryo, and praxair (now part of linde) collectively account for a large share of the order book. These companies need cryogenic tanks as fundamental infrastructure for their gas distribution businesses. They are repeat buyers - every time they expand storage capacity or build a new distribution terminal anywhere in the world, they need to procure tanks. The switching costs are high: the gas companies have approved supplier lists, and getting on to the list requires certifications, audits, reference installations, and track record. Once you are approved, the gas company defaults to you for repeat orders unless something goes wrong.

The dynamic is somewhat unusual: inox india’s customers (the gas companies) are simultaneously competitors to inox india’s promoter group (inox air products, which is itself an industrial gas manufacturer). This potential conflict is managed through the listed entity’s independent operations and has not been publicly identified as a material issue.

isro, iter, research institutions are the cryo scientific customers. iter is a multi-year, multi-crore relationship. isro relationships go back to the hydrogen transport tank collaboration. the fair project in germany would be a new marquee client. these customers don’t buy standard products - they buy engineering capability, manufacturing precision, and the ability to deliver to specs that no one else in india (and few globally) can meet. the switching cost here is extremely high - replacing a supplier mid-project for a nuclear fusion reactor is not something that happens.

Oems and infrastructure developers are the LNG customers. tata motors and ashok leyland buy fuel tanks for lng truck programs. island governments and private power producers commission mini-lng terminals. shell, total, and downstream distributors buy lng storage. the bahamas contract with island power producer ltd is a good example: a power utility on an island without gas pipeline connectivity needs to import lng by ship, store it, regasify it, and burn it for electricity. the entire system - storage, regasification, distribution - is a turnkey order.

Competitive Landscape

The global picture. The global cryogenic equipment market peers include chart industries (us), linde (germany/us), nikkiso (japan), wessington cryogenics (uk), cryolor (france, now a chart subsidiary), cryofab (us), isisan (turkey), lapesa (spain), and vrv spa (italy). Chart industries is the scale comparison: it is a much larger, publicly traded us company with multiple acquisitions and a broader product portfolio. linde is vertically integrated - it makes the gases and the equipment.

Where inox india fits. Inox india is not competing with chart for the very large lng import terminals or complex us natural gas infrastructure. It competes on standard and mid-complexity industrial gas tanks globally, on lng infrastructure for small-scale and island markets, and on cryo scientific projects where its iter relationship and isro collaboration create credibility.

Why inox india wins orders in industrial gas. Cost is the primary factor. Inox india’s manufacturing cost base in india - even accounting for freight - is substantially lower than a european or us manufacturer. an industrial gas tank that would cost x from linde engineering or chart will cost materially less from inox india, with comparable quality (evidenced by the fact that air liquide, linde as gas distribution customers, and others consistently reorder). Once a customer has taken delivery of tanks from inox india and verified quality through installation and operation, subsequent purchases become easier. The customer has already done the audit, approved the factory, and trained maintenance staff on the equipment design.

The second factor is certification breadth. inox india carries approvals for virtually every major market - asme for the us, ce for europe, as1210 for australia, kgsc for korea, gb150 for china. this is years of accumulated compliance work that a new entrant cannot replicate quickly.

Why inox india sometimes loses. On the cryo scientific side, european institutions have historical preferences for established european suppliers. The competition for the fair project in germany involves competitors who are geographically proximate and have stronger local relationships. On large-scale lng infrastructure, chart industries and linde engineering have capabilities that inox india has not yet demonstrated at scale.

Chinese competition is the emerging threat on standard industrial gas tanks. chinese manufacturers can also manufacture at low cost, hold relevant certifications, and are aggressively marketing globally. inox india’s moat here is quality consistency, certification breadth, and relationships - not a fundamental technology advantage on standard products. management flagged in the q4 fy25 concall that securing an australia order for oxygen, nitrogen, and co2 imo containers “positions us in direct competition with chinese” manufacturers - suggesting the company views this as a meaningful competitive battleground.

Domestic competition is limited for the specialized products. there is no credible indian competitor in cryo scientific, no competing indian manufacturer of iter transfer lines, and no other indian manufacturer with iatf 16949 certification for cryogenic fuel tanks. For standard industrial gas tanks in india, inox india has an effective domestic monopoly among larger orders.

Industry

Demand drivers. the fundamental demand for cryogenic equipment comes from several converging trends: (1) industrial gas consumption growth, driven by steel, chemicals, healthcare, and food processing expansion; (2) lng infrastructure buildout globally as gas replaces coal in power generation; (3) the energy transition and the role of lng as a “bridge fuel” for heavy transport and island economies; (4) green hydrogen, which requires cryogenic storage and transport at -253°c (liquid hydrogen); and (5) scientific and government research spending on fusion energy, space programs, and particle physics.

Market size. The global cryogenic equipment market (broadly defined) was valued at approximately usd 26-27 billion in 2025 across various research estimates, with forecasts ranging from 7% to 10% cagr through 2032-2035, implying a market roughly doubling in size over a decade. The more focused cryogenic tanks/vessels sub-market was around usd 7-8.5 billion in 2025. Asia-pacific dominates with approximately 35-47% of global demand, driven by china, india, japan, and south korea.

India-specific drivers. India’s manufacturing sector is the largest consumer of industrial gases domestically, accounting for approximately 45% of the market in 2024 per the mncl research note - driven primarily by steel, which uses oxygen and nitrogen extensively. India’s steel capacity expansion (multiple large greenfield projects) will require corresponding industrial gas infrastructure. The government’s semiconductor push - a usd 8.87 billion program with 6 fabs approved and 5 more under construction by mid-2025 - creates demand for ultra-high purity gas delivery systems. and india’s lng adoption as a vehicle fuel, while slower than initially hoped, is expanding as the regulatory framework (smpv rules) has been updated to approve lng vehicles.

Regulation. Cryogenic equipment is heavily regulated because the gases involved (oxygen, lng, hydrogen) are either oxidizers, flammables, or asphyxiants at scale. every major market has its own pressure vessel standards (asme in the us, ped in europe, etc.) and inspection/certification requirements. This regulation creates a barrier to entry that favors incumbents with established certifications. It also makes switching suppliers more costly and slower for customers, since a new supplier must go through the same certification process. India’s own peso (petroleum and explosives safety organisation) regulations govern the installation and operation of cryogenic systems domestically.

Cyclicality. The industrial gas segment is relatively stable - gas companies make recurring capital investments in storage and distribution as they add capacity or upgrade old tanks. The lng infrastructure segment has project-driven lumpiness. The cryo scientific segment is the most lumpy, driven by funding cycles of scientific institutions that can be unpredictable. the vehicle fuel tank segment (if it scales) would be more regular, tracking truck production volumes and adoption of lng powertrains.

The chinese factor. Chinese manufacturers (primarily zhangjiagang cimc sanctum and associated entities) have been expanding their presence in global cryogenic equipment markets, particularly for standard-specification industrial gas tanks. They carry the relevant certifications and can match inox india on price in some segments. This competitive pressure has been intensifying and is the single most important structural threat to inox india’s standard-product order flow over the next 5 years.

Growth Triggers

• LNG vehicle fuel tank scale-up: Management stated on the q1 fy26 concall that the company was “expanding capacity and building capabilities to scale our lng drill tank production up by 10x over the next few years, supported by favourable regulatory changes and increasing domestic and export demand.” The iatf 16949 certification (february 2025) removed the key barrier to oem supply and the kalol plant has dedicated production lines. management described lng as a “winner fuel for 8-10 years.”

• Semiconductor and high-purity gas applications: Management called india’s semiconductor buildout - rs 1.6 lakh crore in planned investment - as “very bullish” for inox india’s prospects. The company delivered 9 tanks to a us semiconductor customer in q4 fy25 and launched india’s first ultra-high purity ammonia iso containers in q1 fy26. Management stated: “almost 75% projects are coming” online.

• ISRO and space infrastructure: Management noted active engagement with isro on a large cryogenic systems tender, expected rfq by december 2025. separately, the company is bidding for the fair (facility for antiproton and ion research) project in germany. cryo scientific orders are large, lumpy, and high-margin.

• Island and off-grid lng infrastructure: The bahamas project (10 x 1,500 m3 tanks, awarded november 2024) was followed in q2 fy26 by two additional island power station projects in the caribbean. Management described these as “part of a broader island energy infrastructure development plan.” islands without pipeline access represent a recurring market for mini-lng terminals globally - the company’s execution in the bahamas and antigua creates a reference portfolio that is hard to replicate.

• US aerospace and large vessel orders: management confirmed receipt of orders from a “leading us-based aerospace company” for 2 x 1,500 m3 cryogenic storage tanks in q2 fy26 (november 2025 concall) and again in q3 fy26 (february 2026 concall). Aerospace and space launch customers are new and high-value. management described it as demonstrating “customer confidence in inox india’s engineering capabilities.”

• liquid air energy storage (laes) - new segment: inox india delivered 5 x 690 kl cryogenic storage tanks to highview power (uk) for the world’s first commercial-scale liquid air energy storage facility in carrington, manchester. management called this the company’s “first order for a liquid air energy storage project.” laes stores electricity by liquefying air during cheap/excess generation, then re-expanding it through a turbine when power is needed - a grid-scale battery concept. if laes scales globally, this creates a new demand vector for large cryogenic tanks.

• beverage keg approvals secured: management confirmed on the q3 fy26 concall that both heineken and ab inbev approvals had been secured, giving the company approximately 40% exposure in the stainless steel keg market. the peak brewing season (january to july) should convert these approvals into meaningful revenue.

• co2 battery storage and new applications (q1 fy26): the company launched co2 battery storage as a product category and secured a pilot order from italy. while still early stage, management described “global potential” for this application.

Key Risks

• US tariff exposure on disposable cylinders. the disposable refrigerant cylinder segment relies heavily on us customers. Tariffs on indian-manufactured goods sold into the us market were flagged explicitly in q4 fy25 - management acknowledged that tariff uncertainty caused customers to pause orders, saying “people were just waiting because they are confused what to do... we were almost having ready tanks available at our shop almost 2 million to 2.5 million and people were just waiting.” The company ultimately negotiated duty pass-through with some customers, but this remains live. A significant tariff escalation (which us policy in 2025 made more plausible) could materially reduce the disposable cylinder order book from the us.

• LNG adoption pace risk - india stations. The thesis on lng vehicle adoption includes a vision of 1,000+ lng dispensing stations along indian highways. Actual build-out has been dramatically slower. Management explicitly admitted on the q2 fy26 concall that “lng station somehow is not picking up that fast to our expectation.” If the station buildout remains slow, the vehicle fuel tank business grows much more slowly than the 10x capacity expansion plan implies - that capacity would sit underutilized.

• Lumpy order book and revenue concentration. The cryo scientific division is inherently project-driven. Management has consistently noted that order inflows in q3 fy26 were rs 392 crore against a targeted rs 450+ crore, partly because large csd and lng orders “did not materialize in q3.” If a few large orders slip quarters, reported revenue and margins can be significantly affected. This is not unique to inox india, but it means that quarterly numbers will be volatile around the trend.

• Chinese competition on standard products. Chinese manufacturers are qualified on asme, ce, and other standards, and can compete on both price and delivery for standard industrial gas tanks. Inox india’s advantage on standard products is gradually narrowing. the company’s response has been to move up the value chain (aerospace tanks, semiconductor applications, laes, iter) where chinese competition is less developed, but the standard product segment is a meaningful portion of current revenue.

• Customer concentration in key segments. While the industrial gas segment serves air liquide, linde, and air products globally, these three companies together likely represent a significant share of the industrial gas division order book. Any strategic shift by one of them - building internal tank manufacturing, qualifying a chinese supplier, or slowing their own capex - would have a disproportionate effect on inox india.

• Raw material costs. stainless steel and special alloys are the primary inputs. price volatility in these materials affects margins, especially on fixed-price contracts. The q3 fy26 concall noted “gross margins were slightly lower this quarter, attributed to fluctuations in commodity prices and project-specific factors.”

Valuation & Scenario Analysis

Bull case

The convergence of three demand vectors turns inox india into a much larger company by fy28-29. First: india’s semiconductor manufacturing buildout - six fabs approved by mid-2025 with five more under construction - creates a wave of demand for ultra-high purity gas systems and specialized cryogenic storage. Inox india has positioned itself with the right products (ammonia iso containers, helium systems) ahead of this demand. Second: the 10x scale-up of lng fuel tank production at kalol, enabled by iatf certification and supported by oem adoption from tata motors and ashok leyland, turns the vehicle fuel tank business from a niche into a meaningful segment. If india deploys even 100,000 lng trucks over the next five years, that is a sustained manufacturing program. Third: the isro and scientific project pipeline materializes - an isro cryogenic systems order, the fair project in germany, and follow-on iter work all arrive within the same 18-24 month window. CYRO scientific margins are high, the projects are milestone-based, and each win creates a reference for the next.

Base case

Inox india grows steadily at the 18-20% revenue growth pace management has guided. The industrial gas segment continues to compound off a growing global gas infrastructure base. The LNG segment contributes through vehicle fuel tanks (kalol expansion bears partial fruit) and episodic turnkey project wins (one or two island/mini-terminal projects per year). The cryo scientific segment delivers lumpy but accretive revenue from iter refurbishment work, some isro contracts, and potentially fair project participation. The keg approvals from heineken and ab inbev add incremental volume. Exports remain 55-65% of revenue. The company does not face a severe tariff shock or a major customer loss. The order backlog stays in the rs 1,400-1,600 crore range, providing 9-12 months of revenue visibility at any given time. This is the trajectory the last three quarters of fy26 suggest - steady, above-market, but not transformative.

Bear case

Two things go wrong at the same time: us tariffs on disposable cylinders escalate materially, causing the us cylinder order book to dry up, and the lng vehicle fuel tank business continues to grow slowly because the station infrastructure rollout remains stuck at 50-100 stations rather than scaling to the government’s 1,000-station vision. The cryo scientific segment delivers no new large orders for 12-18 months because isro’s rfq process drags on and the fair project award goes to a european competitor. In this scenario, revenue growth slows to high-single-digits to low-teens. The savli plant runs at reduced utilization, creating operating leverage headwinds. The standard industrial gas tank business faces increasing pressure from chinese competitors who are winning at the margin on price-sensitive mid-complexity orders. The keg business is delayed further because brewery approvals, while secured, do not translate to volume until fy28. The company remains profitable and the balance sheet stays healthy (net debt was minimal through fy25 and fy26), but the growth story that attracted investors at ipo is less compelling than it appeared.

Thanks for reading! Do check out Investorstack.

Subscribe now

Without wasting your time, Here’s what we offer:

1. Research Reports for every listed company: One of the reasons why I built growth triggers (now called Investorstack) in the first place was, I wanted to research companies faster. I wanted to leverage AI to make decisions faster. With Research Reports, you get access to 1,500 to 2,000 word deep dives covering business overview, segments, growth triggers, walk the talk, and risks for all 1,000+ companies.

Sector Intelligence Briefs: Detailed peer-to-peer analysis across 200+ industries to find the companies leading, the ones lagging, and most importantly to understand the themes and commentary driving any sector.

Industry Dashboards: Live RS ratings, dominant market stages, and sentiment across every industry. Spot sectoral trends, see the companies leading the momentum, and track growth themes across the entire industry.

Growth Triggers (our legacy product, now even better)

The original feature that started it all, rebuilt with deeper coverage, faster updates, and cleaner tagging across 1,000+ companies.

Check out the landing page for an interactive demo. I built Investorstack for myself first. I wanted a faster way to analyse companies and industries, and nothing on the market did it the way I wanted. Some context: I’m in my third year of college with no coding background. When I launched Growth Triggers two months ago, I had zero followers. Two months later, we’re close to 200 customers.

Investorstack hasn’t officially launched yet, it’s in beta. If you try it, share your feedback on X and tag me @abhayjainp, I’m shipping new features every day based on what users ask for.

Check out Investorstack

Heads up: beta pricing ends in 2-3 days and prices go up after that. If you’ve been on the fence, now’s the right time.

Note for legacy customers: You’ll keep access to the Airtable for the next three months before we fully migrate everyone to the web app. Both features from Growth Triggers (Growth Triggers Tracker and Industry Dashboards) are already live on Investorstack and included in your existing plan, no extra charge.

To access them, just head to investorstack.in and sign in with the same email you registered with on Growth Triggers. You’ll land straight into your account.

Start here: Investorstack. Excited to build this with you.

Subscribe now

Sterlite Technologies (stl) makes the physical infrastructure that carries the world’s data. The core product is glass - specifically, optical fibre drawn from pure silicon dioxide, turned into cables, and shipped to telecom operators, data centre operators, and internet service providers across more than 100 countries. When a british telecom engineer cables a street cabinet for fibre-to-the-home, or when a hyperscaler in virginia connects two server racks, the glass they are pulling through ducts is very likely made in aurangabad or silvassa.

The company was founded in 1988 as a copper cable manufacturer in aurangabad by the agarwal family - the same family that controls vedanta resources. The telecom division was formally demerged from sterlite industries in 2001 and relisted as sterlite technologies. The pivot from copper to optical fibre happened incrementally through the 1990s as stl built an optical fibre plant in aurangabad in 1995 and an optical fibre cable unit in silvassa in 1993. The critical transformation happened in 2016 when stl divested its power transmission segment entirely to focus purely on optical networking and digital infrastructure.

What makes stl structurally different from a pure cable reseller is backward integration. most optical fibre cable companies buy optical fibre from suppliers and cable it up. stl starts one step earlier - it manufactures optical fibre from glass preforms, the cylindrical slugs of ultra-pure silica from which fibre is drawn. The preform plant “gaurav” in aurangabad is one of the largest greenfield semiconductor-grade preform facilities in the world. Drawing fibre from preform requires extremely precise furnace control - the glass must be heated to approximately 2000 degrees celsius and drawn at speeds of up to 2000 metres per minute, with the resulting strand thinner than a human hair. stl has mastered this process and owns it end-to-end from raw glass to finished cable. This “glass to gigabit” vertical stack is the source of its cost leadership in india and its margin structure globally.

Post the april 2025 demerger of its global services business (now listed as invenia - stl networks), stl today operates as a focused optical networking and digital solutions company. The global services business - which built bharatnet middle-mile infrastructure and deployed fibre networks for telcos - has been separated into a distinct listed entity. What remains in stl is the manufacturing and technology business, supplemented by stl digital, a small IT services arm.

Business Segments

Optical networking business (ONB)

The optical networking business is the core of stl. it accounts for roughly 93% of revenues post-demerger and encompasses everything from optical fibre and fibre cables to specialty cables and optical connectivity products.

What it does: the onb designs and manufactures optical fibre, optical fibre cables of every configuration (loose-tube, ribbon, tight-buffered, aerial, armoured, micro-duct), specialty cables (ultra-thin 160-micron fibre for high-density applications, ribbon cables like the celesta ibr that packs 864 fibres in an 11.7mm diameter), and optical connectivity hardware (patch panels, splice trays, pre-terminated assemblies, fibre management systems). It also makes multiverse multi-core fibre (mcf) - a next-generation product where multiple cores are embedded in the same cladding as a standard fibre, multiplying capacity without multiplying cable count.

The core capability: making optical fibre at scale with consistent quality is harder than it looks. The preform-to-fibre process involves thousands of variables - draw speed, tension, coating thickness, refractive index profile, attenuation - and any deviation means scrap or quality rejection. stl has invested in machine learning models to optimise preform-to-fibre matching (a documented collaboration with mathworks). the result is lower scrap rates, lower cost per fibre-kilometre, and consistent compliance with itut standards that tier-1 operators like british telecom demand.

Why it exists as the primary segment: Optical networking is the reason stl exists. After the 2016 power segment divestiture and the 2025 global services demerger, this is the business. It has over 10 global manufacturing plants - india (aurangabad, silvassa), italy (acquired optotec spa), china (jiangsu sterlite tongguang fiber, fully acquired in 2022), brazil, and a manufacturing facility in lugoff, south carolina (sterlite technologies inc., or sti). The south carolina plant was specifically built to comply with the us “build america, buy america” (baba) provisions required for eligibility in the federal bead broadband infrastructure programme.

Competitive position: stl claims 8% market share in the global ex-china optical fibre cable market (per q4 fy25 concall, may 2025), down from 12% in fy23. The market share decline reflects the 2022-2024 global inventory correction where north american carriers drew down existing stock before placing new orders - a systemic issue, not specific to stl. The company operates at roughly 50% utilisation of its 50+ million fibre-km glass/fibre capacity and 42+ million fibre-km cable capacity (per q3 fy25 concall, january 2025). As the global upcycle begins, utilisation recovery is the primary margin driver.

The data centre sub-segment within onb has become the growth story within the segment. Enterprise and data centre revenue contributed 20% of stl’s ytd fy26 revenues, and management has guided for this to reach 30% over the next 12-18 months. The reason is an ai data centre uses significantly more fibre per rack than a conventional cloud data centre - gpu-dense compute clusters require high-bandwidth, low-latency intra-facility connectivity that demands high-density fibre solutions. stl’s celesta ibr cable, launched in q2 fy26, is specifically engineered for this environment - 864 fibres in a sub-12mm diameter, optimised for jetting in micro-ducts inside data halls.

STL Digital

STL digital is a wholly owned it services and consulting subsidiary. It provides cloud migration, cybersecurity, data analytics, ai services, and enterprise saas (sap and oracle implementations) to enterprises across communications/media, healthcare, life sciences, energy, and manufacturing sectors. It has delivery centres in india, the us, and the uk, and a team of 1,120 consultants as of q3 fy26.

What it does: It is not a pure telecom IT shop. it does traditional enterprise IT - sap s/4hana implementations, oracle erp, cloud migration on aws/azure/gcp, cybersecurity managed services. March 2026 launch of securennov, an ai-driven cybersecurity portfolio, signals a push toward a differentiated product-led offering rather than purely staff augmentation.

The core capability: The connection to stl’s optical networking heritage gives stl digital a specific niche in communications and media technology - building bss/oss systems and digital transformation programmes for telecom operators. That is genuinely differentiated versus a generalist IT firm. but the healthcare and life sciences vertical is a pure enterprise it play with no natural stl advantage.

Products and Business Detailed

Optical fibre is the most upstream product. stl draws single-mode fibre from preform at its aurangabad facilities, compliant with itut g.652 (standard singlemode), g.654.e (ultra-low loss, long-distance), and g.657.a1 nova (bend-insensitive, access networks). Each fibre type solves a different problem: g.652 is the workhorse for backbone networks, g.654.e is used in submarine and long-haul routes where every 0.1db of attenuation matters, and g.657 bends around tight corners in homes and offices. stl also makes ultra-thin 160-micron and 180-micron fibre - 37% thinner than standard 250-micron fibre - which allows cable manufacturers to pack more fibre into smaller ducts, critical for dense urban deployments where duct space is exhausted.

Optical fibre cables (ofc) convert raw fibre into deployable products. stl makes loose tube cables (the standard outdoor backbone cable), ribbon cables (stacks of flat fibre ribbons for high-density applications), tight-buffered cables (for indoor use), micro-duct cables (ultra-slim for blowing through ducts with compressed air), armoured cables (for direct burial), and aerial cables (self-supporting with integrated messenger wire). the celesta ibr (intermittent bonded ribbon) launched in q2 fy26 packs 864 fibres in an 11.7mm diameter - described by management as “the world’s slimmest” at that fibre count - which is specifically for ai data centre intra-building high-density deployments.

Specialty cables include military-grade, subsea-armoured, and industrial variants. stl’s dadra facility produces specialty cables and has received near-zero waste to landfill intertek certification.

Optical connectivity products include pre-terminated assemblies, patch cords, fibre management systems, splice trays, and high-density celesta ibr technology enclosures. the “optical connectivity attach rate” - the percentage of stl’s fibre cable revenue that also carries connectivity product revenue - hit 22% in fy25 (per q4 fy25 concall, may 2025) before moderating to 17% in ytd fy26, primarily due to project timing and product mix shifts. management wants to grow this attach rate to 30%+ over time because connectivity products carry meaningfully higher margins than bulk cable.

Next-generation products include:

• multi-core fibre (mcf): stl’s “multiverse” mcf embeds 4 cores in the same cladding diameter as standard single-mode fibre. it successfully trialled with colt technology services on the london metro network in january 2026, carrying 800 gbps line rate over 9km and 63km segments.

• hollow core fibre (hcf): announced in march 2026, this is india’s first hollow core fibre hybrid cable. light travels through an air-filled core rather than solid glass, enabling speeds 46% faster than standard fibre with dramatically lower latency. badri gomatam, stl’s cto, described it as “the speed-of-light infrastructure required for the ai revolution.” hcf is commercially nascent but positions stl for hyperscaler and ai data centre applications where latency is the primary constraint.

Manufacturing footprint:

• aurangabad, maharashtra: optical fibre preform and optical fibre manufacturing (the core of the glass-to-gigabit chain)

• silvassa, dadra and nagar haveli: optical fibre cable and specialty cable manufacturing

• haridwar, uttarakhand: additional cable manufacturing

• piacenza, italy: acquired via optotec spa - serves european market proximity requirements

• jiangsu, china: fully acquired joint venture, serves asian customers

• brazil: cable manufacturing

• lugoff, south carolina, usa: optical fibre cable manufacturing, baba compliant for us federal programmes

The us plant at lugoff was strategically invested ahead of the us bead broadband funding programme and is directly relevant to stl’s north american market share ambitions. It also provides a natural hedge against us import tariffs - stl can supply us customers locally for projects requiring american-made content.

Customers

stl’s customer base cuts across four distinct buyer types, each with different purchasing logic, switching costs, and relationship dynamics.

Telecom operators are the largest and most strategically important customers. these are companies like british telecom, vocus (australia), netomnia (uk), archtop fiber (us), connexin (uk), wyre (belgium), and du telecom (uae). They buy optical fibre cables in large volumes to build fibre-to-the-home, 5g fronthaul, and backbone networks. The buying decision sits with the head of network procurement or cto office, and the sales cycle is typically 6-18 months - it involves technical qualification (the fibre must meet itut standards and the operator’s specific network design parameters), commercial negotiation, and often multi-year framework agreements. stl has secured “multi-year supply agreements with leading european operators” and “regained strong order inflows from top-tier us telecom players after a year’s pause”. Switching costs for a contracted operator are moderate - the fibre is fungible once qualified, but switching mid-project creates logistics complexity and risks certification issues.

Hyperscalers and data centre operators are the growth frontier. Companies like aws, microsoft, google, and meta are building ai-optimised data centres at an extraordinary pace. Global dc capex is expected to approach $600 billion by 2027 (per cru data cited by management). Each ai data centre requires substantially more fibre per rack than a conventional cloud facility - gpu clusters need high-bandwidth, low-latency intra-facility connectivity. STL has built a specific portfolio for this segment including the celesta ibr cable and pre-terminated high-density assemblies. Hyperscaler procurement is typically done through a vendor-approved list process, and getting onto that list requires significant qualification effort - once in, volumes are large and relationships tend to be sticky.

Citizen networks / government - before the demerger of invenia, stl had a large presence in bharat net and government broadband programmes. Post-demerger, this work has moved to invenia. However, stl still serves as the optical fibre cable supplier to such projects - the march 2025 rs 2,631 crore bharatnet contract in jammu and kashmir/ladakh was technically awarded to stl networks (the demerged entity) in consortium with dilip buildcon, but stl still supplies the cable. Government segment is characterised by long project timelines, payment delays, and working capital intensity - which is partly why stl chose to separate it.

Enterprise customers for stl digital - these are medium-to-large enterprises in healthcare, communications, life sciences, and manufacturing that need digital transformation programmes. given stl digital’s scale (rs 64 crore quarterly revenue), these are predominantly mid-market accounts rather than global fortune 500 engagements. Two healthcare providers in the middle east were signed on multi-year contracts in q1 fy26.

Competitive Landscape

The optical fibre cable market has a specific three-tier structure that is important to understand: at the top sit the chinese manufacturers (yangtze optical fibre / yofc, hengtong, zhongtian), who dominate volume but face increasing trade restrictions in western markets. In the middle sit the western integrated players (prysmian, corning, ofs/furukawa, sumitomo electric). and then there is stl, which competes as the primary indian player with a cost structure anchored in india but a western-qualified product.

Prysmian (italy/usa): the largest fibre cable manufacturer outside china. It has filed a lawsuit against stl’s us subsidiary for trade secrets violation (see risks section). prysmian has a clear market interest in slowing stl’s north american expansion. it has invested heavily in us manufacturing (a $50 million modernisation at claremont, nc and a $56 million palmetto plant in south carolina). It is stl’s most dangerous competitor in the north american market.

Corning (usa): the inventor of modern optical fibre. Corning does not manufacture finished cables but sells optical fibre to cable makers and operates its own cable business. It has a premium positioning and deep relationships with tier-1 north american carriers. STL competes with corning’s cable business on cost.

Sumitomo electric (japan): strong in asia and selectively in europe. Not a primary competitor in stl’s core european market.

HFCL (india): The second-largest indian optical fibre cable manufacturer. hfcl has also backward-integrated into fibre drawing and is a direct competitor for indian telecom operator contracts. However, hfcl does not have stl’s international scale or the italy/usa manufacturing presence.

Yangtze optical fibre (yofc) and Hengtong (china): Massive volume manufacturers whose export pricing creates structural pressure on the market. However, us and european tariffs on chinese optical cable have been increasing, reducing the competitive threat in stl’s two primary western export markets. This is a genuine tailwind for stl.

Growth triggers

• North america revenue scaling on bead and hyperscaler demand: Management guided that enterprise and data centre business contributed 20% of ytd fy26 revenues and they “remain on track to scale this to 30% and expect it to be a key growth driver in the medium term”. North america’s revenue share rose from 25% in fy25 to 36% in ytd fy26, driven by data centre connectivity wins and breakthroughs with tier-1 north american telecom customers.

“our enterprise and data center business is gaining traction with 20% revenue contribution in year to date fy26 and we remain on track to scale this to 30% and expect it to be a key growth driver in the medium term.”

- ankit agarwal, managing director (q3 fy26 concall, january 23, 2026)

• Utilisation recovery to 70%+ improving ebitda margins toward 18-20% target: stl is currently operating at approximately 50% utilisation on its 50+ million fkm glass/fibre and 42+ million fkm cable capacity. Management has guided that increasing utilisation from 50% to 70% “should improve ebitda margins from 14% to 20%”. The upcycle in global fiber demand starting 2025 is the primary mechanism for this utilisation recovery.

“as demand returns, they aim to increase utilization from 50% to 70%, which should improve ebitda margins from 14% to 20%.”

- ankit agarwal, managing director (q4 fy25 concall, may 2025)

• Optical connectivity attach rate expansion: The attach rate (the percentage of cable revenue that includes connectivity hardware) rose from 13% in fy24 to 22% in fy25. Management aims to grow this toward 30%+. Each percentage point of attach rate improvement carries margin expansion because connectivity products are higher-margin than bulk cable. The celesta ibr launch in q2 fy26 is a specific product driving this.

• Bead programme us demand commencing in earnest: Management in q3 fy25 (january 2025) guided bead-driven demand to begin in calendar year 2026, with benefits in stl’s q3-q4 fy26. ankit agarwal in q4 fy25: “sterlite expects the bead programme to progress, potentially starting in q4 this year or q1 next year.” north america’s revenue share growth to 36% in ytd fy26 suggests this is materialising. full bead implementation could sustain north american demand through 2030.

• India tariff barriers against chinese optical cable: stl management has noted that tariff and non-tariff barriers on chinese optical cable imports have tightened in india, benefiting domestic manufacturers. The government’s preference for domestic supply in bharatnet and 5g-related procurement reinforces this.

• Multi-year european supply agreements locking in volume: “we have secured multi-year supply agreements with leading european operators, and regained strong order inflows from top-tier us telecom players”. These multi-year agreements provide revenue visibility and reduce the lumpiness that characterised stl’s order book during the inventory correction.

• Hollow core fibre and multiverse mcf as premium product lines: The colt technology services multi-core fibre trial on the london metro network (announced january 22, 2026) and the hollow core fibre hybrid cable launch (march 25, 2026) represent stl’s entry into premium-priced next-generation fibre products. If hyperscalers and tier-1 operators adopt these at scale, the average selling price for stl’s fibre mix improves.

Scenarios & Valuation

Bull case

The global fibre upcycle that CRU is projecting develops into a multi-year super-cycle driven by the convergence of three forces: ai data centre buildout, bead-funded rural broadband in the us, and european fttx programmes. Stl’s order book, which has already crossed rs 5,325 crore with 40% yoy intake growth, accelerates further. North america scales to 40-45% of revenues as tier-1 us telecom carriers commit to multi-year supply agreements and hyperscalers source from stl’s south carolina facility for domestic supply chain security. Utilisation climbs from 50% toward 75-80%, and ebitda margins push toward the guided 18-20% range. The optical connectivity attach rate reaches 30%+ as the celesta ibr cable gains traction in ai data centre deployments. The prysmian litigation is settled or overturned on appeal, removing the contingent liability overhang. STL digital finds its footing in communications-vertical cybersecurity through the securennov platform, growing to rs 400-500 crore in annual revenue. The demerger of invenia has simplified the capital story, and with net debt declining below 2x ebitda, the balance sheet no longer constrains investments.

Base case

Demand in 2025-2026 recovers to historical trend levels rather than a super-cycle. bead provides a steady north american uplift but execution is state-by-state and lumpy. stl’s revenues grow at a mid-teens cagr from fy26 onward, driven by north america and india. Utilisation improves to 60-65% by fy27, pushing ebitda margins to 14-16% - an improvement from the current trough but short of the 18-20% target. The connectivity attach rate recovers to 22-25% as data centre orders ramp. stl digital stays subscale but profitable, contributing a small but growing earnings stream. The prysmian litigation drains capital (either through settlement or eventual payment) but does not threaten the parent’s operational continuity. Net debt trends below 2x ebitda as free cash flow improves on better margins. Europe remains the largest market at 38-40% of revenues. In this scenario, stl is a better business than it was in fy24-fy25, but it has not yet translated its capacity and global footprint into the dominance it has aspired to.

Bear case

The prysmian appeal fails, forcing a rs 810 crore payment through sti that requires capital infusion from the parent. China eases its export controls on germanium, but also resumes aggressive optical cable pricing in global markets as it seeks to capture the ai data centre opportunity. stl’s market share recovery in the ex-china global market does not happen because chinese manufacturers find ways around tariff barriers or europeans source locally. Utilisation plateaus at 55-60% because bead execution in the us is slower than projected and india’s 5g fiberisation pace is disappointing (telcos delay capex due to arpu pressure). Ebitda margins stay in the 10-13% range with no path to the 18-20% target. stl digital continues to consume capital without scale. Debt stays above 2x ebitda. in this scenario, stl remains a structurally important company in global optical infrastructure but with economics that do not justify its capacity investments, and the period of building for growth extends further without a clear payoff horizon.

Subscribe now

Thanks for reading!

Subscribe now

KSH international makes the wire that sits inside almost every large electrical machine in india. When a power transformer steps up voltage to transmit electricity across the country, or a traction motor pulls a locomotive, or an alternator generates power inside a wind turbine, there is winding wire at the core - copper or aluminium conductor, precisely insulated, wound thousands of times into a coil that creates the electromagnetic field that makes the machine work. KSH makes that wire.

The company was originally incorporated in 1979 as bhandary metal extrusion private limited in maharashtra. it began commercial operations in 1981 at taloja in raigad district, manufacturing the most basic form of magnet winding wire - paper insulated rectangular copper conductors - for transformer makers. For the next two decades the business was privately held and relatively modest. The pivot that defines the company today happened in 2006, when ksh pioneered the indigenisation of continuously transposed conductors (ctc) in india. CTC is a high-complexity, high-value product used inside large power transformers, and until ksh built the capability, india’s transformer manufacturers depended on imports. This decision to move upstream in complexity was the defining strategic bet of the company’s history, and it is the source of most of what distinguishes ksh from standard wire manufacturers today.

The company was renamed ksh international in 1996, a reflection of its growing export ambitions. By fiscal 2025 it had become the largest exporter of magnet winding wires from india by export revenue, according to care ratings. It listed on the nse and bse on december 23, 2025, via a rs 626 crore ipo.

The business model goes like: ksh buys copper rod and aluminium rod as raw materials, draws them down to precise dimensions, applies insulation layers - enamel coating, paper wrapping, or complex transposition - and sells the finished conductor to OEM customers who wind it into their electrical equipment. The margin profile depends almost entirely on how complex the insulation and processing is, not on the metal itself. Copper prices are passed through to customers, and the per-ton economics that management tracks - ebitda per metric ton - is the real measure of whether the business is improving.

What ksh actually does, in a technical sense, is manage the gap between raw copper and a precisely engineered conductor. A standard round enamelled wire involves drawing copper rod through progressively smaller dies and coating it with enamel at controlled temperatures. a continuously transposed conductor involves assembling multiple individually enamelled rectangular strands, transposing them continuously through a mechanical process so each strand occupies every possible position in the bundle, then wrapping the bundle in paper tape. The transposition eliminates circulating currents in large transformer windings, reducing electrical losses. Getting the transposition geometry right, consistent across thousands of meters per production run, requires process control that took ksh nearly two decades to develop. The company can currently produce ctc strands from 5 to 47 in number, in widths from 3 to 12.5mm and thickness from 1.1 to 3.2mm, with up to 24 layers of paper insulation. No other manufacturer in india matches this specification range in ctc.

The customer problem ksh solves is simple to state but hard to serve: oems building power transformers, generators, and electric motors cannot buy off-the-shelf wire. Every winding requires a precise conductor cross-section, insulation specification, and mechanical tolerance. ksh custom-engineers each order to the customer’s drawing. this is not commodity distribution - it is engineered manufacturing to specification on a per-order basis, which is why the company has managed over 90% repeat customer revenue.

Business Segments

Specialized Winding Wires

Specialized wires contributed approximately 75% of ksh’s total revenue in q3 fy26, growing 61% year-on-year in that quarter. This is the higher-complexity, higher-margin half of the portfolio, and it is what distinguishes ksh from commodity wire producers.

Specialized wires consist of continuously transposed conductors (ctc), paper-insulated rectangular copper and aluminium conductors (picc/piacc), and wrapped rectangular wires. ctc is the flagship. it is used in the high-voltage windings of large power transformers - typically above 10 mva in size - where eliminating eddy current losses in the windings matters enormously. In hvdc (high voltage direct current) transformers, which operate at 400kv and above and are used in india’s long-distance power evacuation projects, ctc is mandatory. ksh is the only indian company approved to supply wire for 400kv hvdc transformers, which means it has no domestic competition in this segment. The approval from pgcil, the entity that builds india’s national transmission grid, took years of qualification and testing.

The mechanism of the hvdc advantage is worth understanding. india is building multiple hvdc corridors to move solar power from rajasthan and gujarat to load centres in the north and east. every hvdc converter transformer in these corridors uses ksh’s wire. these are large, high-value orders placed by companies like hitachi energy india, ge vernova t&d india, and bhel. As of q3 fy26, ksh had received cumulative orders for 37 hvdc transformers, all to be supplied over 12-18 months. These orders are sticky because a transformer oem that qualifies a conductor supplier for a specific transformer rating does not switch mid-project. the re-qualification process is expensive and time-consuming.

PICC (paper insulated copper conductor) serves similar customers - power transformer and reactor manufacturers - but at lower voltage classes. It is the conductor used in transformer windings below hvdc grades, and it is simpler to make than ctc. ksh is approved for picc supply to pgcil, ntpc, npcil, and rdso. The rdso approval is specifically for traction transformer applications in locomotive drives - a growing segment as indian railways electrifies.

The specialized segment also includes wrapped rectangular wires with fiberglass or other specialty insulation, which find use in generators (turbo and hydro), windmill generators, and niche industrial applications. ksh makes specialized stator coils and rotor bars for windmill generators as well.

Standard Winding Wires

Standard Winding Wires - primarily round enamelled copper and aluminium wires - constituted approximately 25% of ksh’s revenue. These serve a different customer set: manufacturers of motors, alternators, gensets, compressors, home appliances, refrigeration equipment, and automotive electrical components.

Round enamelled copper wire (ewcr) is the most common form of magnet wire globally. ksh draws copper rod down to fine gauges, applies enamel insulation in a continuous pass-through oven at controlled temperatures, and spools the finished wire for delivery. The applications range from transformer low-voltage windings to motor armatures to alternator windings in gensets. A genset manufacturer building a 100 kva alternator specifies a particular wire gauge and enamel class; ksh delivers to that specification.

Round enamelled aluminium wire (ewal) is used where weight reduction matters - in compressors, refrigeration motors, and certain large motor applications. Aluminium is 60% lighter than copper for equivalent cross-section but has lower conductivity, so motor designers use larger cross-sections. The economics work when the weight saving justifies the design change.

Standard wires are more commoditised than specialized wires - competitors like precision wires india, ram ratna wires, and vidya wires all produce similar products. ksh competes here primarily on reliability, proximity to customers (both maharashtra-based facilities are within 250km of major oemclusters), and the ability to supply both standard and specialized wire from a single vendor relationship.

Manufacturing Facilities:

KSH operates four facilities, all in Maharashtra:

• Chakan unit 1 and unit 2 (pune, maharashtra): The primary manufacturing base for specialized wires including ctc and picc. Located in chakan industrial zone, which sits within 50km of bharat bijlee, hitachi energy india, siemens energy india, and other key customers. Two separate plants at the same location, with combined annual capacity that forms the bulk of the pre-supa footprint.

• Taloja unit (raigad, maharashtra): The original 1981 facility. Located in taloja midc near navi mumbai. Proximity to jawaharlal nehru port allows efficient import of copper rod and export of finished wire. This facility primarily handles standard round wire production. The port proximity is a genuine cost advantage - copper rod arrives from international markets, and wire is exported to 24 countries, so port distance directly affects working capital (copper in transit) and freight costs.

• Supa unit (ahilyanagar, maharashtra): The new greenfield facility commissioned in phases. Phase 1 operations began in september 2025, adding 12,000 mt of capacity. By q3 fy26 (december 2025) a further 2,400 mt was added, bringing supa capacity to approximately 14,400 mt. Total capacity across all four facilities was 43,445 mt as of december 2025. Management guided 59,045 mt total capacity within 14 months from q3 fy26, implying approximately february 2027 completion for full supa ramp.

The combined installed capacity of 29,045 mt at the three older facilities operated at 80.7% utilisation in fy25. The supa addition more than doubles total capacity over the two-year ramp-up period. The capital expenditure for supa was approximately rs 90 crore for machinery, partly funded by the ipo proceeds of rs 420 crore (the remainder was applied to debt repayment of rs 226 crore, completed in december 2025, and general corporate purposes).

Customers

ksh serves oem customers - companies that build the electrical equipment into which the wire is wound. it does not sell to distributors or to end-users of electrical equipment.

The customer base numbered 122 in fy25 and 117 in fy24 and fy23. over 90% of revenue comes from repeat customers - buyers who have been sourcing from ksh across multiple years. The company served approximately 120 domestic and global oem customers as of q3 fy26.

Export mechanics: exports represented 27-30% of revenue. ksh exports to 24 countries as of june 2025, including the usa, uae, kuwait, romania, saudi arabia, germany, oman, spain, bangladesh, and japan. The export business predominantly consists of ctc and picc - the specialty products that indian wire makers can actually compete with on quality at a cost advantage. Standard round wire exports are smaller because the cost advantage narrows for commodity-grade products. In q3 fy26, export revenue grew 37% year-on-year.

Competitive Landscape

The indian magnet winding wire industry is a concentrated oligopoly with meaningful differentiation at the top end and commoditization at the bottom.

Precision Wires India limited (pwil): The largest manufacturer in india and south asia by production capacity, headquartered at silvassa with facilities in silvassa and overseas. PWIL makes the full range from standard round copper wires to ctc and picc. It has a larger absolute capacity than ksh and serves a similar customer set. pwil competes directly with ksh in every product category. pwil’s advantage is scale and the breadth of its product range - it makes the widest gauge range of enamelled round copper wire in india. ksh’s counter-advantage is its ctc leadership for the hvdc segment specifically, where ksh’s approvals go further (400kv hvdc transformer applications vs. pwil’s standard ctc range).

Ram Ratna Wires limited: The second-largest winding wire manufacturer in south asia by volume. Focused primarily on enamelled round copper wires with a broader product mix that has expanded into copper tubes and bunching/compacting products. Ram ratna competes with ksh on standard round wire but does not have the same depth in specialized transformer conductors. Ram ratna’s strategy has been geographic diversification and product category expansion rather than going deeper in complexity.

Vidya wires limited and Sh haryana wires limited: Smaller players in standard round wire. not meaningful competitors in the specialized ctc/picc space where approvals and technical capability are the barriers.

What actually differentiates ksh

The barriers to entry in specialized wire - particularly ctc for hvdc applications - are formidable. There are three layers:

First, the technical capability to manufacture ctc consistently at specified dimensions requires dedicated machinery and process knowledge. The ctc machine is not off-the-shelf capital equipment; it requires calibration and process development. ksh spent years developing its ctc manufacturing process after starting in 2006.

Second, the regulatory approvals from pgcil, ntpc, npcil, and rdso are not transferable and are not granted quickly. They require sample submissions, destructive testing, factory inspections, and in some cases performance monitoring on actual transformer deployments. a new entrant cannot simply buy a machine and start competing in hvdc-grade ctc; it needs 3-5 years of approval process even if the manufacturing capability is in place.

Third, the global oem approvals from hitachi, ge, siemens, toshiba, and others are equally slow to obtain. These companies run their own vendor qualification programmes with multi-year timelines. a wire manufacturer that wants to supply to hitachi energy’s hvdc transformers needs to pass hitachi’s own qualification, which involves detailed testing at hitachi’s facilities.

ksh is the only indian company approved to supply wire for 400kv hvdc transformers. This is a monopolistic position in a segment that is growing rapidly. The next competitor to challenge it would need to get pgcil avl approval for this specific product category, which starts the clock on a multi-year process.

On the standard wire side, competition is more intense. precision wires, ram ratna, and numerous smaller regional players compete on price, delivery, and service. margins are thin. ksh’s standard wire business competes primarily on the strength of relationships that come from being a one-stop supplier for both specialized and standard wires - a transformer oem that already buys ctc from ksh is more likely to also consolidate its round wire sourcing with ksh.

Industry

Magnet winding wire is an input to the electrical equipment industry. Its demand is a direct function of how much electrical equipment is being built. Understanding ksh’s demand environment requires understanding what is driving electrical equipment production.

India’s power sector investment cycle: India has committed to 500 gw of renewable energy capacity by 2030. Solar and wind generation is inherently located far from load centres - solar in rajasthan and gujarat, wind along coastlines - which means every megawatt of renewable capacity added requires transmission infrastructure to bring the power to cities. Each kilometer of high-voltage transmission line requires transformers at both ends. India’s transmission buildout is running at multiple times the historical rate. The central transmission utility (ctu, which pgcil operates) and state transmission utilities are placing large transformer orders, and transformer manufacturers are at near-capacity utilisation. According to icici securities, india’s transformer manufacturing capacity is set to triple from approximately 110 gva to 300 gva by fy28. Every single transformer in this expansion requires ctc, picc, and winding wire.

HVDC specifically: India is building its first hvdc corridors - long-distance direct current transmission lines that transmit power at much higher voltages than conventional ac transmission, enabling power flows of thousands of megawatts over distances of 1000+ kilometres. Each hvdc project uses converter transformers at both ends - massive, complex, high-value machines that require hvdc-grade ctc. The current pipeline includes projects connecting rajasthan solar zones to the north and east. KSH is the only approved indian supplier for this specific conductor category.

Growth Triggers

• Supa facility full ramp to 59,045 mt capacity: Total capacity was 43,445 mt as of december 2025. Management guided reaching 59,045 mt within 14 months - approximately february 2027. Q4 fy26 was characterised as the first full quarter of supa phase 1 operations. The supa facility is specifically designed for specialized winding wires, targeting the ctc and specialty markets.

• HVDC order pipeline execution: KSH has received cumulative orders for 37 hvdc transformer winding wire packages as of q3 fy26. All 37 orders are to be executed over 12-18 months. These are high-margin, high-value-addition orders with no domestic competition. The hvdc pipeline in india is multi-year in nature - the national transmission plan calls for multiple hvdc corridors, so new orders are expected to continue as projects move from planning to procurement.

• Only approved indian supplier for 400kv hvdc transformers: This approval gives ksh exclusive access to every new hvdc converter transformer order placed by indian oems. As india’s renewable energy evacuation buildout accelerates, this position becomes more valuable with each new project announcement.

• EV traction motor wire development via hpw metallwerk: Through an exclusive licensing agreement with hpw metallwerk, announced january 2026, ksh is developing peek-insulated round wires for 800v ev traction motors. Management guided entry into the 4-wheeler ev traction motor market within 12-18 months from q3 fy26. 2-wheeler ev motors are already being supplied. PEEK wire for 800v applications commands substantially higher per-ton pricing than standard enamel.

• India transformer manufacturing capacity tripling: External data point cited by icici securities, consistent with industry sources - India’s transformer manufacturing capacity is targeting a scale from approximately 110 gva to 300 gva by fy28. KSH as the approved ctc supplier to the transformer oems at the core of this expansion is directly positioned to benefit.

• Copper payables normalisation improving working capital: As of q3 fy26, ksh was paying copper suppliers on advance payment terms because of its relatively small scale. Management indicated that as volumes grow, they expect to shift to credit-based procurement, lengthening payable days from the current 5 days to a more normal range. This would release significant working capital tied up in prepayments and reduce the cash cycle.

key Risks

• Copper price volatility and working capital trap: Copper accounts for approximately 85-90% of raw material cost. Copper prices can move 20-30% in a year. While ksh passes through copper price changes to customers, the mechanics create a working capital trap: KSH buys copper at spot or near-spot, processes it, and invoices at the processed price after a 30-45 day manufacturing and delivery cycle. If copper prices rise sharply, ksh needs more cash to fund the inventory build before the revenue is collected. As of q3 fy26, working capital days were approximately 75-80, partly inflated by inventory stocking of critical insulating materials. KSH currently pays suppliers in advance (payable days of approximately 5), meaning it funds its entire inventory before any credit from suppliers. A sustained copper price spike combined with customer payment delays would compress liquidity rapidly. The company had rs 519 crore of debt as of october 2025, partially paid down to approximately rs 293 crore (rs 226 crore repaid) by december 2025.

• Customer concentration in the power t&d sector: While ksh has 117-122 active customers, the dominant revenue share comes from transformer oems supplying the power t&d sector. A slowdown in india’s transmission capex - which is fundamentally a government spending decision - would directly hit demand for ctc and picc. India’s t&d capex has historically been lumpy; planned transmission additions have been delayed by land acquisition issues, financing constraints, and bureaucratic timelines. If the hvdc pipeline is delayed by 12-18 months relative to current expectations, ksh’s 37-order hvdc backlog would still be executed but the next wave would slow. This would affect the supa facility utilisation since it is being built to capture exactly this demand.

Scenarios & Valuation

Bull Case

India’s transformer manufacturing capacity expansion plays out faster than the historical pace. PGCIL and state utilities accelerate procurement to catch up with delayed projects, and the hvdc pipeline - which currently has 37 orders in backlog - continues generating new orders as three or four new hvdc corridors are tendered over the next 18 months. KSH executes the full supa ramp to 59,045 mt on schedule by early 2027, giving it the capacity to absorb the demand without turning away orders.

In this world, the supa facility runs at high utilisation in specialized wire from the start because the demand is already there in the form of hvdc orders. Export growth continues at 30%+ as western transformer manufacturers accelerate their india sourcing following the us tariff changes. The peek-wire licensing bears fruit and ksh becomes a qualified supplier for one or two 4-wheeler ev oems by late fy27, opening an entirely new margin accretive revenue stream. the shift from advance payment to credit-based copper procurement happens more quickly than expected as ksh’s volumes give it bargaining leverage with copper rod suppliers, releasing working capital and reducing the cash cycle. care ratings upgrades ksh’s credit profile further, reducing borrowing costs on the large working capital facility needed for a business at this scale.

The new ceo brings operational discipline and helps ksh scale up its commercial team to match its manufacturing capability. the company deepens its customer relationships with international oems - adding one or two new global transformer manufacturers to its export base who are specifically qualifying non-chinese ctc sources. Management builds on the monopoly position in hvdc-grade ctc to extend into 1200kv uhv transformer applications, which india is beginning to plan for its next-generation transmission network.

Base case

The supa facility ramps on approximately the guided timeline, reaching full capacity somewhere in fy27-28. hvdc orders continue at the current pace - roughly matching execution of the existing backlog with modest additions as new hvdc projects reach procurement stage. Exports grow at 20-30% annually as the china+1 shift plays out gradually rather than rapidly. The standard wire business grows broadly in line with india’s electrical equipment production, which benefits from manufacturing capex and the government’s infrastructure push.

The peek wire opportunity develops but takes longer than 12-18 months to generate material revenue - qualifying for 4-wheeler ev traction motors involves extensive testing and the 800v platform rollout in india is gradual. The working capital situation improves modestly as copper payment terms normalise over fy27. The new ceo settles into the role without major disruption.

ebitda per ton improves gradually from the current rs 65,000-67,000 range as the product mix shifts further toward specialized wires and operating leverage from the supa facility kicks in. The company emerges from the supa capex cycle as a substantially larger business - roughly double the fy25 scale by fy28 - with a stronger balance sheet having eliminated most of its term debt.

Bear Case

The hvdc order pipeline stalls. India’s renewable energy buildout is slower than planned, as it frequently has been historically. Land acquisition delays, grid integration challenges, and state utility financing constraints push hvdc commissioning timelines to the right. the 37 orders in backlog are executed, but the next wave of orders is delayed by 18-24 months. The supa facility, specifically built to serve the specialized wire market, runs at low utilisation. The fixed cost base from the new facility creates margin pressure during the under-utilisation period.

Simultaneously, copper prices spike sharply - which has happened before - compressing the cash cycle and straining the working capital facility. KSH finds it difficult to shift to credit-based copper procurement faster than anticipated because copper suppliers demand advance payment from any customer whose volumes are not yet established at the new supa-level scale. The balance sheet, though improved post-debt repayment, gets stretched again as working capital requirements grow with revenue but payable terms do not improve.

The peek wire opportunity does not materialise within the guided timeline - ev oem qualification takes longer than 18 months, and the 800v architecture rollout in india is pushed to fy28-29. A competitor - potentially precision wires, which has a larger manufacturing base and relationships with the same oem customers - obtains a competing hvdc qualification from pgcil, eliminating ksh’s monopoly position in this segment.

The management transition - the new ceo installed in april 2026 - proves disruptive to a business that has historically operated as a closely held family enterprise. execution slows during the transition. meanwhile, the ipos of fy25-26 in the capital goods sector have set high bar expectations, and ksh’s muted listing premium means there is little goodwill cushion if results disappoint even modestly.

Thanks for reading!

Subscribe now

Industry Triggers (revamped)

We completely rebuilt the industry analysis from scratch. Every industry now has its own triggers pulled from the latest concalls of all companies in that sector. Instead of generic sector commentary, you get specific, numbers-backed catalysts driving each industry right now. 253 industries covered, each with sentiment ratings (bullish/bearish/mixed), RS rankings, and dominant stage analysis.

Walk the Talk (Management Consistency)

This one’s our favourite. Agents read all 4 quarters of concall transcripts for each company and check: did management actually deliver on what they promised? Every company gets rated as one of four categories:

• Overdeliver - consistently beat their own guidance

• Consistent - did what they said they’d do

• Mixed - hit some targets, missed others

• Hype Man - big promises, weak delivery

Guidance Monitor

We now track whether management upgraded, maintained, or downgraded their forward guidance compared to previous quarters. You can see both the old and new guidance side by side.

You can now filter for companies upgrading their guidance and go one level deeper to scan for industries with the most guidance upgrades.

Check Growth Triggers out!

Aequs is a precision components manufacturer. It takes raw aluminium, titanium, and steel, and turns them into flight critical parts for Airbus, Boeing, and Safran. It also makes plastic toys for Hasbro, cookware for Tramontina, and (more recently) smart device casings for a global consumer electronics giant widely reported to be Apple.

Aequs operates across two segments:

The company was founded in 2000 by Aravind Melligeri, a mechanical engineer from Mangalore University with a master’s from Penn State. He built India’s first precision engineering SEZ in Belagavi, attracted Airbus as a customer, and spent 15 years turning the company into a Tier I supplier for every major aerospace OEM. The IPO in December 2025 raised INR 922 crore through a fresh issue at INR 124 per share.

The Belagavi SEZ: A Factory Within a Factory

The core of Aequs is a 250+ acre Special Economic Zone in Belagavi, Karnataka. Within this single campus, a titanium billet arrives and exits as a finished, surface-treated, assembled aircraft component.

The manufacturing chain inside the SEZ runs in sequence:

Raw material intake (aluminium from Thyssen Krupp in Germany, Hindalco domestically; titanium alloys from European suppliers) -> Forging (SQuAD JV, 10,000-ton hydraulic press) -> Precision machining (420+ CNC machines) -> Surface treatment (API JV with Magellan Aerospace, NADCAP certified) -> Assembly (aerostructures, door panels) -> Finished goods and delivery (air cargo to customers in France, USA, Vietnam)

The distance components travel within the SEZ is under 500 meters. Without this integration, parts would travel 5,000+ km between forging, machining, and surface treatment facilities across multiple countries. That logistical compression is the core competitive advantage.

Aerospace Segment

Aequs manufactures 5,200+ distinct aerospace part numbers as of 9MFY26, up from 4,500+ at end-FY25. The product portfolio breaks down as follows:

The high value items are engine systems and landing systems. An engine front spinner (a rotating component mounted on the front of a turbine blade assembly for the LEAP engine) carries more revenue per unit than a standard structural bracket. Aequs has achieved 100% in-country value addition for select products like front spinners and landing system wheels. That means no step in the manufacturing process leaves India.

Aequs supplies parts for both single-aisle aircraft (A220, A320, B737) and long-range aircraft (A330, A350, B767, B777, B787). The mix matters. Single-aisle production rates are far higher (Airbus targets 75 A320s per month by 2027), which drives volume. Long-range parts tend to be larger and more complex, carrying higher unit values.

Key Customers

Airbus is the largest customer. The relationship is 15 years old. Aequs holds D2P (Detailed to Parts) status, awarded to only the top 100 suppliers globally. Aequs has won this award six times between FY16 and FY23. It has also received Airbus’s Ramp-up Champion award and SQIP (Supplier Quality Improvement Process) awards. Airbus increased its India sourcing from USD 0.5bn in FY16 to USD 1.4bn in FY25 and plans to reach USD 2.0bn by FY30. Aequs is one of the primary beneficiaries of this shift.

Boeing has been a customer for eight years. Aequs has been a Tier I supplier since 2017. Boeing’s India sourcing stands at USD 1.25bn annually from 300+ suppliers and the company plans to roughly double this figure. The India-US trade pact removing tariffs on aircraft parts accelerates this trend.

Safran has been a customer for nine years. Aequs supplies engine-related components. Safran is the third-largest aerospace customer by revenue contribution.

Collins Aerospace has been a customer for 10 years. Aequs services Collins from its facility in Cholet, France.

Other customers include Spirit AeroSystems, Honeywell Aerospace, Dassault Aviation, GKN-Fokker, Bombardier, EATON, Premium AEROTEC, and SABCA.

Order Book

The aerospace order book stood at USD 814mn as of 9MFY26. At an average annual execution rate of USD 200mn+, this provides roughly 3-4 years of revenue visibility extending to about 2031. The order book is growing as Aequs wins additional programme share from Airbus and Boeing.

Three factors driving aerospace growth for Aequs: Airbus/Boeing increasing India sourcing, Aequs gaining wallet share within existing customers, and the product mix shifting toward higher-value landing systems and engine components.

Key Joint Ventures

SQuAD Forging India Pvt Ltd (JV with Aubert & Duval, France): Forges small to medium-sized aero-structural parts for engines, landing gear, and braking system components. Works with aluminium, steel, titanium, and nickel-based alloys. The JV operates a 1,200-ton screw press and a 10,000-ton hydraulic close die-press. Holds ISO 9001, AS9100, ISO 14001, and OHSAS 18001 certifications. Heat treatment lines are NADCAP certified.

Aerospace Processing India (API) (JV with Magellan Aerospace, Canada): Provides surface treatment solutions including chemical processing, surface enhancement, and non-destructive testing. First unit in India to achieve NADCAP accreditation across all three disciplines. API is the approved surface treatment facility for Boeing and Airbus. Magellan and Aequs recently announced a sand casting JV as well, expanding capabilities further. An MRO (Maintenance, Repair, and Overhaul) facility is under development in partnership with Magellan, planned for completion in 2025.

Aerostructures Assemblies India (AAI) (JV with Saab AB, Sweden): Specializes in build-to-print assemblies for commercial and defense aircraft. Aequs is the first Indian company to assemble plug doors and over-wing exit doors for Airbus and Boeing. The JV is positioned to capture defense offset opportunities.

International Facilities

Cholet, France (acquired 2016 via SIRA Group): Services Collins Aerospace and Safran. Proximity to European OEMs reduces lead times and deepens customer relationships.

Texas, USA (facility established 2015): Services Boeing and Spirit AeroSystems. Approved for exports. Provides a North American delivery point for US-based customers.

Both facilities give Aequs on-the-ground presence near customer engineering teams, which helps win new programme qualifications.

Consumer Segment: The Three Verticals

The consumer segment has three distinct product lines:

1. Consumer Electronics (the new growth driver)

Aequs has secured orders from a global consumer electronics major for manufacturing smart watch enclosures and laptop bottom casings. Media reports (Swarajya Mag, among others) have identified this customer as Apple. The parts are precision-machined in India at Aequs’s Hubballi facility (0.30mn sqft dedicated to high-precision consumer products) and then flown to Vietnam for final assembly by the customer’s existing vendors.

Production of laptop components commenced on July 31, 2025. Aequs has deployed 218 CNC machines specifically for consumer electronics as of 9MFY26. Utilisation has climbed from 19% in 3QFY25 to 31% in 3QFY26. Despatches to Vietnam are ongoing.

The customer reportedly has plans to expand production in Vietnam for smart devices. The manufacturing capacities Aequs will eventually set up in Karnataka are contingent on the customer’s demand projections. The products (mechanical enclosures) qualify for government PLI incentives, which can support margins.

This is the part of the business that draws comparisons to Luxshare in China. Luxshare grew from CNY 35.9bn in revenue in 2018 to CNY 268.8bn in 2024, a 40% CAGR, by scaling machining capabilities for a single dominant consumer electronics customer. Its EBITDA margins settled at 8-9% at scale, with ROCE above 12%. If Aequs can replicate even a fraction of that trajectory, the consumer segment alone could generate INR 10,000-15,000mn in revenue by FY30.

2. Plastics (Toys)

Aequs began making plastic toys at the Belagavi SEZ in FY16. The customer base includes Hasbro (nine-year relationship, the longest), Mattel (shipments began from 3QFY26), Spin Master (five years), and others. Products include outdoor games, darts, toy vehicles, figures, dolls, role-play toys, and STEM toys.

The toy business is seasonal, peaking in Q3 (October-December, ahead of the global holiday season). It has been volatile. FY25 saw particularly sharp swings in sales and margins. Hasbro had a product recall in FY21 due to high lead content (partly covered by insurance), though there have been no recalls in the last three years.

Manufacturing facilities for toys are at Belagavi and Koppal (0.30mn sqft). The company operates 161 plastic moulding machines (80-450T capacity), 7 blow moulding machines, and 46 assembly lines. Mattel recently closed its factory in China and is relocating manufacturing to India and Vietnam, a trend that benefits Aequs. Hasbro is also sourcing more from India as part of the broader China-plus-one supply chain shift.

3. Consumer Durables (Cookware and Appliances)

Aequs manufactures non-stick cookware and small home appliances. The key relationship is a joint venture with Tramontina, the Brazilian cookware giant with 113 years of history. This is Tramontina’s only manufacturing facility outside the Americas. The JV was formalized in June 2024.

Wonderchef has been a customer for seven years. Other customers include Borosil and Playshifu. The consumer durables business is small relative to the other two verticals and contributes modestly to segment revenue.

Consumer Segment: The Scale Challenge

The consumer segment’s core problem is under-absorption of fixed costs. At 31% utilisation (9MFY26), the segment generates negative EBITDA. Every CNC machine, every assembly line, every worker on the floor costs money whether or not parts are being machined. The EBITDA loss in consumer widened from INR 95mn to INR 159mn in Q3 FY26 even as revenue grew 157% YoY, because Aequs is still investing in start-up costs for the electronics ramp.

The capex required is large. Aequs will need to keep adding CNC machines for electronics, moulding machines for toys, and capacity for cookware.

Workforce

Aequs employs roughly 4,000+ people across its facilities. The company planned to add 1,000 employees by March 2026, including 300-400 in aerospace. A team of 300+ engineers (process, tools, and testing specialists) handles new product development, receiving customer technical specifications and simulating and industrializing products. This engineering bench is a competitive moat. Qualifying new aerospace parts takes 12-18 months of testing and certification. Once qualified, switching costs for the customer are high.

Karnataka Expansion

In March 2026, Aequs signed a non-binding MOU with the Government of Karnataka to invest INR 2,856 crore over five years starting FY26. The expansion focuses on Belagavi and Hubballi, strengthening both aerospace and consumer manufacturing capacity. This is separate from the ongoing capex for CNC machine additions and represents a longer-term commitment to the state.

Global Aerospace Supply Chain: The India Shift

The global aerospace supply chain is rebalancing toward India. Two forces drive this.

First, production rate increases. Airbus plans to produce 75 A320 neo-family aircraft per month by 2027, up from roughly 50 in 2024. Boeing is ramping the 737 MAX toward 38/month. Every additional aircraft per month requires proportionally more parts from the supply chain. OEMs need suppliers who can scale.

Second, supply chain diversification. COVID and the subsequent recovery exposed concentration risk in the aerospace supply chain. European and North American Tier II/III suppliers struggled with labor shortages, inflation, and raw material availability. India offers lower labor costs (roughly 60-70% cheaper than France or the US for equivalent machining work), a growing pool of engineering talent, and government incentives through the SEZ framework.

The Competitive Set in India

Aequs competes with a growing set of Indian aerospace manufacturers:

Competition is increasing, however. Airbus expanded its India vendor pool from 45 suppliers in FY16 to 100+ by FY24. Boeing sources from 300+ suppliers. New entrants are qualifying. Pricing pressure exists through annual price-reduction initiatives that OEMs impose on suppliers.

Consumer Electronics: The China-Plus-One Opportunity

The consumer electronics manufacturing shift from China is accelerating. Apple targets sourcing 20% of global iPads and Apple Watches, 5% of MacBooks, and 65% of AirPods from Vietnam. India is gaining share as well, with Apple planning to manufacture 50mn iPhones in India.

The precision machining segment within consumer electronics (casings, enclosures, structural components) carries higher margins than assembly. Foxconn and Pegatron do assembly. Luxshare and (potentially) Aequs do machining. The machining step requires expensive CNC equipment, tight tolerances, and quality systems. This naturally limits the competitor set.

Luxshare’s trajectory in China provides a reference point. Revenue grew from CNY 35.9bn (2018) to CNY 268.8bn (2024). EBITDA margins settled at 8-9% at scale. ROCE stabilized above 12%. The company was capex-intensive for years before turning consistently free cash flow positive. Aequs is at the very beginning of what could be a similar curve, but at much smaller scale and with execution risk that Luxshare, already deeply embedded in the supply chain, did not face.

Aerospace Growth Drivers

Wallet share gains with Airbus: Aequs currently supplies 5,200+ parts. The total addressable part count on Airbus programmes is many multiples of that.

Boeing ramp: Boeing’s India sourcing at USD 1.25bn is set to double. Aequs’s Tier I status and Texas facility position it to capture incremental share.

Product mix enrichment: The shift toward landing systems (124 SKUs) and engine systems (39 SKUs) carries higher unit values than structural brackets (4,093 SKUs). As Aequs wins more high-value programmes, revenue per part should rise.

MRO entry: The planned MRO facility with Magellan Aerospace adds a new revenue stream. India’s MRO market is expanding as the domestic fleet grows (1,000+ commercial aircraft on order from Airbus and Boeing combined for Indian carriers).

Consumer Growth Drivers

Electronics scale-up: The consumer electronics contract is the single largest growth lever in the business. If utilisation climbs from 31% to 70%+ by FY29-30, consumer electronics alone could generate INR 8,000-10,000mn in revenue.

Toy manufacturing shift from China: Mattel closed its China factory and is relocating production to India and Vietnam. Hasbro is also increasing India sourcing. Aequs’s existing relationships (Hasbro for nine years, new Mattel relationship from 3QFY26) position it to capture this shift.

Tramontina JV scale-up: Tramontina’s only facility outside the Americas is with Aequs. As the JV ramps, cookware exports could grow.

Key Risks

1. Consumer electronics ramp-up is the swing factor, and it’s binary. If the global electronics customer scales orders as expected, consumer revenue could reach INR 10,000mn+ by FY30 with positive EBITDA. If orders stall or the customer shifts to alternate suppliers, Aequs has deployed 218 CNC machines (at roughly INR 15-20mn each) with no revenue to absorb the depreciation. Industry commentary draws parallels with Luxshare, but Luxshare was already deep in Apple’s supply chain when it scaled. Aequs is at trial/early production stage.

2. The company will burn cash for years. Capex of INR 450-550cr annually, negative free cash flow, and rising debt are the near-term reality. If the consumer ramp is slower than expected, debt/equity could breach 1.5x by FY29. At some point, the balance sheet constrains growth.

3. Aerospace competition is intensifying. Airbus expanded its India supplier base from 45 to 100+ between FY16 and FY24. Boeing sources from 300+ Indian suppliers. New entrants like Azad Engineering, Unimech Aerospace, and PTC Industries are qualifying for programmes. While Aequs’s integrated capability and D2P status are difficult to replicate, OEMs actively pursue price reductions from existing suppliers.

4. Customer concentration. Airbus is the largest customer by a wide margin. Any disruption to Airbus’s production plans (supply chain delays, regulatory issues, demand slowdown) would flow directly through to Aequs’s revenue.

Valuation

TLDR on Aequs

• Only precision component manufacturer in India with fully vertically integrated aerospace ecosystem within a single SEZ

• Over 90% single-source (sole supplier) parts in aerospace - strong competitive moat with 5-7 year contracts

• USD 814M aerospace order book (TCV) through 2031, continuously replenished via RFP pipeline

• aerospace segment EBITDA margin at 24%, sustainable at 20%+ per management - well above consolidated due to consumer drag

• consumer electronics capacity (Apple ecosystem + Mattel + Tramontina) at only 31% utilization on Rs 638 Cr invested - massive operating leverage as volumes ramp

• Tamil Nadu MoU for Rs 1,900 Cr over 10 years targeting higher-value landing gear, engine, and systems components - move up aerospace value chain

• SQuAD JV with Aubert & Duval for 10,000 ton hydraulic closed-die forging press - unique forging capability in India for aerospace

• post-IPO net cash balance sheet (net debt/equity 0.10x) provides runway for capacity expansion without dilution

• India currently only 2% of global aerospace supply chain vs 10% target - structural tailwind for domestic precision manufacturers

• Airbus D2P (Direct-to-Partner) status since 2016 - preferential access to new contract opportunities

• expanding from aerostructures into higher-margin engine and landing gear systems - content per aircraft increasing

• defense UAV JV with Accel India and Vagus Defense for indigenous drone manufacturing - India defense budget capex up 30% for FY27

• management targeting long-term 50:50 balance between aerospace and consumer revenue - consumer at only 14% currently

Subscribe now

If you want to see what I’ve been building, you can check it out here

More of Me

THE BUSINESS STORY

It all began with a woman making oils in her kitchen. In the 1940s, in a modest home in Raipur, a housewife named Manorama would crush groundnuts and other seeds by hand, extracting oil that her husband Janakilal Agarwal would sell door-to-door. It was a humble beginning, a bucket of oil and a bicycle, for what would eventually become a company supplying specialty fats to some of the world’s largest chocolate and cosmetics makers. This is the story of Manorama Industries.

The piston expeller that changed everything

Janakilal Agarwal was born into a family of modest means in what is now Chhattisgarh. As a young man in the 1940s, he watched his wife laboriously press seeds to extract their precious oils. He saw an opportunity. In 1955, he acquired a piston expeller, a mechanical device that could crush seeds far more efficiently than human hands and set up a small factory in Raipur. He named the business after his wife: Manorama.

But Janakilal wasn’t content to simply run a small-scale oil operation. He had a curious mind, and he wanted to understand the science behind his trade. In an era when few Indian businessmen pursued advanced education, Janakilal traveled to London to earn a PhD in fat chemistry. This decision would prove transformational.

In London, Janakilal studied the molecular structures of fats. He learned how different oils behaved at varying temperatures, how they crystallized, and how they could be blended to mimic more expensive fats. He discovered that oils from seemingly worthless sources (banana peels, mango kernels, sal seeds) had properties valuable in industrial applications. The seeds that tribal communities in central India had been ignoring or discarding for centuries contained fats that, properly processed, could substitute for far more expensive ingredients in chocolate and cosmetics.

The legendary trade fair story

What happened next has become company legend. Armed with his PhD and samples of his specialty fats, Janakilal traveled to international trade fairs in Germany and France in the 1970s, hoping to attract buyers from global food and cosmetics companies. But he had no money for elaborate booth displays or professional marketing materials.

His solution was audacious. Unable to afford display materials, Janakilal reportedly smeared his products (cocoa butter alternatives and cosmetic butters) all over his own body. He stood at the exhibition hall, his skin glistening with mango butter and sal fat, inviting potential customers to touch and feel the quality of his products. It was unconventional, to say the least, but it worked.

At one such trade fair, his unorthodox demonstration caught the attention of Ferrero, the Italian chocolate giant behind Ferrero Rocher. They were intrigued by this Indian entrepreneur covered in exotic butters, and more importantly, by the quality of his products. The cocoa butter equivalents he had developed from sal seeds and mango kernels could help stabilize chocolate, preventing the dreaded “bloom” that occurs when chocolate experiences temperature fluctuations. A partnership was born.

From waste to wealth: the business model takes shape

What made Manorama’s proposition uniquely compelling was the raw material sourcing. In the dense forests stretching across Chhattisgarh, Jharkhand, Odisha, and Madhya Pradesh, tribal communities had long collected sal seeds (from the Shorea robusta tree) and mango kernels during the monsoon season. For them, these were minor forest products, useful for making traditional soaps or oils, but largely overlooked as a commercial opportunity.

Janakilal realized that these discarded seeds, properly processed, could become cocoa butter equivalents (CBE). These fats mimic the crystallization properties of expensive cocoa butter but at a fraction of the cost. Cocoa butter, derived from cocoa beans grown primarily in West Africa, is essential for chocolate manufacturing but increasingly expensive and supply-constrained. Sal fat, in contrast, could be sourced abundantly from India’s forests.

The business model that emerged was genuinely innovative: buy “waste” seeds from tribal collectors, process them into high-value specialty fats, and sell to multinational food and cosmetics companies. It was “waste to wealth” before that phrase became fashionable. They turned what nobody wanted into ingredients for Ferrero Rocher chocolates and L’Oréal cosmetics.

Over decades, Manorama built a procurement network spanning over 18,000 villages, engaging an estimated 6-8 million forest dwellers (predominantly tribal women) as suppliers. During the collection season (May-June for sal seeds, June-August for mango kernels), these women would gather seeds from forest floors, dry them, and sell them to Manorama’s collection agents at prices typically higher than what middlemen offered.

The next generation takes the helm

Janakilal Agarwal passed the torch to the next generation, and the company’s transformation from a trading operation to a sophisticated manufacturing enterprise would be led by his grandson Ashish Saraf and his wife Vinita.

Ashish Saraf, who has over 30 years of experience in the specialty fats sector, joined the family business and brought modern management practices while retaining the core relationships with tribal communities that his grandfather had built. In 2005, the family formally incorporated Manorama Industries Limited, signaling a new chapter of growth and professionalization.

Vinita Saraf, a commerce graduate from Mount Carmel College, Bangalore, joined her husband in building the business. Her entrepreneurial drive and operational focus complemented Ashish’s expertise in procurement and product development. Together, they transformed what had been a family trading business into a vertically integrated specialty fats manufacturer with global reach.

Going public: the 2018 IPO

By 2018, Manorama had established itself as a leading supplier of cocoa butter equivalents in India, with long-term contracts with global confectionery and cosmetics giants. The company decided to access capital markets, filing for an IPO on the BSE SME platform.

The October 2018 IPO raised ₹64 crore by issuing shares at ₹188 each. The primary use of funds: building a greenfield integrated manufacturing facility in Birkoni, Chhattisgarh, that would dramatically expand production capacity. Until then, Manorama had been heavily focused on procurement and primary processing, but the new plant would allow them to produce finished specialty fats meeting the exacting specifications of global food companies.

The IPO prospectus revealed the company’s customer list, a who’s who of global consumer goods giants. Ferrero, the maker of Ferrero Rocher and Nutella. L’Oréal, the cosmetics behemoth. The Body Shop, which used Manorama’s mango butter in its popular Mango Body Butter line. These relationships, built over decades, provided revenue stability and growth visibility.

Building the Birkoni plant

The Birkoni plant, commissioned in 2019-2020, represented Manorama’s transformation from a trading company to a full-fledged manufacturer. Located near Raipur in Chhattisgarh, the facility could process sal seeds and mango kernels into refined specialty fats, fractionated butters, and customized fat blends tailored to specific customer requirements.

The timing was challenging. Just as the plant was ramping up production, the COVID-19 pandemic struck. As Vinita Saraf noted in the company’s FY2021 annual report, the pandemic created “unprecedented challenges” in operations. Lockdowns disrupted both raw material collection (tribal communities couldn’t gather seeds as usual) and factory production.

Yet the company persevered. By FY2022, the Birkoni plant was operating at fuller capacity, and Manorama was beginning to see the benefits of vertical integration. Margins improved as the company captured value previously flowing to third-party processors.

The African expansion

While building capacity in India, Manorama also looked outward. Shea nuts, another source of specialty fats widely used in cosmetics and chocolate, grow abundantly in West Africa’s “shea belt,” stretching from Senegal to Uganda. Unlike sal seeds, shea has a well-established global market, with European cosmetics companies sourcing shea butter for premium skincare products.

In 2017, Manorama established Manorama Africa Ltd, a subsidiary focused on sourcing and processing shea nuts from West African countries including Ghana, Burkina Faso, Nigeria, and Togo. The strategy mirrored what the company had done in India: build relationships with local communities (again, predominantly women who collect shea nuts), establish collection centers, and process the raw materials into high-value ingredients.

By 2024, Manorama had established wholly-owned subsidiaries across multiple West African countries: Manorama Savanna Nigeria, Manorama Savanna Togo, Manorama Savanna Ghana, and Manorama Savanna Burkina Faso. This sourcing network reduced dependence on Indian raw materials while tapping into a $300+ million global shea market.

Explosive growth: 2022-2025

The years 2022-2025 marked an inflection point for Manorama. Several factors converged:

Cocoa prices surged. Global cocoa prices hit multi-decade highs due to supply constraints in West Africa (climate change, aging trees, disease). This made cocoa butter equivalents, Manorama’s specialty - increasingly attractive to chocolate manufacturers looking to manage costs.

Capacity expansion completed. The Birkoni plant reached full operation, and in April 2024, Manorama commissioned an additional fractionation plant with 25,000 tonnes per annum capacity, bringing total fractionation capacity to 40,000 TPA.

Product mix improved. Manorama shifted from selling basic fats to higher-value customized products like MILCOA (their branded cocoa butter equivalent) and MilcoSpread (for spreads and fillings), commanding better margins.

Revenue nearly tripled from FY2023 to FY2025. Profits exploded from ₹30 crore in FY2023 to ₹112 crore in FY2025, nearly a 4x increase. Operating margins, which had compressed during the capacity-building years, expanded back toward historical highs as scale benefits and premiumisation took hold.

The stock market noticed. Manorama’s shares, which had listed at ₹188 in 2018, climbed to over ₹1,000 by late 2024. That’s a 5x return in six years. By January 2026, the company’s market capitalization exceeded ₹6,000 crore, placing it firmly in smallcap territory with significant institutional ownership from domestic mutual funds.

The tribal connection: sustainability as strategy

Throughout its growth, Manorama has maintained its unique sourcing model. This model has become increasingly valuable as global consumers and corporations demand supply chain sustainability.

The company works with an estimated 100,000+ tribal collectors across Central India, predominantly women from Gond, Baiga, and other indigenous communities. During sal seed season, these women walk into the forests surrounding their villages, gather fallen seeds, dry them, and sell them to Manorama’s collection network. The company has established approximately 18,000 collection centers to facilitate this process.

The economics work for all parties. Tribal families earn income during the lean agricultural season (May-July), supplementing their farming income. Manorama gets reliable raw material supply at predictable costs. And the company’s products can be marketed as sustainably sourced, an increasingly important differentiator in pitching to multinational cosmetics and food companies with ESG commitments.

In 2017, Manorama signed a Memorandum of Understanding with the Chhattisgarh government to formalize its tribal engagement, and the company has won multiple awards for fair trade and sustainable sourcing practices. The company is a member of the UN Global Compact, aligning its operations with global sustainability development goals.

The cosmetics opportunity

While chocolate and confectionery remain Manorama’s largest market (approximately 80% of revenues), the cosmetics segment represents a growing opportunity. The same butters used in chocolate (sal butter, mango butter, shea butter) are prized in skincare for their moisturizing properties.

L’Oréal uses Manorama’s butters in premium skincare formulations. The Body Shop sources mango butter for its popular body butter range. These relationships, built over years, provide access to the fast-growing natural cosmetics market, where consumers increasingly seek plant-based, sustainably sourced ingredients.

The cosmetics segment typically commands higher margins than food applications, and management has indicated that growing this segment is a strategic priority.

Leadership transition

In October 2024, the company announced a leadership change: Ashish Saraf was appointed Chairman and Managing Director, consolidating leadership as the company entered its next phase of growth. His son Shrey Saraf, armed with a BBA from the University of Exeter, joined the board as Whole Time Director, representing the third generation of family leadership.

Vinita Saraf continues as Vice-Chairperson and Whole Time Director, while professional managers including CFO Ashok Jain (a chartered accountant) and Whole Time Director Gautam Kumar Pal (who holds a doctorate in management and oversees the Birkoni plant) - round out the leadership team.

Looking ahead

From Manorama Agarwal’s kitchen in the 1940s to a ₹1,000+ crore revenue company supplying global giants, Manorama Industries has traveled an extraordinary journey. The business survived the founder’s passing, navigated multiple economic cycles, went public, and built manufacturing capabilities while maintaining the tribal sourcing relationships that make its model distinctive.

The road ahead holds both opportunity and challenges. Cocoa prices remain elevated, driving demand for CBE. The cosmetics segment offers margin expansion potential. African operations can diversify and expand raw material supply.

But competition is intensifying as other players recognize the CBE opportunity. The company remains dependent on monsoon-driven collection seasons and tribal labor. And as scale grows, maintaining the community relationships that underpin sustainable sourcing will require continued attention.

What started with Janakilal Agarwal covered in butter at a German trade fair has become a company with a market cap exceeding ₹6,000 crore, supplying some of the world’s most recognizable consumer brands. It’s a distinctly Indian business story, one that turned forest waste into chocolate gold.

Subscribe now

INDUSTRY CONTEXT

The specialty fats industry exists because of a fundamental tension in the chocolate world. Cocoa butter, the fat that gives chocolate its silky texture and snap, is expensive, volatile in supply, and difficult to source sustainably. For decades, confectioners and cosmetic manufacturers searched for alternatives that could replicate cocoa butter’s unique properties: a melting point just below human body temperature, solid at room temperature but liquid in the mouth, and stable during storage. The answer came from an unlikely source: seeds that fall from trees in Indian forests, collected by tribal women for generations as a supplementary source of income.

Cocoa Butter Equivalents (CBE) emerged as a distinct product category when European chocolate regulations in 2000 permitted up to 5% vegetable fats other than cocoa butter in chocolate products. This regulatory shift transformed what had been a niche product into a legitimate industry. CBEs are specialty fats engineered to match cocoa butter’s triglyceride profile, allowing chocolate manufacturers to reduce costs while maintaining product quality. The key to CBE production lies in the fatty acid composition, specifically the symmetric triglycerides POS, SOS, and POP (palmitic-oleic-stearic, stearic-oleic-stearic, and palmitic-oleic-palmitic), which give cocoa butter its distinctive crystallization behavior.

The global CBE market was valued at approximately USD 1.23 billion in 2024 and is projected to grow at a CAGR of 6.9%, reaching USD 1.84 billion by 2030. The broader specialty fats and oils market, which includes CBEs alongside other functional fats for bakery, dairy, and cosmetic applications, reached USD 14.12 billion in 2023 and is expected to grow at 7.4% CAGR through 2030. Within this landscape, the Asia-Pacific region, particularly India, has emerged as both a major production hub and a rapidly growing consumption market.

The NCB-CBE Price Gap: A Structural Tailwind

The relationship between Natural Cocoa Butter (NCB) prices and CBE prices is the single most important industry dynamic driving Manorama’s growth. Historically, NCB prices traded at a modest 20-30% premium to CBE prices. However, this relationship has become dramatically more volatile:

Major cocoa-producing countries in West Africa, mainly Côte d’Ivoire and Ghana (accounting for about 70% of global cocoa production), suffered 11-14% production declines. The causes: Cocoa Swollen Shoot Virus, climate impacts, and aging tree stocks. Even after partial price corrections, NCB remains 2-3x the price of CBE, making substitution economically compelling for chocolate manufacturers operating within the EU’s 5% CBE allowance.

While CBE offers cost savings and stability for mass-market products, natural cocoa butter remains essential for the rich, nuanced flavor in gourmet and premium chocolates. This creates a stable bifurcation: premium chocolate uses 100% cocoa butter as a selling point, while mass-market and industrial chocolate maximizes CBE usage within regulatory limits.

What makes India’s position in this industry unique is the availability of raw materials that cannot be cultivated. They must be collected from the wild. Sal trees (Shorea robusta) cover approximately 14% of India’s forest area, concentrated in Chhattisgarh, Jharkhand, Odisha, Madhya Pradesh, and West Bengal. The seeds, which fall from these trees during monsoon season, were traditionally collected by tribal communities for centuries but held little commercial value beyond local oil production. Similarly, mango kernels (the seeds inside mango pits) were considered agricultural waste until specialty fat manufacturers recognized their potential.

The chemistry is what matters. Sal fat contains 40-47% stearic acid and specific triglyceride profiles that, when refined and fractionated, produce a fat with crystallization properties remarkably similar to cocoa butter. Mango butter shares these characteristics. Shea butter from West Africa completes the trinity of raw materials used for CBE production, though shea’s supply chains have been more developed due to longer European engagement with African sources.

India’s tribal belt spanning central and eastern states hosts an estimated 6-8.5 million forest dwellers who participate in Minor Forest Produce (MFP) collection. This collection network operates through roughly 18,000 villages with established aggregation points, creating an informal but extensive supply chain. The government’s Minimum Support Price (MSP) scheme for MFP, including sal seeds, has provided price floors that support collector incomes while ensuring supply security for processors.

The regulatory environment shapes market structure significantly. The European Union’s Chocolate Directive (2000/36/EC) permits vegetable fats up to 5% in chocolate products, creating the primary end market for CBEs.

However, regulations require clear labeling when CBEs are used, and pure chocolate producers often market "100% cocoa butter" as a premium distinction. In India, FSSAI regulations govern food-grade specialty fats, while the cosmetic-grade market follows separate quality standards. The specialty fats industry benefits from government initiatives promoting agro-processing and export-oriented manufacturing, with Manorama holding "Star Export House" status.

CBE Value Chain Flowchart

Climate and seasonality create operational challenges. Sal seeds have a concentrated harvest window of approximately 60-90 days during and after monsoon season, requiring processors to build significant inventory to maintain year-round production. Storage of oilseeds without quality degradation demands controlled environments and working capital. Mango kernel collection follows different seasonality, coinciding with the summer mango processing season, allowing some diversification in procurement timing.

The industry’s tailwinds are compelling. Global chocolate confectionery consumption continues rising, particularly in emerging markets where per-capita chocolate consumption remains a fraction of European levels. India’s chocolate market, though small by global standards, has grown at double-digit rates as urbanization increases and Western consumption patterns spread. Rising cocoa butter prices (driven by supply constraints from West African political instability, climate change impacts on cocoa yields, and growing demand) make CBEs increasingly attractive to cost-conscious manufacturers. CBE pricing typically runs at 50-60% of cocoa butter costs, offering meaningful savings for large-scale chocolate producers.

Headwinds include consumer preferences in premium chocolate segments for “pure” cocoa butter formulations, though this matters less in compound chocolate, coatings, and confectionery fillings where CBEs predominate. Sustainability scrutiny has intensified around palm oil-based specialty fats, creating differentiation opportunities for manufacturers using forest-sourced or certified sustainable inputs.

COMPETITIVE LANDSCAPE

Manorama’s Global Position

Manorama Industries is the only company globally to offer specialty oil/fat from a basket of exotic seeds (sal, mango, kokum, mahua, shea), and the largest in India to supply CBE to the world. The company is ranked among the top 3-4 global players in the Cocoa Butter Equivalents and exotic fats space, commanding approximately 8% of the global CBE market. This positioning makes Manorama a strategic supplier rather than a commodity producer. the company’s unique raw material access and processing capabilities have embedded it into the supply chains of Fortune 500 food and cosmetics companies.

The top 10 global CBE producers command approximately 80% of the market, making it a highly concentrated industry. Manorama’s position as a top-5 player globally, and the only significant Indian producer, provides both competitive insulation and strategic importance to customers seeking supply chain diversification.

The global specialty fats industry is dominated by a handful of multinational corporations that have built integrated supply chains spanning tropical regions. AAK AB, the Swedish-Danish specialty oils and fats company formed from the 2005 merger of Aarhus United and Karlshamns, stands as the industry leader with annual revenues exceeding EUR 4 billion. AAK operates refineries across Europe, the Americas, and Asia, maintaining direct sourcing relationships in West Africa for shea butter and Southeast Asia for palm-based inputs. Their strategy emphasizes customer co-development: working with chocolate manufacturers to create customized fat solutions rather than selling commoditized products. AAK India, with manufacturing facilities and a presence across 25+ states, represents their regional platform.

Bunge Loders Croklaan, part of Bunge Limited’s global oilseed processing network, competes directly in the CBE segment with manufacturing facilities in the Netherlands, Malaysia, and the United States. Their advantage lies in integration with Bunge’s crushing and refining infrastructure, providing cost advantages in palm kernel oil processing. The company has invested heavily in sustainability certification and traceability systems, responding to European customer demands.

Fuji Oil Holdings, the Japanese specialty fats producer, brings strong technical capabilities in fat modification and crystallization science. Their CBS (cocoa butter substitutes) and CBE products serve major Asian chocolate manufacturers, and the company has expanded globally through acquisitions including Blommer Chocolate Company in 2019 (though subsequently divested in 2022). Fuji Oil’s strength lies in formulation expertise for compound chocolate and confectionery coatings rather than pure CBE production.

Wilmar International, the Singapore-based agricultural commodities group, maintains the largest palm oil plantation and processing operations globally. While CBE represents a small portion of their portfolio, Wilmar’s scale in palm kernel oil provides cost advantages in CBS production. Their challenge in the Indian market lies in competing with forest-sourced alternatives that carry sustainability narratives palm oil cannot match.

Olam Food Ingredients operates cocoa and specialty fats businesses with particular strength in African sourcing networks. Cargill’s cocoa and chocolate business includes specialty fats operations, though the company has been more selective in this segment compared to their core commodities trading.

Within this global landscape, Manorama Industries occupies a distinctive position as the only significant processor globally using sal and mango-based raw materials. The company’s origins trace to the 1950s when founder Janakilal Agarwal began a seed-crushing operation in Raipur, Chhattisgarh. What began as a local oil producer transformed when Agarwal pursued fat chemistry studies in London during the 1960s, returning with knowledge of triglyceride modification and European market requirements. The breakthrough came through persistence and product development. They demonstrated to Ferrero in the 1990s that Indian sal-based fats could enhance chocolate stability in tropical climates, leading to a partnership that continues today.

Manorama’s competitive moat derives from supply chain control rather than manufacturing sophistication. The company’s network of 18,000 collection centers across tribal areas represents decades of relationship building that would be nearly impossible to replicate. These aren’t commercial arrangements that can be renegotiated. They’re embedded community relationships where Manorama representatives have become trusted aggregators for forest produce. The company employs over 6 million forest dwellers in its collection network, predominantly tribal women who supplement agricultural income through seasonal seed gathering.

The global CBE market has three tiers of competitors. Tier 1 comprises the multinationals (AAK, Bunge Loders Croklaan) with integrated global supply chains, multiple raw material sources, and extensive customer relationships. These companies can blend shea, palm kernel, and illipe-based fats to optimize cost and supply security. Tier 2 includes focused regional players and diversified commodity companies like Wilmar and Olam that participate opportunistically. Tier 3 encompasses specialized producers like Manorama that compete on unique raw materials and niche positioning.

What competitors say about this space is revealing. AAK’s India operations explicitly market sal-based fats as part of their sustainable sourcing narrative, highlighting work with women farmers. This validation from the industry leader confirms the raw material’s viability while intensifying competition in Manorama’s home market. However, AAK’s sal sourcing scale appears modest compared to their global shea and palm kernel volumes. It’s a product line rather than a strategic focus.

The barriers to entry in India’s CBE market are substantial but asymmetric. Manufacturing specialty fats requires fractionation and refining equipment costing tens of crores, along with quality systems meeting food-grade and often customer-specific certifications. These capital requirements screen out small entrants. However, the larger barrier is raw material access. New entrants cannot simply enter tribal areas and begin purchasing seeds. The collection network requires years of community engagement, government permissions for MFP trading, and established aggregation infrastructure.

Manorama’s expansion strategy addresses both capacity and geographic diversification. The company commissioned a new fractionation plant in Raipur in 2024, increasing total capacity to 40,000 tonnes per annum. The company has also established subsidiaries in West Africa (for shea sourcing) and the UAE (for trading), signaling ambitions beyond India-centric operations. This geographic expansion hedges raw material risk while accessing shea supplies closer to source.

The customer base reveals competitive positioning. Manorama supplies major global brands including Ferrero, Mondelez, and Nestlé in confectionery, plus L’Oréal and The Body Shop in cosmetics. The long-term supply agreement with The Body Shop for mango butter, announced in 2023, demonstrates the company’s value in sustainable sourcing narratives that premium cosmetic brands seek. These relationships have been built over decades (Ferrero’s partnership dates to the 1990s) and represent switching costs that protect Manorama’s position.

Competition in India’s specialty fats market has intensified as domestic chocolate consumption grows. AAK India, with modern facilities and global parent company support, represents the most capable domestic competitor. However, the market appears to accommodate multiple players given distinct raw material bases and customer segments. Manorama’s focus on sal and mango-based products doesn’t directly compete with palm-based CBS manufacturers serving different quality tiers and applications.

The pricing dynamic favors CBE producers when cocoa butter prices spike. With cocoa prices reaching multi-year highs due to West African supply disruptions, chocolate manufacturers face pressure to increase CBE usage within regulatory limits. This creates volume opportunities but also attracts attention from larger players considering market entry. Manorama’s forest-sourced positioning provides some insulation. The raw materials cannot be commodity traded like palm oil or shea butter, making price-based competition less intense.

Proximity Advantage Over European Competitors

A critical but underappreciated competitive advantage is Manorama’s geographic proximity to raw material sources. European and American CBE manufacturers (AAK in Sweden, Bunge Loders in Netherlands, Cargill in the USA) are located far from both the Indian tribal forests that produce sal and mango kernels and the West African shea belt. This distance translates into higher logistics costs, longer supply chain lead times, and reduced ability to manage raw material quality from source.

Manorama’s facilities in Chhattisgarh sit within the heart of India’s sal seed production zone, while the company’s African subsidiaries operate directly in shea-producing countries. This dual positioning enables procurement cost advantages that European competitors cannot replicate even with superior manufacturing scale. Notably, even competitors like AAK, Mewah, Olam, and Cargill purchase CBE and stearin from Manorama due to the company’s cost effectiveness and unique product specifications. This is a remarkable validation of Manorama’s competitive position.

The competitive landscape appears set for consolidation and vertical integration. Global players will likely seek to secure raw material access in India, potentially through partnerships or acquisitions. Manorama’s scale and relationships make it an attractive partner or target, while its family ownership and community relationships complicate any transaction. The company’s listing in 2018 provided growth capital while maintaining promoter control at approximately 54%, suggesting the founding family intends to pursue independent growth rather than sale.

HOW THE BUSINESS ACTUALLY WORKS

Understanding Manorama requires tracing money through the system, from forest floor to Ferrero Rocher. The elegance lies in transforming near-zero-value raw materials into premium specialty fats through a series of value-adding steps, each protected by distinct competitive advantages.

Step 1: Collection Network Activation (The Foundation)

When sal trees flower and fruit during monsoon season (June-August), seeds fall to the forest floor across central India’s tribal belt. Manorama’s collection infrastructure activates through a three-tier pyramid: village-level collectors (predominantly women from scheduled tribes), local aggregators who consolidate from multiple villages, and regional collection centers with basic storage and transport.

The economics here matter. Tribal collectors earn ₹10-25 per kg of sal seeds gathered. This supplementary income often exceeds their agricultural earnings during collection season. Manorama’s aggregators typically pay ₹30-50/kg depending on quality and moisture content. Government Minimum Support Price for sal seeds (under the MFP scheme) provides a floor price, protecting both collectors and processors from market volatility.

This network wasn’t built overnight. Ashish Saraf and his predecessors spent decades establishing trust in tribal communities, often providing advance payments during harvest season when families need cash most. These relationships cannot be replicated through capital expenditure. They require cultural understanding, local language capability, and generational continuity. The company leverages a long-standing network of over 1,000 tribal collectors, self-help groups (SHGs), and forest communities, which it has nurtured over decades.

Raw Material Supply Security

The scale of natural production significantly exceeds Manorama’s procurement needs, providing headroom for continued growth:

Sal seeds contain 13-14% butter content and are collected primarily during the May to July season. Shea nuts have a significantly higher butter content of 45-50% and contain symmetrical triglycerides, making them a critical raw material for CBE formulation after fractionation.

Step 2: Seed Processing to Crude Fat

Seeds arrive at Manorama’s facilities in Raipur with varying moisture content and quality. Initial processing involves:

1. Cleaning and grading: Removing foreign matter, sorting by quality

2. Drying: Reducing moisture to prevent degradation during storage

3. Dehulling/Decortication: Separating the oil-bearing kernel from outer shell

4. Oil extraction: Using mechanical pressing (expeller) followed by solvent extraction to maximize yield

Sal kernels yield approximately 35-42% fat content, while mango kernels yield 10-15%. This extraction step is relatively commoditized, the equipment and processes are standard in the oilseed industry. Manorama’s advantage here lies in consistent raw material supply rather than processing superiority.

The crude fat at this stage has limited value, it contains impurities, free fatty acids, and compounds that affect color, odor, and stability. Selling crude fat would position Manorama as a commoditized raw material supplier, subject to price competition and margin compression.

Step 3: Refining, Bleaching, Deodorizing (RBD)

The RBD process transforms crude fat into a food-grade ingredient:

• Degumming and Neutralization: Removing phospholipids and free fatty acids through alkali treatment

• Bleaching: Using activated earth/clay to remove color pigments and oxidation products

• Deodorization: Steam distillation at high temperature and vacuum to remove volatile compounds that create off-flavors

This is where quality differentiation begins. Food-grade fats must meet strict specifications for free fatty acid content (typically <0.1%), color (measured on Lovibond scale), and peroxide value (indicating oxidation). Cosmetic-grade products face even tighter specifications. Manorama’s quality systems, certified to FSSC 22000 and multiple customer-specific audits, enable sales to premium customers who won’t accept substandard inputs.

Step 4: Fractionation (The Value Multiplier)

This is the critical step that transforms generic vegetable fat into Cocoa Butter Equivalent. Fractionation separates fat into components with different melting points through controlled crystallization:

1. Fat is melted and slowly cooled under precise temperature control

2. Higher-melting-point fractions (stearin) crystallize first

3. Liquid fraction (olein) is separated through filtration

4. Multiple passes produce narrow melting-point fractions matching cocoa butter specifications

The stearin fraction from sal fat (the hard component melting around 34-36°C) mimics cocoa butter’s behavior almost perfectly. This fraction commands premium pricing because it enables chocolate that snaps at room temperature but melts smoothly in the mouth. Stearin typically accounts for approximately 50% yield from exotic seeds like sal, shea, and mango, with the remaining 50% being olein (the liquid fraction).

Stearin: The Strategic Intermediate

Stearin serves a dual role in Manorama’s business model. It can be sold as a standalone product for applications in bakery shortenings, margarines, confectionery coatings, cosmetics (creams, soaps, candles), and industrial oleochemicals. However, its most valuable use is as the critical building block for CBE production, approximately 90% of Manorama’s stearin volumes are channeled into confectionery applications through CBE blending.

The company also produces enzymatic stearin, a premium variant that undergoes enzyme-based interesterification to achieve tailored melting profiles and higher functionality. Enzymatic stearin commands realizations up to 3.5x higher than base olein, underscoring its margin-accretive nature. This premium product represents Manorama’s move up the value chain from bulk specialty fats toward higher-margin, customized solutions.

The CBE production process blends stearin with Palm Mid-Fraction (PMF) to replicate the functional properties of natural cocoa butter. A typical CBE formulation requires 500-600 grams of stearin combined with 400-500 grams of PMF to produce 1 kg of CBE. This blending expertise (achieving specific triglyceride profiles that match customer specifications) represents accumulated know-how that differentiates Manorama from commodity fat processors.

Manorama’s fractionation capacity expansion from 15,000 TPA to 40,000 TPA represents the company’s strategic bet. Each additional tonne of fractionation capacity enables converting lower-value crude fat into higher-value CBE. The 25,000 TPA brownfield expansion commissioned in July 2024 cost approximately ₹80-100 crores, capital deployed specifically to capture value-added production. The expanded capacity reached 70% utilization by Q1 FY26, demonstrating strong demand pull from global customers.

Step 5: Product Customization and Customer Co-Development

Major chocolate manufacturers don’t buy generic CBE, they specify exact triglyceride profiles matching their chocolate formulations. Ferrero’s requirements for a Ferrero Rocher hazelnut-chocolate shell differ from Mondelez’s specifications for a Dairy Milk coating.

Manorama’s R&D team (led by founders with decades of fat chemistry expertise) works with customer technical teams to develop:

• Specific melting point ranges (±0.5°C tolerance)

• Triglyceride composition matching customer specifications

• Compatibility testing with customers’ cocoa butter sources

• Shelf stability validation under various storage conditions

This co-development creates switching costs. Once a customer’s production line is calibrated for Manorama’s CBE specifications, changing suppliers requires reformulation and revalidation. That’s a 6-12 month process that production managers avoid unless necessary.

Revenue Recognition and Cash Flow Timing

Understanding seasonality is critical:

• Q2 (July-September): Peak sal seed collection. High working capital deployment for inventory build

• Q3-Q4 (October-March): Production and delivery ramp. Revenue recognition accelerates

• Q1 (April-June): Lower sal collection. Mango kernel season begins. Capacity for shea processing

This seasonality creates cash conversion cycle patterns where working capital peaks in Q2, converts to receivables in Q3-Q4, and cash collection catches up by Q4/Q1. Investors watching quarterly results should expect margin variations tied to production timing rather than business deterioration.

UNIT ECONOMICS: WHY THIS BUSINESS PRINTS MONEY

The economic logic of Manorama’s business becomes clear when examining margins at each stage and the structural advantages driving profitability.

The Zero-Waste Production Model

Manorama operates a fully sustainable, zero-waste production process where every fraction of raw material is commercially monetized. A typical production run illustrates this efficiency:

This zero-waste model provides multiple revenue streams from a single procurement cost. De-oiled cakes, refinery residues, and olein are all sold for various applications, enhancing the company’s ESG profile while extracting maximum economic value from each kilogram of seeds procured.

Raw Material Cost Advantage

The foundational advantage is raw material cost, forest-sourced seeds cost a fraction of alternatives:

Even accounting for processing costs, CBE from forest seeds costs ₹350-500/kg versus cocoa butter at ₹1,500-3,000+/kg. This structural cost advantage persists regardless of market conditions, it’s embedded in the nature of raw materials.

Processing Margin Breakdown

For every ₹100 of CBE revenue (selling at approximately ₹400/kg for premium fractionated product):

FY25’s Margin Expansion Explained

Manorama’s FY25 results showed dramatic margin improvement, EBITDA margin expanded from ~16% (FY24) to ~25% (FY25). Three factors drove this:

1. Operating leverage from new capacity: The 25,000 TPA fractionation plant added high-value production without proportional fixed cost increases. Fractionation’s incremental margin is significantly higher than company average, pulling overall margins up as its share of production increased.

2. Cocoa butter price spike creating demand pull: Natural cocoa butter prices became highly volatile and peaked in late 2024, reaching historic highs of US$43/kg before settling at current levels of ~US$15/kg (versus stable CBE pricing of US$5-5.5/kg). Even at normalized prices, cocoa butter trades at 2-3x CBE prices, making CBE substitution economically compelling. This accelerated the shift from NCB to CBE because of CBE’s stable pricing and customized solutions.

3. Product mix improvement: The share of value-added products (CBE and stearin) in the sales mix increased from 51% in FY24 to 73% in FY25. CBEs command EBITDA margins of approximately 35% versus ~10% for other segments, making them the dominant driver of both revenue and margin expansion.

The shift toward CBE-dominant revenue mix is the most important driver of sustainable margin expansion. Management’s strategy is clear: as fractionation capacity scales, CBE’s share of revenue is projected to increase from 30% in FY25 to approximately 50% by FY28, while stearin’s relative weight moderates despite continued volume growth.

CUSTOMER ANALYSIS: WHO BUYS AND WHY

Manorama’s customer base divides into two distinct segments with different buying behaviors, switching costs, and growth dynamics.

Chocolate & Confectionery (80% of Revenue)

Manorama supplies customized products like stearin, CBE, and specialty fats to well-known brands in the chocolate, confectionery, and cosmetics industries. These products undergo strict quality control and product approval processes, with annual contract renewals providing revenue visibility. In FY25, 73% of Manorama’s turnover came from export markets (up from 57% in FY24), with sales spanning over 20 countries.

Ferrero Group (Estimated 30-40% of chocolate revenue)

Ferrero’s relationship with Manorama predates the company’s formal incorporation. The partnership began when Janakilal Agarwal demonstrated that sal-based fats could stabilize Ferrero Rocher’s chocolate shell in tropical climates where pure cocoa butter formulations suffered bloom and melting issues.

Why Ferrero stays:

• Technical validation: Decades of product performance in market

• Supply security: Manorama’s forest network provides reliable supply when global cocoa markets tighten

• Sustainability narrative: “Forest-sourced” ingredients align with Ferrero’s sustainability commitments

• Cost management: CBE provides hedge against cocoa butter volatility

Switching risk: Low. Ferrero would need to reformulate products and find alternative suppliers capable of meeting their exacting specifications. That’s a 12-18 month process with execution risk.

Mondelez International (Estimated 20-30% of chocolate revenue)

Mondelez’s portfolio (Cadbury, Milka, Toblerone) spans mass-market to premium segments. Their CBE usage likely varies by product line and geography, with more usage in compound coatings and fillings, less in premium bars.

During Mondelez’s Q2 2024 earnings call, CEO Dirk Van de Put discussed challenges from cocoa pricing, stating the company would use “selective pricing strategies” and explore “new products at varied price points.” This signals openness to cost management through ingredient optimization. That’s favorable for CBE suppliers.

Other Chocolate Customers

Manorama supplies Nestlé, Hershey’s, Barry Callebaut (the world’s largest chocolate processor), Mars Wrigley, and regional confectionery companies. The customer base has diversified significantly as capacity expanded, reducing concentration risk. Mars and Barry Callebaut have engaged with Manorama specifically around the company’s Brazilian toll manufacturing arrangement (discussed below), signaling new customer acquisition tied to geographic expansion.

Expanded Global Client Portfolio

The company has established long-standing relationships with leading Fortune 500 corporations across chocolate, confectionery, bakery, dairy, cosmetics, and HoReCa industries. Key client relationships by segment:

Solutions are often co-developed with customers, embedding Manorama’s products into formulations through long product qualification cycles that create significant switching costs.

Cosmetics & Personal Care (20% of Revenue)

L’Oréal Group

L’Oréal’s Garnier and L’Oréal Paris brands use plant-based butters in hair care, skin care, and lip products. Mango butter’s moisturizing properties (high oleic and stearic acid content) suit leave-in conditioners and body lotions.

The Body Shop

The Body Shop’s ethical sourcing narrative aligns perfectly with Manorama’s forest-sourced model. The company’s Community Trade program sources ingredients from marginalized communities globally, Manorama’s tribal collection network fits this positioning precisely.

The 2023 supply agreement announcement confirmed a long-term partnership for mango butter, providing revenue visibility and validating Manorama’s value in sustainability-focused supply chains.

Cosmetics Segment Dynamics

• Higher realizations: Cosmetic-grade butters command 20-40% premium over food-grade equivalents

• Smaller volumes: Cosmetic applications use grams per product versus kilograms in chocolate

• Specification sensitivity: Organic certification, traceability documentation, and batch consistency matter more than in food applications

• Longer sales cycles: New product development in cosmetics takes 18-36 months

HoReCa (Hotels, Restaurants, Catering) – Emerging Segment

The global HoReCa sector, valued at USD 3.39 trillion in 2023, is projected to reach USD 6.45 trillion by 2032, implying a 6.7% CAGR. India’s HoReCa industry, valued at USD 212 billion in 2023, is expected to nearly double to USD 443 billion by 2035. This massive expansion creates structural growth tailwinds for specialty fat suppliers.

Manorama has entered the HoReCa market with palm-free blends and customized fats for bakery, confectionery coatings, and industrial frying applications. The HoReCa segment is particularly attractive because it provides a margin-accretive outlet for the company’s olein business (the lower-value liquid fraction from fractionation). Rather than selling olein at commodity prices, Manorama can formulate customized blends for food service operators seeking clean-label, sustainable ingredients.

With growing demand for clean-label specialty fats and a strong B2B focus, Manorama is well-positioned to serve HoReCa clients across bakery, confectionery, and industrial frying segments. The company’s MILCOCREAM product line serves this segment with bake-stable fillings and solutions for frozen desserts.

PRODUCTS & SERVICES BREAKDOWN

Manorama’s product portfolio spans multiple raw material sources, processing stages, and end applications. Understanding the product matrix helps identify margin drivers and growth opportunities.

Cocoa Butter Equivalents (CBE) : Premium Segment

CBEs are the highest-margin products, commanding prices of ₹350-500/kg depending on specification and customer.

Technical differentiation: Manorama’s sal-based CBE offers specific triglyceride profiles (high SOS content) that competitors using palm fractions cannot replicate. This creates a defensible niche.

Cocoa Butter Substitutes (CBS) : Volume Segment

CBS products are lower-cost alternatives for compound chocolate and coatings where exact cocoa butter compatibility isn’t required.

• Lauric CBS: Palm kernel oil-based; good gloss and snap but not cocoa butter-compatible

• Non-lauric CBS: Harder fats for tropical climate stability

Manorama participates in this segment but at lower margins than CBE. It’s volume rather than premium business.

Cosmetic Butters : Specialty Segment

Cosmetic butters achieve 20-40% premium over food-grade equivalents because of stricter specifications, certification requirements, and smaller batch sizes.

Specialty Oils

Manorama produces refined oils for various applications:

• Sal oil: Industrial and food applications

• Mango oil: Cosmetic formulations

• Castor oil, Neem oil: Specialty applications

These represent lower-margin products, often by-products of butter production, but contribute to capacity utilization and raw material yield optimization.

Branded Product Lines

• MILCOA: Branded CBE product for chocolate applications

• MilcoSpread: Specialty fat for spreads and fillings

• Cosmetic butter range: Organic-certified butters for personal care

Product Development Pipeline

Management commentary suggests focus on:

• Plant-based fats for dairy alternatives (ice cream, cheese)

• Clean-label bakery fats (replacing hydrogenated oils)

• Expanded cosmetic butter range (mahua, phulwara)

• Palm-free alternatives to address sustainability concerns in European markets

• Specialty fillings and spreads building on the MILCOA® range

• Customized cosmetic ingredients engineered for skin-care, hair-care, and medicinal applications

These extensions leverage existing raw material access and processing capabilities while accessing higher-growth application segments.

R&D Capabilities and Client Co-Development

The company follows a client-centric co-development model, working directly with Fortune 500 confectionery and cosmetics players to design customized solutions. This approach strengthens customer stickiness by embedding Manorama’s products in long product qualification cycles. The R&D team (led by founders with decades of fat chemistry expertise) develops products meeting customer-specific triglyceride profiles, melting point ranges (±0.5°C tolerance), and compatibility requirements.

Key R&D focus areas include:

• Fat modification technologies including enzymatic interesterification for tailored melting profiles

• Crystallization behavior optimization for chocolate bloom resistance

• Compatibility testing with various cocoa butter sources

• Shelf stability validation under tropical storage conditions

Comprehensive Certification Portfolio

Product and process credibility is reinforced by a comprehensive suite of global certifications that enable acceptance among blue-chip clients:

KEY RISKS TO THE BUSINESS MODEL

1. Cocoa Butter Price Normalization (Impact: High; Probability: Medium)

The 2024-25 cocoa price spike created exceptional demand for CBE as chocolate makers sought cost relief. If West African cocoa production recovers and prices return to historical US$5-10/kg range, the urgency driving CBE adoption diminishes.

Mitigant: Even at normalized cocoa prices, CBE remains 50-60% cheaper. The cost-saving case persists. Additionally, sustainability and supply diversification motivations for CBE usage don’t depend on price differentials.

2. Customer Concentration (Impact: High; Probability: Medium)

Estimated top 3 customers represent ~50-55% of revenue. Loss of a major customer (Ferrero contract non-renewal, Mondelez supplier consolidation) would significantly impact financials.

Mitigant: Long qualification cycles and co-developed specifications create switching costs. Capacity expansion enables customer diversification. Cosmetics segment growth reduces chocolate dependency.

3. Raw Material Supply Disruption (Impact: High; Probability: Low)

Climate change affecting sal flowering, government policy restricting MFP collection, or tribal community relations deteriorating could disrupt raw material access.

Mitigant: Multi-seed sourcing (sal, mango, shea) provides redundancy. Geographic diversification with West African shea operations reduces India-specific risk. Government relations appear strong (state MoUs, recognition awards).

4. Regulatory Changes (Impact: Medium; Probability: Low)

Tightening of CBE regulations in key markets (EU reducing 5% allowance) or Indian regulations further restricting domestic chocolate CBE use would limit addressable market.

Mitigant: Regulatory trend has been toward relaxation, not restriction. EU directive has been stable for 20+ years. Cosmetics segment unaffected by food regulations.

5. Competition from Integrated Players (Impact: Medium; Probability: Medium)

AAK, Bunge Loders, or other multinationals could invest in Indian sal/mango sourcing infrastructure, using global scale to compete on price.

Mitigant: Sourcing network requires decades to build, not a capital deployment exercise. Manorama’s customer relationships predate competitors’ interest. Product differentiation (sal-based unique profiles) provides technical moat.

6. Foreign Exchange Volatility (Impact: Medium; Probability: High)

With 73% export revenue, INR appreciation versus EUR/USD compresses margins when measured in rupees.

Mitigant: Natural hedge from some imported inputs (shea from Africa). Pricing contracts may include currency adjustment mechanisms. This is an earnings volatility risk rather than business model risk.

7. Quality/Food Safety Incident (Impact: Very High; Probability: Very Low)

A contamination incident traced to Manorama’s products could result in customer departures, regulatory action, and reputational damage.

Mitigant: FSSC 22000 certification, customer audit compliance, and quality systems are in place. The “wild-harvested” sourcing model has inherent contamination risks that must be managed through testing protocols.

8. Environmental and Social Risks in Tribal Sourcing Regions (Impact: High; Probability: Low)

Manorama’s operations are concentrated in forest-rich tribal regions of central India and West Africa, which are both critical to its raw material base and inherently exposed to environmental and social sensitivities. Any disruption in these regions (whether from climate events, political instability, or community conflicts) could affect operations, infrastructure, and stakeholder confidence.

Mitigant: The company maintains strict compliance with local environmental and social regulations, conducts regular impact assessments, and engages transparently with tribal communities. Inclusive development initiatives support community welfare and strengthen long-term partnerships, reinforcing Manorama’s reputation as an ESG-compliant operator.

9. African Subsidiary Regulatory Risk (Impact: Medium; Probability: Medium)

Manorama’s expansion into West African countries (Ghana, Burkina Faso, Togo, Nigeria) exposes the company to unstable regulatory frameworks, political volatility, and currency risks in these markets. Policy changes affecting agricultural commodity exports or foreign ownership could impact operations.

Mitigant: Diversification across multiple African countries reduces single-country risk. Local subsidiary structures with local partnerships provide regulatory navigation capability.

Risk Assessment Matrix

GROWTH TRIGGERS

Capacity Expansion & Operational Leverage

• New 25,000 TPA fractionation plant commissioned in July 2024, bringing total fractionation capacity to 40,000 TPA. This capacity reached 70% utilization by Q1 FY26, demonstrating strong demand pull

• Capacity is set to increase nearly 7x over the next 4 years, with plans to reach 97,000 TPA of fractionation capacity by FY28 through successive expansions

• Management targeting continued capacity expansion to meet growing global demand for sustainable CBE and specialty fats

Geographic Expansion – Africa

• MoU signed with Government of Burkina Faso (August 2025) to establish a new shea nut processing factory through wholly-owned subsidiary Manorama Burkina Industries SA, with investment of CFA 1.6 billion

• Expanding African footprint across Ghana, Nigeria, Togo, Benin, and Burkina Faso for shea sourcing, utilizing associates like Manorama Africa Limited (MAL) to streamline procurement directly from millions of tribal women

• Africa produces approximately 1.76 million MT of shea nuts annually. Manorama sources 40,000-80,000 MT (~3-5% of available supply), leaving ample headroom for growth without structural supply constraints

Geographic Expansion – Latin America (Major Untapped Opportunity)

• Strategic partnership with DEKEL Agroindústria to produce CBE and specialty fats in Brazil through a toll manufacturing arrangement, with production commencing November 2025

• First global CBE producer to manufacture in Brazil, positioning Manorama to serve the fast-growing ~50,000 TPA Latin American CBE market directly from regional facilities

• Major customers including Barry Callebaut and Mars have already engaged with Manorama to secure capacity from the Brazilian facility, providing immediate orderbook visibility

• This geographic expansion is margin-accretive and opens an entirely untapped market segment previously served only through exports from Europe/Asia

Product Mix Premiumization

• Shift toward higher-value fractionated CBE products (MILCOA, MilcoSpread) commanding better margins versus crude/RBD fats

• Growing cosmetics segment (currently ~20% of revenue) offers 20-40% margin premium over food-grade applications. Management has indicated cosmetics growth is a strategic priority

Favorable Industry Tailwinds

• Regulatory environment supportive: EU Chocolate Directive permits 5% CBE in chocolate products. Sustainability and traceability requirements favor forest-sourced suppliers like Manorama

Sustainability Moat Strengthening

• Forest-sourced, tribal community-based procurement model increasingly valuable as global corporations demand supply chain sustainability

• Long-term supply agreements with premium cosmetics brands (The Body Shop mango butter contract in 2023) validating Manorama’s position in ESG-focused supply chains

Disclaimer: I am not a registered analyst. I’m just a student trying to study different businesses/sectors. Don’t take my word for it; try to study the business independently. I might have positions in the securities discussed.

Subscribe now

If you want to see what I’ve been building, you can check it out here

More of Me

Business Overview

Jamna Auto Industries makes springs for trucks. It is the largest manufacturer of automotive leaf springs in India. The company ranks among the top three producers globally. It has operated for over 65 years since incorporation in 1965.

The company commands 62 to 65 percent of the commercial vehicle OEM market for leaf springs in India. In the parabolic spring segment, its share reaches 95 percent. This position makes Jamna the default supplier for truck manufacturers.

Jamna operates 10 manufacturing plants across India. These facilities are in Yamunanagar, Malanpur, Chennai, Jamshedpur, Hosur, and Pune. All plants hold ISO certification. The combined annual capacity exceeds 300,000 metric tonnes of springs.

Products and Segments

Jamna produces five main product categories. These are multi-leaf springs, parabolic springs, lift axles, trailer mechanical suspensions, and air suspensions. Each product serves a distinct function in commercial vehicle suspension systems.

Multi-Leaf Springs

Multi-leaf springs are the traditional suspension solution for commercial vehicles. They consist of multiple curved steel plates stacked together. The leaves flex under load to absorb road shocks. This design has served trucks and buses for decades.

These springs suit heavy-duty applications. Mining trucks, tippers, and off-road vehicles use them. The robust design handles rough terrain and extreme loads. Jamna holds 67 percent market share in conventional leaf springs.

Parabolic Springs

Parabolic springs represent the modern evolution of leaf spring technology. The steel thickness tapers from the center toward the ends. This geometry distributes stress evenly across the spring length. The design requires fewer leaves to carry the same load. Parabolic springs weigh 40 percent less than conventional multi-leaf springs. This reduction directly improves fuel efficiency for trucks. It also increases payload capacity. A lighter suspension means more cargo per trip.

Jamna developed this technology through a collaboration with NHK Spring of Japan. The partnership brought advanced manufacturing techniques to India. Jamna now controls 95 percent of the parabolic spring market in the country.

Lift Axles

Lift axles are auxiliary axles that can be raised or lowered. Trucks use them when carrying heavy loads. The axle lowers to distribute weight across more wheels. When the truck runs empty, the axle lifts to reduce tire wear and fuel consumption.

Jamna offers both steerable and non-steerable lift axles. These products improve fuel economy by 3 to 5 percent when running unladen. The reduced tire contact also cuts maintenance costs. Fleet operators see the benefit in total cost of ownership.

Trailer Suspensions

Jamna manufactures mechanical suspensions for trailers. These systems include spring assemblies, hangers, and mounting hardware. The company offers complete suspension solutions rather than individual components.

Trailer air suspensions form a separate product line. These systems use air springs instead of steel. They provide a smoother ride for sensitive cargo. The ride height stays consistent regardless of load. Jamna makes these for mono, twin, and tridem axle configurations.

Air Suspension Systems

Jamna entered the air suspension market through a technology tie-up with Ridewell Corporation of the USA. The partnership provides design and manufacturing expertise for air suspension axles. This product serves the bus and trailer segments.

The company launched air suspension kits for buses in 2025. These kits allow bus operators to upgrade existing vehicles. The aftermarket opportunity extends the addressable market beyond new vehicle sales.

Allied Components

Jamna produces supporting components through its subsidiary Jai Automotive Components. The product range includes U-bolts, center bolts, bushes, hanger brackets, spring pins, and air bellows. These parts complete the suspension system.

A new plant in Pithampur near Indore will manufacture U-bolts and springs. The first phase became operational in April 2025. This facility adds capacity for allied components that accompany the main spring products.

Technology Partnerships

Jamna has built its product portfolio through two key technology partnerships. NHK Spring of Japan provided tapered leaf spring technology. The collaboration transferred manufacturing know-how for parabolic springs. This enabled Jamna to offer weight-saving suspension solutions.

Ridewell Corporation of the USA partnered for air suspension axles. The American company specializes in trailer suspension systems. This tie-up brought air suspension capability to Jamna’s product range. The partnership covers both design and manufacturing.

Customers

Tata Motors and Ashok Leyland are the two largest customers. Together they account for roughly 65 percent of Jamna’s revenue. Both companies are leading truck manufacturers in India. Tata Motors holds 46 percent of the domestic MHCV market. Ashok Leyland holds 31 percent.

The customer list extends to other OEMs. Daimler India, Volvo Eicher, Force Motors, and AMW all source springs from Jamna. The company supplies suspension components across the commercial vehicle industry.

Jamna also serves the replacement market. The aftermarket division offers 800 part numbers. The company recently strengthened distribution in South India. Aftermarket sales provide revenue diversification beyond OEM dependence.

Export markets contribute to the business. Jamna ships to over 15 countries. The company plans to add 40 new export markets within 12 months. International sales reduce reliance on the Indian commercial vehicle cycle.

Industry Context

CV Cycle Turning Up

The Indian commercial vehicle industry stands at the early stages of an upcycle. CV cycles from peak to peak have averaged six years historically. The next upcycle is likely to culminate in FY27 to FY28. Initial signs were visible in November 2025 when domestic MHCV volumes grew 31 percent year-on-year. The MHCV industry grew moderately in the past few years. Growth is now expected to accelerate to 8 percent in FY26 and 10 percent in FY27. This compares to earlier expectations of 4 to 5 percent. MHCV volumes are projected at 404,000 units in FY26, 444,000 units in FY27, and 466,000 units in FY28.

Light commercial vehicles show similar momentum. LCV volumes are expected at 646,000 units in FY26, 698,000 units in FY27, and 733,000 units in FY28. The growth rates are 8 percent, 8 percent, and 5 percent respectively. LCV demand picked up well after GST cuts. Exports are also improving.

Structural Drivers

Four structural factors support the upcycle. First, freight rates are firming up. Rising rates improve profitability for fleet operators. Better economics encourage new vehicle purchases and trigger replacement demand.

Second, GST cuts have improved affordability. Lower rates increased operator margins. The September 2025 reform reduced tax on commercial vehicles from 28 to 18 percent. This cut acquisition costs and enabled higher-tonnage truck purchases.

Third, the fleet is aging. The average age of trucks in the system is now close to 10 years. The long-term norm is 7 to 7.5 years. This gap highlights the likelihood of a replacement cycle. Old trucks need to be replaced.

Fourth, regulatory norms will trigger pre-buying. New safety and braking regulations become effective around FY27 to FY28. These norms will increase vehicle costs. Fleet operators will advance purchases to avoid higher prices. This creates a demand surge before implementation.

Tractor-Trailer Mix Shift

Tractor-trailers have gained share in the industry mix. They increased from 9 percent in FY21 to 22 percent in FY25. This shift benefits Jamna’s trailer suspension business. Each tractor-trailer requires suspension systems for both the truck and the trailer.

The Dedicated Freight Corridor is now 96 percent operational across Eastern and Western regions. However, non-bulk cargo at 30 percent of freight continues to rely on road transport. The diversified CV freight base limits the rail impact on truck demand. Tractor-trailers may see some normalization as bulk freight shifts to rail.

Infrastructure Tailwinds

Infrastructure spending supports the outlook. Road construction, logistics parks, and warehousing create demand for trucks. The government’s capital expenditure program continues. These projects need commercial vehicles for execution and subsequent freight movement.

New model launches across powertrains strengthen near-term prospects. OEMs are introducing vehicles that meet upcoming emission and safety norms. Healthier demand indicators across segments point to sustained momentum through FY28.

Competitive Position

Jamna’s dominant market share creates a self-reinforcing position. OEMs prefer a single source for suspension components. This reduces supply chain complexity. Jamna’s 10 plants across India ensure proximity to major truck manufacturing hubs.

The technology partnerships provide product differentiation. NHK Spring’s tapered leaf technology offers weight savings competitors cannot match. The Ridewell tie-up adds air suspension capability. Few Indian players have equivalent technical depth.

Scale economics favor the market leader. Spring manufacturing requires significant capital investment. Jamna’s 300,000 tonne capacity spreads fixed costs. Smaller competitors face higher per-unit costs. The installed base creates a barrier to entry.

Competition comes from Munjal Showa, NHK Automotive Components India, Vikrant Springs, and smaller regional players. None matches Jamna’s scale in the commercial vehicle segment. The competition is fragmented.

Growth Triggers

CV Upcycle Leverage

Jamna’s revenue tracks MHCV volumes closely. The expected 8 to 10 percent volume growth in FY26 and FY27 will flow through to spring demand. With 62 to 65 percent market share, Jamna captures most of the incremental volume. Operating leverage should improve margins as utilization rises.

Parabolic Spring Adoption

Parabolic springs carry higher value than conventional leaf springs. Each conversion from multi-leaf to parabolic increases revenue per vehicle. Fuel efficiency regulations favor lighter components. OEMs are shifting specifications toward parabolic springs.

Jamna controls 95 percent of this segment. Rising adoption directly benefits the company. The 40 percent weight reduction appeals to fleet operators seeking lower operating costs. Payback periods are short given fuel savings.

Trailer Market Growth

The tractor-trailer mix shift from 9 to 22 percent of the industry creates demand for trailer suspensions. Each trailer needs mechanical or air suspension systems. Jamna’s trailer suspension products address this growing segment.

The company launched new trailer mechanical suspensions in 2025. It also introduced air suspension for trailers. These products target the aftermarket and replacement demand. The trailer market could outgrow the truck market.

Export Expansion

Jamna is pursuing European expansion. The company showcased its portfolio at Automechanika Dubai 2025. It plans to add 40 new export markets. International sales provide diversification from domestic cycles.

The aftermarket export segment offers 800 part numbers. These replacement springs serve global truck populations. Export revenue is less volatile than OEM sales. Currency tailwinds can boost margins on foreign sales.

Aftermarket Development

Jamna is building its aftermarket presence. The company strengthened distribution in South India in 2025. It launched new products specifically for replacement demand. The aftermarket offers higher margins than OEM supply.

Allied components like U-bolts and bushes expand the addressable market. The Indore plant adds capacity for these products. Complete suspension kits bundle multiple components per sale.

Risks

Cyclicality

Commercial vehicle sales are cyclical. The peak-to-peak cycle averages six years. While the current position is early in an upcycle, the eventual downturn will affect Jamna. MHCV volumes have historically swung between peaks of 276,000 units in FY07 to 390,000 units in FY19.

Technology Disruption

Electric trucks may change suspension requirements. Battery weight alters load distribution. Air suspensions could gain share from steel springs. Jamna’s product portfolio may need to evolve.

Raw Material Costs

Steel is the primary input. Price volatility affects margins. The ability to pass through cost increases depends on OEM relationships. Long-term contracts may lag spot market movements.

If you want to see what I’ve been building, you can check it out here

Growth Triggers

Now, let’s get into today’s piece.

Samhi Hotels operates 31 hotels with 4,862 rooms across 13 cities in India. The company partners with Marriott, Hyatt, and IHG under long-term management agreements. Unlike most hotel companies that build from scratch, Samhi buys existing properties, renovates them, and hands them to global brands for operations.

This approach has made Samhi one of the fastest-growing hotel owners in India by rooms added per year.

Business Model

Samhi acquires underperforming properties in high-demand locations, spends capital on renovation and rebranding, then contracts Marriott, Hyatt, or IHG to run day-to-day operations.

The model works like this: Samhi identifies a hotel trading below replacement cost in a strong commercial corridor. It buys the asset, invests in upgrades, and attaches a global brand. The brand brings distribution reach, loyalty programs, and operating expertise. Samhi collects the property-level profits minus management fees.

Marriott operates 66% of Samhi’s rooms. Hyatt operates 17%. IHG operates 15%. The remaining 2% is unbranded.

Building a hotel from the ground up in India takes five to seven years. The process involves land acquisition, zoning approvals, construction, brand affiliation, staffing, and ramp-up. Capital remains tied up for years before generating returns. Buying an existing property compresses this timeline. Samhi can acquire, renovate, and rebrand a hotel in 18 to 24 months. Cash flows begin sooner. Risk decreases because the asset already exists and demand in the micro-market is observable.

Sheraton Hyderabad shows how this works. Samhi acquired the property in 2015 when it yielded roughly 2% on invested capital. The hotel had 158 rooms at acquisition. Samhi invested in renovation and expansion. By FY19, RevPAR had grown to INR 4,100. By FY23, it reached INR 6,050. By FY25, with 272 rooms, RevPAR hit INR 9,140. The property now targets 25%+ return on capital employed with 326 rooms upon full expansion.

Portfolio Segments

Samhi divides its hotels into three categories based on brand positioning and pricing.

Upper-Upscale and Upscale includes properties like Hyatt Regency Pune, Renaissance Ahmedabad, Sheraton Hyderabad, Courtyard Bangalore, and Hyatt Place Gurugram. These hotels target corporate travelers, conferences, and events. They command higher room rates and generate stronger margins. This segment currently holds 1,074 rooms across five properties but contributes 43% of room revenue despite holding only 22% of inventory.

Upper Mid-scale covers Fairfield by Marriott and Four Points by Sheraton properties. These hotels sit below the upscale tier but above budget options. They attract business travelers seeking reliable service at moderate prices. Samhi operates 2,189 rooms in this segment across multiple cities including Bangalore, Pune, Hyderabad, Chennai, and Goa.

Mid-scale consists primarily of Holiday Inn Express hotels. These properties focus on value-conscious travelers and serve markets like Ahmedabad, Bangalore, Pune, Gurugram, Hyderabad, Nashik, and Chennai. The segment holds 1,560 rooms but contributes only 15% of revenue while holding 34% of inventory.

The gap between room inventory share and revenue share reflects the pricing power of premium hotels. Upper-upscale properties command rates roughly 60% above the portfolio average. Mid-scale runs about 40% below average.

Geographic Footprint

Samhi’s hotels cluster around India’s major business centers.

Bangalore holds 22% of the portfolio. Hyderabad follows at 17%. Pune accounts for 18%. Delhi-NCR represents 11%. Chennai contributes 9%. The remaining inventory spreads across Ahmedabad (9%), Goa (3%), Coimbatore (3%), Visakhapatnam (2%), Nashik (2%), Jaipur (2%), and Kolkata (2%).

The location strategy targets high-density micro-markets near airports, tech parks, and commercial districts. These areas face barriers to new entry due to land scarcity, long approval timelines, and fragmented ownership. Hotels already operating in these corridors hold structural advantages.

Tier-1 cities generated 13% ROCE in FY25 compared to just 6% from Tier-2 markets. This gap explains why all future expansion targets Tier-1 and metro markets. Office space absorption drives hotel demand in these markets. Bangalore absorbed 13.1 million square feet of office space in FY25. Hyderabad absorbed 8.4 million. Pune absorbed 5.8 million. Delhi-NCR absorbed 8.7 million. When companies lease offices, they also need hotel rooms for visiting employees, clients, and event attendees.

Growth Pipeline

Samhi plans to add roughly 1,500 rooms through FY30, representing a 30% increase in operational inventory over 4-5 years.

Completed projects include Holiday Inn Express Greater Noida (133 rooms), Holiday Inn Express Kolkata (113 rooms), Sheraton Hyderabad expansion (12 rooms), and Holiday Inn Express Whitefield Bangalore expansion (56 rooms).

Fit-out stage projects include 42 additional rooms at Sheraton Hyderabad and 22 rooms at Hyatt Regency Pune.

Design stage projects include:

• W Hotel Hyderabad: 170 rooms, greenfield expansion

• Courtyard by Marriott Pune: 217 rooms, rebranding from Four Points by Sheraton

• Tribute Portfolio Bangalore: 142 rooms, rebranding from Trinity

• Tribute Portfolio Jaipur: 114 rooms, rebranding from Four Points by Sheraton

• Fairfield Sriperumbudur expansion: 86 rooms

• Westin Whitefield Bangalore: 220 rooms, greenfield expansion

• Mid-scale asset in Hyderabad Financial District: 260 rooms, cold-shell fit-out under variable lease

The largest project is a dual-branded Westin and Fairfield development in Navi Mumbai. Phase 1 adds approximately 400 rooms. Full build-out reaches 700 rooms. This marks Samhi’s entry into the Mumbai Metropolitan Region.

The Navi Mumbai project sits near the upcoming Navi Mumbai International Airport and DY Patil Stadium. The Atal Setu bridge improves connectivity. Total investment runs approximately INR 10 billion. Cost per key falls below typical Mumbai replacement rates. At full capacity, the property targets INR 1.80 to 1.85 billion in annual EBITDA.

The Hyderabad Financial District project follows a different structure. Samhi takes a long-term variable lease rather than owning the land and building. The lessor constructs the building shell. SAMHI funds only interior fit-out. This keeps cost per key at INR 45 to 50 lakh, well below typical levels.

City-wise, the planned inventory addition breaks down as: Navi Mumbai (47%), Hyderabad (31%), Bangalore (15%), Chennai (6%), and Pune (1%).

Premiumization Strategy

SAMHI is shifting its portfolio toward higher-priced segments. The upper-upscale and upscale segment currently contributes 43% of room revenue from 22% of inventory. By FY30, room contribution from this segment is expected to reach 43% of total keys as well, up from current levels. This shift happens through rebranding existing properties and adding new upscale inventory.

The Four Points by Sheraton in Pune Viman Nagar will convert to a Courtyard by Marriott. The Four Points in Jaipur will rebrand to Tribute Portfolio. The Trinity property in Bangalore Whitefield will become Tribute Portfolio. Each conversion moves the hotel up the brand ladder.

New builds like Westin Whitefield, W Hotel Hyderabad, and the Westin portion of Navi Mumbai add fresh upscale inventory. The Financial District Hyderabad project adds mid-scale rooms but does so in a micro-market where Samhi already operates Sheraton and Fairfield properties, creating full price-segment coverage.

Upper-upscale hotels generate higher revenue per room. They also produce stronger margins due to better pricing power and event revenue. The upscale and above segment for SAMHI has higher non-room revenue contribution (56% of room revenue) compared to other segments. ARR is expected to register approximately 10% CAGR over FY25-28E. F&B revenues are expected to deliver 8% CAGR over the same period.

Leasehold vs Freehold Assets

Samhi’s portfolio consists of both freehold (owned) and leasehold (rented) assets. The distinction matters for capital efficiency. Leasehold assets generated 18% ROCE in FY25 compared to 11% for freehold properties. The lower capital investment required for leaseholds improves returns even if absolute profits are smaller.

Currently, leasehold assets contribute 13% of revenue. Samhi targets increasing this to 20% over time. The Hyderabad Financial District project under variable lease follows this strategy.

GIC Partnership

In 2024, GIC, Singapore’s sovereign wealth fund, invested approximately INR 7,500 million in SAMHI. Of this amount, INR 6,000 million went toward debt reduction. The remainder provides growth capital. GIC took a 35% stake in five upscale hotel properties that form a joint venture platform.

The partnership delivers three benefits:

• First, it reduced leverage. Net debt to EBITDA dropped from 7.2x in FY24 to 5.1x in FY25 and stood at 2.9x as of September 2025.

• Second, it provides growth capital without diluting Samhi’s equity stake in the broader business. The GIC structure funded approximately INR 1.5 billion in early acquisitions.

• Third, it creates a vehicle for future upscale acquisitions where Samhi can source deals and contribute them to the JV platform, sharing ownership with GIC while maintaining operational control.

Operating Metrics

Occupancy ran at 75% in the September 2025 quarter, up from 72% in the same period of 2024.

Average room rate reached INR 6,997, up 6% year over year. RevPAR (revenue per available room) hit INR 5,026 in the September 2025 quarter, up from INR 4,529 a year earlier.

Portfolio-wide ARR increased from INR 5,316 in FY23 to INR 6,285 in FY25. RevPAR rose from INR 3,803 in FY23 to INR 4,670 in FY25. Occupancy improved from 72% in FY23 to 74% in FY25.

These metrics reflect both industry tailwinds and portfolio improvement. Demand for Indian hotel rooms continues to outpace supply growth. Domestic leisure travel, corporate events, and conference activity remain strong. Foreign tourist arrivals have recovered but remain below pre-pandemic levels, providing further upside as international travel normalizes.

H1 FY26 Performance and H2 Outlook

SAMHI posted 11% revenue growth in H1 FY26. This was impacted by geopolitical tensions and heavy monsoons.

Growth is expected to pick up in H2 due to several factors:

• New inventory absorption: Holiday Inn Express Kolkata (113 rooms), Holiday Inn Express Bangalore expansion (56 rooms), and Trinity Bangalore (142 rooms) are now operational and ramping up.

• Planned room additions: Sheraton Hyderabad adds 42 rooms. Hyatt Regency Pune adds 22 rooms.

• Seasonal strength: Q3 and Q4 typically see strong MICE (meetings, incentives, conferences, exhibitions) demand in Bangalore and Hyderabad, SAMHI’s core markets.

• Renovation impact: Planned renovation and rebranding of Trinity Bangalore, Four Points Pune, and Four Points Jaipur should drive ARR growth in FY27 and FY28.

Balance Sheet and Debt Reduction

SAMHI has seen consistent net debt reduction over the past year.

• Gross debt declined from INR 26.9 billion in FY23 to INR 21.3 billion in FY25. It is expected to reach INR 15.3 billion by FY28.

• Cash and equivalents stood at INR 700 million in FY25 and are expected to reach INR 7.6 billion by FY28.

• Net debt to EBITDA ratio fell from 10.8x in FY23 to 5.1x in FY25. It is expected to decline to 1.2x by FY28.

• Interest rates on borrowings have declined from 13% to 8.5% currently. Annualized interest costs dropped from INR 3,940 million in Q1 FY24 to INR 1,250 million in Q2 FY26.

The interest rate reduction was supported by:

• GIC investment and subsequent deleveraging

• Asset recycling initiatives

• Strong operating cash flow

• Credit rating improvements

Capital Expenditure and Free Cash Flow

Despite planned expansion, capex is expected to remain contained at INR 2.0-2.2 billion per year over FY25-28E. This is because cost per key for Samhi is significantly lower than industry average across most projects due to:

• Acquiring assets below replacement cost

• Variable lease structures that reduce upfront capital

• Brownfield expansions within existing properties

• Efficient renovation approaches

Industry Context

Branded hotel room supply in India grows slower than demand. Adding branded hotel rooms takes years. Land acquisition, permitting, construction, and brand affiliation stretch timelines beyond what demand cycles allow. Meanwhile, air passenger traffic grows at 7-10% annually. Office space absorption in major cities exceeds 50 million square feet per year. Corporate India expands its footprint continuously.

Air traffic reached 173 million passengers in 2024, up from 152 million in 2023. Indian carriers added over 150 aircraft in 2024 alone. The government plans to double operational airports to 300 by 2047.

The MICE segment (meetings, incentives, conferences, exhibitions) grows at roughly 18% annually. Corporate offsites, industry conferences, and large-scale events drive demand for full-service hotels with banquet facilities.

This demand-supply imbalance supports pricing power across the industry. Hotels can raise rates without losing occupancy. Operating leverage improves as fixed costs spread across higher revenues.

Competitive Position

Samhi competes with Indian Hotels (IHCL), Chalet Hotels, Lemon Tree, EIH, and several smaller players. Samhi trades at lower multiples than peers. The stock sits at approximately 10-11x forward EV/EBITDA compared to higher multiples for peers. Part of this discount reflects Samhi’s higher leverage (though declining) and shorter public market track record. Part reflects the market’s tendency to assign premium multiples to well-known legacy brands.

Samhi’s acquisition model creates a different risk profile than competitors focused on new builds or management contracts. The company takes property-level risk but captures full upside from successful turnarounds. It moves faster than new-build competitors but depends on deal flow to maintain growth.

The portfolio’s age presents both opportunity and risk. Older properties require ongoing capital expenditure. Renovation cycles recur every seven to ten years. Samhi must reinvest continuously to maintain competitive positioning.

Key Risks

Execution risk on pipeline projects. The Navi Mumbai development represents Samhi’s largest-ever project. Construction delays, cost overruns, or softer-than-expected demand could impair returns.

Cyclicality. Hotel demand correlates with economic activity. A slowdown in corporate travel, reduced conference spending, or broader economic weakness would pressure occupancy and rates.

Interest rate sensitivity. Samhi carries significant debt. Rising interest rates increase financing costs and reduce free cash flow available for reinvestment or debt reduction. The reduction from 13% to 8.5% has helped profitability; any reversal would hurt.

Concentration risk. Bangalore and Hyderabad together hold roughly 40% of the portfolio. A regional economic shock or tech sector contraction would disproportionately affect Samhi’s performance.

Brand partner dependency. Marriott, Hyatt, and IHG control distribution, loyalty programs, and operating standards. Changes in these relationships could affect hotel performance.

Currency and macro factors. Foreign tourist arrivals depend partly on exchange rates and global economic conditions beyond Samhi’s control.

Renovation execution. Multiple rebranding projects are underway simultaneously. Poor execution on any major renovation could delay expected ARR improvements.

Management Team

Ashish Jakhanwala serves as Chairman, Managing Director, and CEO. He has background in hotel operations, design, consulting, and investment. Before founding Samhi, he worked as Regional Director of Development at InterGlobe Hotels (the Accor franchise partner in India) and as a consultant at Pannell Kerr Forster. He holds qualifications in commerce, hotel management, and a PGDM from the International Management Institute.

Rajat Mehra serves as CFO. He joined Samhi in 2012 after working in finance and change management at Religare Corporate Services. He is a chartered accountant.

Gyana Das heads Investments and has been with Samhi since 2011. He previously worked at InterGlobe Hotels. He holds degrees in architecture and city planning from VNIT Nagpur and IIT Kharagpur.

Summary

Samhi Hotels owns and upgrades branded hotels in India’s major commercial markets. The company buys underperforming properties, invests in renovation, and partners with global brands for operations. The portfolio holds 4,862 rooms across 31 hotels. Upper-upscale properties generate disproportionate revenue. The company plans to add 1,500 rooms by FY30, including a 700-room project in Navi Mumbai.

The GIC partnership reduced leverage and provides growth capital. Net debt to EBITDA fell from over 7x to under 3x and is expected to reach 1.2x by FY28. The portfolio mix is shifting toward premium segments through rebranding and new upscale additions. This should drive ARR growth and margin improvement.

H1 FY26 growth was impacted by external factors. H2 should see improvement from new inventory absorption, seasonal strength in core markets, and completed renovations. Risks include execution on large projects, cyclical demand, interest rate exposure, and geographic concentration.

Subscribe now

If you want to see what I’ve been building, you can check the launch post here

Growth Triggers

Now, let’s get into today’s piece.

Entero Healthcare distributes pharmaceutical and healthcare products across India. The company was incorporated in January 2018 by Prabhat Agarwal, former CEO of Alkem Labs, and Prem Sethi, former Director at IQVIA. Their goal was simple: create an organized, technology-driven healthcare distribution platform in a market dominated by small, local players.

Since inception, Entero has become one of the three national healthcare product distributors in India. The other two are Keimed (owned by Apollo HealthCo) and API Holdings (PharmEasy). Together, these three hold 8-10% of the overall healthcare distribution market. The remaining 90-92% sits with approximately 65,000 traditional local distributors.

Market Share: National vs Local Distributors

Entero operates 104 warehouses spread across 45 Indian cities. The network delivers to 492 districts in 20 states. It serves 86,200+ retail pharmacies and 3,200+ hospitals. The company distributes 76,600+ SKUs from more than 2,500 healthcare product manufacturers.

What Entero Does

The business model has two components: demand fulfilment and commercial solutions.

On the demand fulfilment side, Entero acts as a B2B distributor. It procures pharmaceuticals, nutraceuticals, OTC products, vaccines, medical devices, and consumables from manufacturers. It then distributes these products to retail pharmacies, hospitals, and clinics across India. The company also sells private-label products including nebulisers, digital thermometers, blood pressure monitors, and adult diapers.

The commercial solutions side involves marketing and promotional services for manufacturers. Entero deploys medical representatives to promote healthcare brands to doctors. It develops marketing strategies and channel management to increase product reach. The company has exclusive agreements with manufacturers for promotion, marketing, and distribution of specific brands.

Entero has a partnership with Roche, signed in 2020, for four nephrology drugs. It has another arrangement with a large MNC pharma company for a cardiac device product. These relationships involve promotion, marketing, and distribution. They carry higher margins than pure distribution work.

The Distribution Network

The network has expanded substantially since FY21.

Revenue per square foot of warehouse space has grown at 11% annually over the past four years. This indicates improving utilisation of the distribution infrastructure.

The geographic spread covers major metros and tier-2 cities. The network reaches Mumbai, Delhi, Hyderabad, Pune, Ahmedabad, Kolkata, Chennai, Bangalore, Lucknow, Jaipur, Indore, Bhubaneswar, Guwahati, Patna, Varanasi, Kochi, Coimbatore, Madurai, Visakhapatnam, Goa, Mangaluru, Raipur, Gorakhpur, Dehradun, Amritsar, Panchkula, Karnal, Ghaziabad, Faridabad, Gurgaon, Ujjain, Vadodara, Tirupathi, Vijayawada, Rajahmundry, Khammam, Karimnagar, Kalaburagi, Bijapur, Belagavi, Davanagere, Mysuru, Kozhikode, Kollam, and dozens of other cities.

Technology Infrastructure

Entero has built four proprietary technology platforms that run its operations.

Entero Direct is a cloud-based application for retail pharmacies. It handles order management, tracking, returns, and claims settlement. Pharmacies can see real-time inventory and order status. The platform includes loyalty programs to improve retailer retention. The sales force uses it to plan customer visits, check live inventory, and view ongoing promotions. The delivery fleet uses it to plan deliveries and update delivery status.

Key features include:

• Easy one-touch ordering

• Consolidated view of ledger and payments

• Complete visibility of all pharma company schemes

• Visibility of order and order status

• Live inventory visibility for entire product catalogue

• Ability to run banner ad campaigns for brands or companies

• Loyalty points program

Entero CRM is the customer relationship management tool. Call centre executives can access customer details including past billings and outstanding payments during interactions. The application tracks all customer calling schedules and missed calls. It provides performance dashboards showing call summaries, task summaries, and order metrics.

Entero ERP is a cloud-based enterprise resource planning system implemented across multiple locations. Key benefits include:

• Seamless integration of data across locations

• Complete control over product and customer masters

• Enhanced security features such as web application firewalls

• Better centralised controls

• Lower risk of data loss

Teqtic is a cloud-based data warehouse and business intelligence tool. It generates customised reports for sales, purchases, and inventory levels across distributors and warehouses. It provides identity-based access control to customers. Manufacturers can access secondary sales data, brand performance overviews, and customer insights at a micro-market level.

The platform shows percentage share of top SKUs for specific molecules, inventory levels by product, and shelf life analysis. This data helps manufacturers optimise their sales operations.

These platforms give Entero visibility across its operations and provide data services to manufacturers. A local distributor with 100-500 retailers and basic ERP tools cannot offer this.

The India Pharma Distribution Market

Market Size and Structure

Pharmaceutical Supply Chain Overview

India has approximately 3,000 pharmaceutical companies manufacturing products in over 10,500 industrial units. These supply through 65,000 distributors to approximately 900,000 private retail chemists.

The market structure differs from developed countries.

Market Share Comparison: India vs Developed Markets

Pre-2015, India’s large/national players held only 3-5% share. This improved to 8-10% currently and is expected to reach 20-30% by FY28. Around 25-30% of pharma distribution volume concentrates in tier-1 cities (Mumbai, Delhi, Hyderabad, Pune, Ahmedabad, Kolkata, Chennai, and Bangalore). Tier-2 cities and beyond remain relatively under penetrated by national distributors.

Why Consolidation Makes Sense

The shift toward national distributors benefits both manufacturers and retailers.

For manufacturers, working with fewer large distributors reduces operational complexity. A pharmaceutical company currently maintains relationships with thousands of distributors across the value chain. Consolidating to a handful of national partners simplifies procurement, billing, claims settlement, and communication. Logistics costs run 4-6% of revenue for the industry. Streamlined procurement and distribution through large players can reduce these costs.

Large distributors can also offer marketing services. They have relationships with healthcare professionals and field representatives. They have reach into regional markets and connections with retail pharmacies and hospitals. Pharmaceutical companies spend 4-5% of revenue on marketing and promotion. This implies Rs80-90 billion of annual marketing expenditure in the Indian pharmaceutical sector. National distributors can capture a portion of this spending by offering promotional services.

For retail pharmacies, large distributors offer higher fill rates and better service.

Operational Advantages: Large vs Local Distributors

Typical Cost Structure of Pharma Distribution

The primary cost for pharma distributors remains procurement of traded goods at approximately 90% of total sales. With such thin margins, scale improves profitability because larger distributors have better bargaining power with suppliers and spread fixed costs over higher volumes.

Data as a Competitive Advantage

Micro-market and regional sales data matter to pharmaceutical companies. This information reveals market demand, customer preferences, demand-supply dynamics, and product performance. Companies use it to identify target areas and tailor strategies.

Distributors that compile secondary data on these aspects become valuable information sources. They track micro-market trends, brand performance, and sales data at the company level. Large distributors with sophisticated technology platforms can provide this data systematically. Local distributors with basic ERP tools cannot.

Entero’s Teqtic platform provides this capability. It generates reports showing sales and shelf life of available inventory for specific molecule strengths. It shows percentage share of top SKUs, inventory levels, and product performance across markets.

Supply Chain Simplification

Traditional pharma supply chains with many small distributors create complexity. A manufacturer selling through 500 distributors manages 500 relationships, 500 invoicing processes, 500 claims settlements, and 500 data collection efforts. Each transaction adds friction. The diagram of traditional distribution shows multiple criss-crossing lines between manufacturers and retail pharmacies, with numerous small distributors in between.

Large national distributors simplify this structure. A manufacturer working with three national players manages three relationships instead of 500. The flow becomes streamlined: manufacturers connect to a single large/national distributor, which then connects to multiple retail pharmacies. Procurement, billing, and data collection become efficient.

This simplification drives manufacturer preference for large distributors. It also creates barriers for local players trying to regain lost relationships.

Keimed: The Market Leader

Keimed is India’s largest pharma distributor with more than twice the revenue of the nearest competitor. It was previously owned by the promoters of Apollo Pharmacy and is now part of Apollo HealthCo. Keimed serves 70,000+ high-performing pharmacies across 18 states. It operates 96 distribution centres with cold chain infrastructure. It has 300+ manufacturer relationships and offers 45,000+ SKUs. Warehouse space totals 600,000 sq. ft. Revenue reached Rs103 billion in FY24, having grown at 20% annually over FY21-24. Reported Ebitda margins were 3.4% in FY24.

Keimed is the preferred distributor for Apollo Healthcare Enterprises Limited (AHEL). Shobana Kamineni, a promoter of Keimed, is the Executive Vice Chairperson of AHEL. AHEL and related entities contributed 54% of Keimed’s revenue in FY24, up from 49% in FY23. This relationship affects margins. Keimed provides preferential pricing to Apollo, which reduces margins by 1-1.5%. Adjusting for this, Keimed’s Ebitda margins would be 4.5-5.0%.

Entero vs Keimed Comparison

The warehouse capacity is similar. The SKU count is higher for Entero. The manufacturer relationships are far more extensive for Entero.

Entero’s Acquisition Strategy

Entero has acquired 45 entities since inception.

The selection criteria include:

• Expertise in the domain in which Entero operates or wishes to expand

• Strategic fit with existing business such that businesses are synergistic

• New retail chemist customers/users that Entero can serve with existing capabilities

• Product portfolio or product category adjacencies that can increase wallet share

• Newer service offerings that improve margin profile

• Enhancement of geographical mix

• Strengthening of market share in existing markets

• Identification of a strong management team run by experienced promoters

Acquisitions happen at 0.3-0.35x revenue multiples. This pricing reflects the thin margins in distribution. Sellers are typically local distributors facing competitive pressure from national players and lacking capital for technology investments.

Of the 32 companies acquired between CY18 and CY22, approximately 30 grew revenue at 20-25% annually over the subsequent two to three years. The acquired entities typically have blended Ebitda margins of 6-8%, higher than Entero’s consolidated margins. Integrating these businesses improves the overall margin profile.

Entero’s established acquisition process is data-driven and well-tested. It can be replicated in existing markets and new geographies. This repeatable model allows continuous expansion through acquisitions.

Market Share Trajectory

Entero’s Market Share in Healthcare Distribution

Entero’s market share in the healthcare distribution market has grown from 0.8% in FY21 to 1.3% in FY24. The share gain reflects both organic outperformance and acquisitions. The combined market share of the three national distributors improved from 3-5% in 2015 to 8-10% currently. Industry participants expect this to reach 20-30% by FY28. This implies the national players will grow at 25-30% annually, taking share from local distributors.

Growth Triggers

Several factors support continued growth for national distributors.

The underlying IPM grows at 9-10% annually. Medical devices grow at 11-12%. This provides a 10-11% baseline growth rate for the distribution market.

Consolidation provides additional growth. As national players take share from local distributors, they grow faster than the market. The share shift from 8-10% to 20-30% over the next few years implies substantial above-market growth.

New product categories offer expansion opportunities. Medical devices, diagnostic equipment, consumables, and nutraceuticals carry higher margins than pharmaceuticals. Expanding into these categories improves both growth and margins.

Commercial services add revenue streams. Marketing, promotion, and data services for manufacturers generate fee income beyond distribution margins.

Geographic expansion remains available. Tier-2 and tier-3 cities remain underpenetrated by national distributors. Expanding into these markets adds new customers.

Acquisition opportunities continue. The fragmented market with 65,000 distributors provides targets. Local players facing competitive pressure and lacking capital for technology investment become acquisition candidates.

Risk Factors

Future acquisitions not yielding desired results: Entero acquires smaller distributors in strategic locations throughout India as a part of its growth strategy. Historically, acquisitions have delivered desired results. However, acquisitions may not yield desired results and meet targets. This could impact profitability and lead to lower-than-expected improvement in margins, which in turn will impact free cash flow generation.

Negative FCF not sustainable for long period: Cash flow generation has been negative since inception due to high working capital intensive nature of the business, thin margins, and the ‘buy & build’ strategy. The company might have to raise further debt/equity capital.

Competition from other national players: Keimed and PharmEasy compete for the same customers and acquisition targets. Intensified competition could reduce margins or increase acquisition prices.

Margin compression: Pharma manufacturers may pressure distributor margins. Retail pharmacies may demand better pricing. Competitive dynamics could prevent margin expansion.

Technology disruption: New distribution models could emerge. Direct-to-pharmacy platforms from manufacturers or e-pharmacy players could alter the competitive landscape.

Regulatory changes: Changes in pharmaceutical distribution regulations, pricing controls, or trade margins could affect the business model.

Dependence on key customers: Concentration of revenue with specific manufacturers or retail chains creates dependence. Loss of major relationships would affect growth.

The Industry Maturation Path

The pharma distribution industry in India appears to be following the consolidation path seen in other countries. In the US, the market consolidated from hundreds of distributors to three dominant players over several decades. AmerisourceBergen, Cardinal Health, and McKesson now control 90-95% of the market.

In Germany, five players control 95-97%. In China, consolidation brought the top four to 40-45% share, up from 30-35% before 2015.

India’s consolidation started later and remains in early stages. The top players moved from 3-5% share in 2015 to 8-10% currently. The trajectory toward 20-30% by FY28 would represent meaningful progress but would still leave India far less consolidated than developed markets.

The consolidation thesis rests on structural advantages of scale. Large distributors offer better service, lower costs, and technology capabilities that local players cannot match. This drives manufacturer and retailer preference for national players. The preference accelerates share gains, which reinforce the scale advantages.

Market Position Summary

Entero operates in a large market undergoing structural change. The Rs3.3 trillion healthcare distribution market grows at 10-11% annually. Consolidation is shifting share from 65,000 local distributors to three national players. Entero ranks among the top three national distributors. Its network of 104 warehouses, 86,200+ retail customers, 2,500+ manufacturer relationships, and 76,600+ SKUs provides national reach. Proprietary technology platforms enable operational efficiency and data services.

The acquisition strategy has proven effective. Forty-five entities acquired since inception, with approximately 30 showing 20-25% revenue growth post-acquisition. The process is repeatable and can drive continued expansion.

Organic growth consistently outperforms the market at 1.5-2x IPM growth. Share gains come from superior service levels, higher fill rates, and technology capabilities that local distributors cannot match. The margin profile has room to improve. Gross margins can expand through procurement efficiencies and product mix. Operating leverage can drive Ebitda margin expansion. The benchmark of Keimed’s 4.5-5% adjusted Ebitda margins suggests the potential.

The risks center on acquisition execution, working capital management, and competitive dynamics. The growth strategy consumes capital and depends on successful integration of acquired businesses. The consolidation thesis provides a structural tailwind. As long as national distributors maintain service advantages over local players, share gains should continue. The market appears early in a multi-year consolidation cycle that has played out in other countries.

What distinguishes Sai from Indian peers is its near-complete focus on innovator business. Unlike Neuland with its generic API pricing pressure, Laurus with ARV portfolio exposure, or Aarti and BlueJet with commodity chemical segments, SAI operates almost entirely in high-science, high-margin work. The technical capabilities span chiral chemistry, targeted protein degradation, ADC linkers, peptides, and oligonucleotides. This positions Sai as the closest Indian comparison to global integrated players like WuXi AppTec and Pharmaron.

follow on x

The company operates through two segments. The Discovery (CRO) segment contributed Rs 4.9bn in FY24 and provides medicinal chemistry, biology, DMPK, and computational chemistry services. The Development and Manufacturing (CDMO) segment generated Rs 9.7bn in FY24 and supplies APIs and intermediates for clinical trials and commercial production. This 34:66 revenue split between CRO and CDMO positions SAI with a manufacturing-heavy model that drives stickier, longer-duration customer relationships.

SAI serves 300+ active customers across the US, UK, EU, and Japan. The customer base includes marquee names such as AbbVie, Eli Lilly, Bristol Myers Squibb, Pfizer, Merck, GSK, Genentech/Roche, AstraZeneca, and Sanofi. SAI has Material Supply Agreements with 8 of these large pharma companies. The company has maintained a 100% successful track record across all regulatory inspections, with facilities approved by the US FDA and Japan’s PMDA. No single customer accounts for more than 10% of revenue, and the average relationship tenure with top-10 customers exceeds 12 years.

Discovery Segment (CRO)

SAI operates India’s third-largest drug discovery services business with Rs 4.9bn in FY24 revenue, a 25% CAGR from FY18. The CRO segment has grown 35% over the last five years, with 38% of revenue now coming from Big Pharma (up from 33% in FY24) and 62% from biotech companies. The discovery team has worked on over 140 small molecule programs in the last five years. Of these, 40 have advanced to Investigational New Drug (IND) filing and 5 have achieved commercial drug approval. This track record of taking 5 drugs from discovery to commercial is the highest for any Indian CRDMO. The business operates primarily on FTE contracts (65%) with the remainder through fee-for-service arrangements.

A key differentiator is SAI’s integrated service offering. 69% of discovery revenue comes from customers who use both chemistry and biology/DMPK services. The number of customers opting for integrated discovery programs grew from 29 in FY19 to 60 in FY24. This cross-selling reduces customer switching costs and increases wallet share.

The CRO segment provides a built-in funnel for CDMO business. Unlike peers where winning large manufacturing contracts involves an element of luck, SAI can nurture molecules through discovery and development, then convert them to commercial manufacturing. This funnel currently contains 160 programs in various stages of development.

Discovery Infrastructure

The Hyderabad campus houses 343 fume hoods for chemistry, over 42,650 sq ft of biology lab space (with 11,000 sq ft expansion underway), and 26,300 sq ft of DMPK facilities. SAI maintains overseas presence through a 20,000 sq ft biology lab in Watertown, Massachusetts staffed by 30 scientists, and a process R&D laboratory in Manchester, UK with 60 scientists and a GLP kilo lab. The Manchester facility has developed and transferred over 11 manufacturing processes to plants in India. More than 20 biology assays have been developed and transferred from Boston for larger programs in India.

SAI and Aragen are the only Indian CRDMOs with labs located in Western innovation hubs, allowing scientists to work alongside innovator clients. This proximity accelerates technology transfer and provides IP security comfort that purely India-based operations cannot match.

Schrodinger Partnership

In January 2023, SAI entered a 5-year strategic agreement with Schrodinger to establish Sai Schrodinger Research Laboratories (SSRL) in Hyderabad. This dedicated facility supports multiple discovery programs across medicinal chemistry, biology, process chemistry, and analytical chemistry. The partnership currently deploys 75 FTEs and provides revenue visibility through 2028.

Development and Manufacturing Segment (CDMO)

SAI’s CDMO business generated Rs 9.7bn in FY24 revenue with a 16% CAGR from FY18. The segment focuses almost exclusively on innovator customers, with over 95% of revenue derived from on-patent or clinical-stage products. This innovator focus differentiates SAI from peers like Divi’s and Piramal, which have significant generic API exposure.

SAI manufactures products across diverse therapeutic areas including CNS, oncology, infectious diseases, cardiovascular, and antihistamines. The company has completed technology transfer of 11 late-phase and commercial products in the last three years, demonstrating its ability to absorb complex manufacturing processes.

Commercial Molecule Portfolio

SAI’s commercial portfolio includes several molecules with substantial market opportunity:

Atogepant/Ubrogepant (Qulipta/Ubrelvy) - AbbVie’s CGRP inhibitors approved in September 2021 for migraine prevention and treatment. Patent expiry extends to 2041. Atogepant is taken daily at 60mg dosage. SAI manufactures a crucial intermediate and is the sole supplier, with WuXi handling the API. SAI captures approximately 50-60% of the value chain. Revenue has scaled dramatically from $4.2mn in CY23 to $5.8mn in CY24 to $15.8mn in CY25 YTD. The addressable market is approximately 40 million migraine patients in the US and another 40 million in Europe. Atogepant/Ubrogepant show superior efficacy to competing drug Rimegepant in reducing Monthly Migraine Days, at lower cost, reflected in stronger prescription growth.

Gepotidacin (Blujepa) - GSK’s first-in-class antibiotic for uncomplicated urinary tract infections, approved March 2025. Patents extend to 2035. The US market alone sees approximately 15 million UTI patients annually, with recurring infections common. While antibiotic stewardship may initially reserve Gepotidacin for resistant cases (currently 5% of market), resistance trends suggest this could reach 10% by 2030 with potential for broader prescribing. Dosage is high at 3,000mg daily for 5 days. EU approval expected in 2025 will expand the addressable market. SAI manufactures two intermediates contributing approximately $17mn in exports in the current year.

Treprostinil (Tyvaso DPI) - United Therapeutics’ pulmonary arterial hypertension treatment. The recent Dry Powder Inhaler approval has driven volume growth for SAI, which manufactures a crucial intermediate at approximately $70,000/kg. Current revenue is approximately $8mn annually and scaling. Patent expiry is May 2027.

Bilastine (Bilaxten) - Faes Farma’s antihistamine for allergic rhinitis, widely used in Europe though not approved in the US. SAI generates approximately $16mn annually from this molecule, though growth has plateaued as patents expire across various countries.

Historical Molecules - SAI previously manufactured for Orladeyo (Biocryst) and Simparica (Zoetis, a chewable flea/tick treatment for dogs). Both stopped around FY22-23, likely due to capacity constraints during SAI’s debt-constrained period when borrowings exceeded Rs 900cr and interest coverage dipped to approximately 2x. The Simparica market was growing exponentially when supply ceased. The IPO proceeds have substantially reduced debt, enabling capacity expansion that may allow SAI to pursue similar large-volume opportunities.

Phase-3 Pipeline

SAI has 6 molecules in Phase-3 or pre-registration stage. Three identified molecules represent significant commercial potential:

Lorundrostat (Mineralys Therapeutics) - Treatment for resistant hypertension. The addressable market is substantial: 11-17% of hypertensive patients exhibit treatment resistance, representing 13-20 million patients in the US alone. Phase-3 has completed successfully. NDA filing expected December 2025. A competing molecule, Baxdrostat (AstraZeneca), is also in Phase-3.

Tradipitant (Vanda Pharmaceuticals) - First-in-class NK1 antagonist for motion sickness. FDA filing completed with approval expected by December 2025. No other NK1 antagonist is approved for motion sickness, giving Tradipitant potential first-mover advantage.

Camizestrant (AstraZeneca) - Oral SERD for breast cancer. Phase-3 readouts have been positive. Commercial supplies likely from 2027.

The remaining three Phase-3 molecules have not been publicly identified but represent additional optionality in SAI’s pipeline.

Manufacturing Infrastructure

SAI’s manufacturing operations span four facilities with current reactor capacity of approximately 640 kL, expanding to 1,200-1,300 kL by 2027.

Capacity expansion has been constrained historically. Reactor volume grew from 200 kL in 2017 to 450 kL in 2020 to 565 kL by 2022, then stalled as debt levels became problematic. The IPO has enabled resumed expansion to 1,200-1,300 kL by 2027, necessary to support scale-up of Atogepant/Ubrogepant, Gepotidacin, and Phase-3 molecules approaching commercialization.

The Integrated Model

SAI’s core competitive advantage lies in its integrated discovery-to-commercial manufacturing platform. The company describes this as the “follow the molecule” approach. Of the 50 late-phase and commercial products currently manufactured by SAI, 34 (68%) underwent process development in SAI’s R&D facilities before entering Phase 3 clinical trials. The remaining 16 products were transferred from external facilities, demonstrating SAI’s ability to absorb technology from customers or their existing CDMOs.

This model provides multiple entry points for customer engagement. A customer might begin with early-stage discovery chemistry, then progress through biology and DMPK services, before moving into process development and commercial manufacturing. Alternatively, a customer might transfer an existing Phase 2 program or even a commercial product to SAI’s manufacturing facilities. Both pathways generate multi-year revenue streams with high switching costs. 40% of CDMO customers (by revenue) use multiple services, while over 70% of discovery customers do so. Revenue per top-10 customer increased from Rs 272mn in FY22 to Rs 442mn in FY24, a 63% improvement in wallet share over two years.

Industry Context

The global small molecule CRO market stands at $55bn with an expected 10% CAGR through CY28. The small molecule CDMO market is larger at $99bn but growing more slowly at 7% CAGR. India’s CRDMO industry is estimated at $7.3bn currently and is projected to reach $14.1bn by CY28, representing a 14% CAGR that outpaces global growth rates.

Small molecules remain dominant in drug development. Of the 302 new chemical entities approved by the US FDA between 2018-2023, 72% were small molecules. This supports sustained demand for small molecule CRO and CDMO services despite growing attention on biologics and cell therapies.

Two structural tailwinds support Indian CDMOs. First, China Plus One supply chain diversification continues as global pharmaceutical companies seek to reduce concentration risk in Chinese manufacturing. Second, the US Inflation Reduction Act creates incentives for pharmaceutical companies to optimize manufacturing costs. Industry reports indicate increasing preference for integrated CDMOs offering one-stop platforms from discovery to commercialization.

Competitive Position

In the Indian CRDMO landscape, Syngene and SAI stand apart as the only purely innovator-focused players with integrated CRO-CDMO capabilities. Anthem Biosciences has approximately 10% CRO exposure. Divi’s and Piramal Pharma have significant generic API or formulations exposure.

SAI vs Syngene

SAI differentiates from Syngene in three ways. First, SAI has a manufacturing-heavy revenue mix (66% CDMO) versus Syngene’s discovery-heavy mix (60% CRO). Manufacturing revenue tends to be stickier with longer contract durations. Second, SAI maintains overseas labs in Boston and Manchester that provide customer proximity, facilitate technology transfer, and offer IP security comfort. Third, SAI has dedicated HPAPI capability for oncology manufacturing, an area commanding premium pricing.

However, Syngene has broader capabilities across biologics, oligonucleotides, ADCs, PROTACs, peptides, and mRNA. Syngene also has significantly larger scale with India’s largest CRO operations. SAI’s overseas sites are not yet breakeven, which weighs on near-term margins.

Syngene has struggled to grow meaningfully in recent years, while SAI has compounded CRO revenue at 35% over five years despite the challenging biotech funding environment.

Growth Triggers

1. Gepant Scale-up. Atogepant/Ubrogepant revenue has scaled from $4.2mn in CY23 to $15.8mn in CY25 YTD. SAI is the sole intermediate supplier with approximately 50-60% value capture. The migraine prevention market addresses 80+ million patients across US and EU. Patent protection extends to 2041.

2. Gepotidacin Launch. GSK’s first-in-class antibiotic for UTI was approved March 2025. SAI supplies two intermediates generating approximately $17mn currently. EU approval in 2025 will expand the addressable market. High dosage (3,000mg/day) supports substantial API volumes.

3. Phase-3 Pipeline Conversion. Lorundrostat (resistant hypertension, NDA filing December 2025), Tradipitant (motion sickness, first-in-class, approval expected December 2025), and Camizestrant (breast cancer, commercial supplies from 2027) represent near-term commercialization opportunities. Three additional unidentified Phase-3 molecules provide further optionality.

4. Capacity Expansion. Manufacturing capacity expanding from 640 kL to 1,200-1,300 kL by 2027. The IPO debt reduction has removed the constraint that previously caused SAI to lose molecules like Simparica when capacity could not scale with demand.

5. CRO-to-CDMO Funnel. 160 programs in the CDMO pipeline provide the healthiest business visibility among Indian peers. The integrated model creates a natural pathway from discovery wins to manufacturing revenue.

6. Customer Penetration. SAI’s presence among top-25 pharma companies doubled from 9 in FY19 to 18 in FY24. Multiple molecules with each major customer and 8 Material Supply Agreements provide recurring revenue visibility.

7. China Plus One. Global pharmaceutical companies continue diversifying supply chains away from China concentration. SAI’s positioning as the only Indian CRDMO comparable to WuXi/Pharmaron makes it a natural beneficiary.

Risks

1. Molecule Loss. SAI lost two crucial molecules (Orladeyo, Simparica) in FY23, likely due to capacity constraints when debt levels became problematic. If losses were due to execution issues rather than capital constraints, this would be more concerning. The capacity expansion post-IPO should mitigate this risk, but the episode demonstrates that manufacturing scale-up failures can result in permanent customer loss.

2. Clinical Trial Failure. Phase-3 molecules may fail trials or face regulatory rejection. The probability of success from Phase-3 to approval averages approximately 60% across the industry. SAI’s 6 Phase-3 molecules represent meaningful revenue concentration in this risk.

3. Customer Concentration Evolution. While current concentration is manageable (no customer >10%), successful molecules like the gepants may grow to overshadow other revenue, increasing concentration risk. Anthem derives approximately 25% of sales from Rimegepant alone. SAI could face similar dynamics if Atogepant/Ubrogepant continues scaling.

4. Patent Expiration. Tyvaso DPI patent expires May 2027, which will impact that revenue stream. Other molecules have longer patent lives (Atogepant to 2041, Gepotidacin to 2035), but portfolio refresh remains necessary.

5. Regulatory Compliance. A failed regulatory inspection at Bidar Unit IV, which handles the bulk of commercial manufacturing, could halt production and trigger customer migration. While SAI maintains a 100% track record, regulatory expectations continue tightening.

6. Overseas Operations. The Boston and Manchester facilities are not yet profitable. These sites provide strategic value through customer proximity and technology transfer but depress group margins. SAI has high lease payments (24% of EBITDA versus 2-4% for peers), partly due to these overseas facilities.

7. Biotech Funding Cycles. Discovery revenue correlates with biotech funding availability. While Big Pharma share has increased to 38% of CRO revenue, 62% remains biotech-dependent.

Subscribe now

Arun Jain founded the company in 2011. He had built Polaris Software Lab from scratch starting in 1993, grew it into a major banking IT firm, then sold it to Virtusa. Intellect was his third venture in financial technology. The company listed on the BSE and NSE in 2014 after a demerger from Polaris. Today Intellect operates in 57 countries and serves more than 500 financial institutions. In India, 14 of the top 15 banks run Intellect products. Globally, 88 large transaction banks use its Digital Transaction Banking platform.

The business splits into four verticals:

Geography splits 45% North America and Europe, 35% Middle East and Africa, 20% India.

Revenue comes from two buckets. Implementation work (installing and customizing the software) makes up 50% of revenues. License-linked revenues (license fees, annual maintenance contracts, subscriptions) make up the other 50%. The company handles implementations itself rather than handing them to system integrators.

When a bank buys core banking software, it stays for a decade or more. Implementations take 12 to 24 months at most vendors. Ripping out a core system and starting fresh is expensive and risky. In March 2023, the company launched eMACH.ai, a platform built on microservices, APIs, and cloud infrastructure. The architecture allows banks to replace individual modules instead of doing full system overhauls. Implementation timelines dropped to 4-6 months. Deal sizes expanded from USD 3 million to USD 7-8 million.

Subscribe now

In August 2024, Intellect launched Purple Fabric, an enterprise AI platform. More than 45 global banks and insurers have adopted it. The platform launched in the US in August 2025. A London brokerage signed a INR 200 crore multi year deal to use Purple Fabric for underwriting transformation. The company targets INR 10 billion in Purple Fabric revenues within 3-5 years.

In December 2025, Intellect won 35 credit unions across 8 Canadian provinces for digital banking transformation. These credit unions manage over $13 billion in assets. This followed an earlier deal to acquire Central 1’s digital banking operations, giving access to about 190 credit unions.

The Problem Intellect Solves

Most large banks in developed markets still run on core banking systems deployed in the 1980s and 1990s. COBOL. Mainframes. Batch processing. Built for an era when banking meant walking into a branch. These legacy systems are monolithic. A single bundled software application handles the database, user interface, and server operations in one place. Everything is vertically integrated. Everything is proprietary. Everything is locked in.

This worked when change was slow. It does not work when customers expect real-time everything. It does not work when regulators demand new reporting formats every quarter. It does not work when fintechs can launch a competing product in weeks. The cost of maintaining this infrastructure compounds every year. Banks spend 70-80% of their IT budgets just keeping the lights on. New features get bolted onto old systems. Technical debt accumulates.

Banks know they need to modernize. Traditional core banking transformations are multi-year projects with massive cost overruns and high failure rates. Many banks have tried and failed. The ones that succeeded often spent five years and hundreds of millions of dollars.

P.S - Read this deep dive in a better format here

The eMACH.ai Architecture

Intellect launched eMACH.ai in March 2023. The name is an acronym: Event-driven, Microservices, API-first, Cloud-native, Headless.

Event-driven means the system responds to things happening in real-time. A payment arrives. An account balance changes. The system reacts immediately rather than waiting for a batch job to run at midnight.

Microservices means the system is built from small, independent components rather than one giant block of code. Each microservice handles one thing. If the payments service needs an update, you update just that piece. You do not risk breaking everything else.

API-first means every capability is exposed as a programmable interface. Other systems can connect. Fintechs can integrate. The bank becomes a platform rather than a closed box.

Cloud-native means the system was designed from the ground up to run on cloud infrastructure. It scales automatically. It handles failures gracefully. It costs less to operate.

Headless means the user interface is decoupled from the business logic. Banks can change how things look to customers without touching the core processing. They can offer the same capabilities through mobile apps, web portals, voice assistants, or embedded banking.

The platform runs on 386 microservices, 650 events, and more than 2,015 APIs.

Implementation Speed

The Union Bank of India cash management implementation went live in 5 months. That is one of the fastest implementations in the industry.

Compare this to the alternatives:

Intellect takes direct ownership of implementations rather than handing them off to system integrators. Most vendors rely on partners like Accenture, Deloitte, or TCS to do the actual deployment work. The trade-off: implementation revenues represent 50% of Intellect’s total revenues. That is higher than typical software product companies. But it also means Intellect controls the customer experience end-to-end. When something goes wrong, there is no finger-pointing between vendor and integrator.

Deal Metrics

The eMACH.ai launch changed Intellect’s commercial trajectory. Deal wins increased. Deal sizes expanded. The proportion of large transformation contracts grew.

Destiny deals are contracts worth more than INR 200 million. These are the transformation projects that reshape a bank’s technology foundation. They take longer to close but generate revenue over many years. The number of deals fell in FY25. But deal quality improved. Destiny deals now represent 65% of total wins, up from 51% in FY22.

Recent Destiny Deal Wins

System Integrator Partnerships

After developing eMACH.ai, Intellect entered partnerships with major system integrators. The company still handles most implementations directly but now collaborates with SIs to expand reach.

Purple Fabric: The AI Platform

Intellect launched Purple Fabric in Q4FY25. This is an enterprise AI platform that transforms enterprise data into actionable insights.

The platform is built on four foundational technologies:

Monetization Models

Intellect charges about USD 1 million per client per year for the platform. Palantir charges about USD 3 million. This pricing differential gives Intellect a competitive wedge.

Four to five use cases are already live:

The Purple Fabric pipeline has reached INR 8 billion and represents 8% of the Q1FY26 deal pipeline. The company has generated 500-600 leads since launch.

Product Portfolio

Wholesale Banking Products (iGTB)

Consumer Banking Products (iGCB)

Risk, Treasury & Capital Markets Products (iRTM)

iTurmeric: The Integration Platform

Before eMACH.ai, Intellect built iTurmeric. This is a cloud transformation accelerator that helps banks modernize progressively without ripping and replacing their entire infrastructure. The platform enables composable banking. Instead of locked functionality bundles, banks can assemble capabilities from modular components. New systems can be tested and run in parallel with legacy systems.

Key capabilities:

• Enterprise integration with API-first architecture

• Cloud-native, microservices-based

• Progressive modernization without business disruption

• Co-existence with legacy infrastructure during transition

Global Expansion: The Central 1 Acquisition

Intellect signed an agreement to acquire the digital banking operations of Central 1 Credit Union in Canada. This deal gives access to about 190 credit unions currently on Central 1’s platform. Intellect will operate and support Central 1’s digital banking software during the transition to its own eMACH.ai platform. The acquisition is only marginally profitable but creates cross-selling opportunities for Intellect’s broader core banking solutions.

The company targets India, UK, and Canada as USD 100 million markets each in the long term.

Business Model Economics

Intellect operates a high gestation, high upfront cost business. Investments in R&D and sales and marketing are front-loaded. But these costs do not remain elevated forever. They come down as the company transitions from investment phase to monetization phase.

Revenue Streams

Cost Drivers

Software has near-zero marginal costs once developed. Creating another copy costs virtually nothing. This scalability combined with subscription-based pricing results in high gross margins and predictable revenue.

Customer Stickiness

Repeat business forms 85-90% of total revenues. Net Promoter Score stands at 60 versus industry average of 43. High NPS with existing customers increases reference ability and reduces customer acquisition costs.

When a bank installs a core banking system, the switching costs are enormous:

• Implementation takes 12-24 months

• Staff training on new systems

• Data migration risks

• Integration with existing systems

• Regulatory approval processes

• Business continuity concerns

Guidance

Management has provided specific targets:

Growth Triggers

• Purple Fabric AI platform targeting ₹1,000-5,000 Cr revenue potential over next 3 years

• ₹200 Cr Purple Fabric revenue guidance for FY26 with 70% of pipeline now AI-integrated

• eMACH.ai platform driving 20% YoY growth design target with 30% EBITDA margin ambition

• Central1 acquisition adding 170 Canadian credit unions and ₹200 Cr ARR base

• Strong US market entry with 3 major deals won in Q1 across core banking, payments and liquidity

• License-linked revenue now 50%+ of total and targeting 60% by FY27

• Global deal funnel crossed ₹12,000 Cr with 11 multi-million dollar destiny deals in Q2

• Purple Fabric embedded across all products creating AI-native banking solutions

• Enterprise Knowledge Garden and Digital Experts differentiating against Palantir/C3.ai

• 9,000+ AI agents deployed internally driving productivity gains without headcount increase

• Consulting business launched to drive business impact transformation deals

• Americas revenue growth accelerating faster than other regions

• 22 digital transformations executed in Q2 alone across 5 continents

• ARR base crossed ₹1,080 Cr establishing predictable revenue foundation

• New 7.25 lakh sq ft Siruseri facility housing Purple Fabric AI Labs and Design Centers

Risks

1. Slowdown in bank IT spending could delay core transformation deals. Banks often cut discretionary technology spending during economic uncertainty.

2. Intense competition from global software vendors (FIS, Temenos, Oracle Financial Services), domestic product players, and large Indian IT service firms in core digital transformation deals.

3. Regulatory and compliance requirements across 57 countries. Each jurisdiction has different rules for banking technology.

4. Purple Fabric scaling slower than expected. The AI platform is new and unproven at scale. Slower adoption could impact growth and margin trajectory.

5. Large deal conversion challenge. Destiny deals take longer to close and have more complex decision processes. Conversion rates can be unpredictable.

6. Implementation execution. Since Intellect handles most implementations directly, any quality issues impact both revenue and reputation.

7. Key person risk. Arun Jain has been central to the company’s evolution from Polaris to Intellect. Leadership continuity matters.

Valuations

This post has been provided solely for information purposes and does not constitute an offer or solicitation of an offer or any advice or recommendation to purchase any securities or other financial instruments and may not be construed as such. The author makes no representations as to the accuracy or completeness of any information in this post, Do your own diligence and consider this blog as just an educational piece.

The company holds roughly 7% of India’s PEB market, which is worth approximately ₹200 billion annually.

Subscribe now

What Interarch Does

Pre-engineered steel buildings (PEB) are structures constructed using fabricated steel components. These buildings are designed and manufactured off-site and then assembled on-site. This method reduces construction time, minimizes waste, and ensures consistent quality, making it an attractive option for industries such as manufacturing, logistics, retail, aviation and warehousing. Everything from design, engineering, production, making the items, delivering it to site and erecting it at site will be all done in one lump sum price.

Interarch operates as a turnkey solutions provider. The process starts with understanding customer requirements through technical sales, moves to in-house design and engineering, then to manufacturing at their facilities, and finally to on-site installation. The company employs over 125 structural design engineers and detailers.

Key components of pre-engineered buildings

Main frame or primary structure: This frame is the main load-carrying and support structure of a pre-engineered building made of rigid steel frames. The primary structure consists of columns, rafters, and other supporting structures. The shape and size of these structures differ based on their application and requirements. The frame is constructed by bolting the end plates of connecting sections together.

Secondary structure: It consists of purlins, grita, and eave struts used to support the wall and roof panels. Purlins are employed on the roof, grits on walls, and eave struts at the intersection of the sidewall and roof.

Roof, wall panels, and insulation: These components are used for sheeting and generally made of ribbed steel sheets. They are used as roof and wall sheeting, roof and wall liners, partition, and soft sheeting. Steel sheets are generally produced from steel coils.

Benefits of PEB

Faster construction: As pre-engineered construction involves components being manufactured at the factory first, it allows for the simultaneous preparation of the foundation at the construction site. This helps accelerate project timelines and decreases overhead site costs, including labour costs. Additionally, as these structures are manufactured at the factory, they also prevent project delays caused by external factors, such as adverse weather.

Flexible offerings: PEBs offer design flexibility and quick installation, making it suitable for a wide range of applications, including industrial buildings and warehouses.

Cost-effective: PEBs are cost-effective due to their reduced construction time (~50% lower) and lower labour costs. Overall cost savings could be 20-40%, apart from the opportunity cost saved in starting the plant early.

Sustainable: PEBs are also sustainable, given steel can be recycled. Further, in- house manufacturing process minimises waste. Further, these require low maintenance as they are resistant to pests, rot, and other issues.

Manufacturing Process

The pre-engineered building construction plan is structured into three primary phases - design, fabrication, and installation. The initial design phase encompasses critical tasks such as site preparation, finalising the design specifications, and obtaining the requisite approvals. The design phase is the first phase of overall PEB construction and is extremely critical to the overall outcome of the PEB building. It is followed by the fabrication phase, which focuses on manufacturing of pre-engineered structures as well as construction of substructures that not only enhance cost efficiency but also accelerate project timelines significantly. Hence, this simultaneous approach contributes to substantial savings in terms of both time and resources.

Finally, the concluding phase of pre-engineered building construction involves the transport of individual building components to the designated construction site, where the final structure is installed with precision.

Manufacturing Footprint

Interarch operates five facilities:

• The Kichha plant in Uttarakhand is the largest at 59,500 MTPA. It produces complete PEB steel structures, primary and secondary framing systems, metal ceilings, corrugated roofing, and light gauge framing systems.

• The Pantnagar facility, also in Uttarakhand, has capacity of 31,000 MTPA for PEB steel structures.

• Tamil Nadu hosts two facilities in Sriperumbudur. One produces metal ceilings and corrugated roofing at 10,000 MTPA. The other manufactures PEB steel structures at 40,500 MTPA.

• The newest facility at Attivaram in Andhra Pradesh has 20,000 MTPA capacity, commissioned in 2024.

Total installed capacity reached 161,000 MTPA by FY25-end. The company plans to expand to over 200,000 MTPA by the first quarter of FY26, adding 40,000 MTPA through brownfield expansion at existing locations. Further expansion is planned for Andhra Pradesh and a new greenfield facility in Gujarat.

Recent Project Wins

The company has won several large orders in emerging sectors. In semiconductors and battery manufacturing, Interarch received two projects worth ₹2.2 billion from Tata Projects. One is for Tata’s semiconductor manufacturing facility in Jagiroad, Assam. The other is for a lithium-ion battery manufacturing unit in Sanand, Gujarat for Agratas Energy Storage Solutions.

In renewable energy, the company secured a project for India’s largest solar photovoltaic module manufacturing unit from Tata Projects for First Solar Power India. Other wins include a greenfield turbine blades manufacturing unit for LM Wind Power Blades in Gujarat and a solar cells and modules manufacturing unit for Renew Photovoltaics. In warehousing and logistics, clients include Indospace, ESR, Logos India, Amazon, Flipkart, Mahindra Logistics, and Concor.

Industry Structure

The Indian PEB industry remains fragmented. Organized players control 40-45% of the market. Unorganized players, enabled by low capital intensity and low technical barriers, hold 55-60%.

Within the organized segment, the top seven players command 80-85% share. These include Kirby Building Systems (market leader at 300,000 MTPA capacity), Interarch (second at 161,000 MTPA), EPack Prefab (134,000 MTPA), M&B Engineering (104,000 MTPA), Zamil Steel (100,000 MTPA), Pennar Industries (90,000 MTPA), and Everest Industries (72,000 MTPA).

Kirby is part of Kuwait-based Alghanim Industries. Zamil Steel is a subsidiary of Saudi Arabia-based Zamil Pre-Engineered Buildings. The rest are Indian companies. Organized players have been gaining share from unorganized players. In FY18, organized players held 32% of the market. By FY24, this rose to 44%. Better execution track record, quality engineering services, and reliability drive this shift. Large industrial clients prefer established players who can deliver complex projects on time.

Growth Triggers

1. Private Sector Capex Cycle Remains Strong

Industry capacity utilization in India stands above 75%, higher than the long-term average of 73.4%. When utilization crosses 75%, companies typically announce expansion plans. The RBI data shows utilization has been trending upward since the Covid lows.

The MoSPI private sector capex survey covering 588 enterprises projects manufacturing capex to increase further in FY26. Manufacturing capex grew from approximately ₹1.4 trillion in FY22 to over ₹2 trillion in FY25. FY26 projections show continued growth. Every new factory, every capacity expansion, every greenfield project needs a building. PEB is the preferred choice for industrial buildings given 40-50% faster construction and 20-40% lower overall costs.

2. Warehousing Expansion at the Top End

India’s warehousing stock is expected to grow from approximately 1 billion square feet in CY24 to 1.3 billion square feet by CY27. That’s an 8% CAGR for the overall market.

The more relevant number is Grade A warehousing growth at 17% CAGR over the same period. Grade A stock was 248 million square feet in CY24 and is projected to reach 398 million square feet by CY27. Grade A warehouses are built by organized developers like Indospace, ESR, Logos India, and Mahindra Logistics. These developers work exclusively with top-tier PEB suppliers who can deliver quality structures on schedule.

Interarch counts all the major warehousing players among its clients: Indospace, ESR, Logos India, Amazon, Flipkart, Mahindra Logistics, Ascendas FirstSpace, Concor, and Seabird Marine. The e-commerce and third-party logistics expansion continues to drive demand. Amazon and Flipkart alone are adding millions of square feet annually.

3. Renewable Energy Manufacturing Buildout

India’s push for domestic solar module manufacturing has created a wave of factory construction. The Production Linked Incentive scheme for solar modules has attracted investments from Tata Power Solar, First Solar, Reliance, Adani, Waaree, and others.

Interarch has already captured significant orders here. The company won the project for India’s largest solar photovoltaic module manufacturing unit from Tata Projects for First Solar Power India. Other wins include a greenfield turbine blades manufacturing unit for LM Wind Power Blades in Gujarat and a solar cells and modules manufacturing unit for Renew Photovoltaics.

The client list in renewable energy includes Avaada, Ampin, Reliance New Energy, Tata Power Solar, ReNew Power, Siemens Gamesa, Voith, First Solar, Exide, Amara Raja, GMR, LM Wind Power, Abellon CleanEnergy, Flovel, Green Global Solutions, and Emmvee.

Solar module manufacturing capacity in India is expected to expand from approximately 20 GW in 2023 to over 100 GW by 2030. Each GW of module manufacturing capacity requires factory space. Wind turbine blade manufacturing is similarly expanding as India targets 140 GW of wind capacity by 2030. Battery cell manufacturing is the next wave. The ACC PLI scheme has allocated ₹181 billion for domestic battery manufacturing. Reliance, Ola Electric, Rajesh Exports, and others have announced plans totaling over 100 GWh of capacity.

4. Semiconductor and Electronics Manufacturing

India’s semiconductor mission has triggered factory construction across the country. Interarch has won two projects worth ₹2.2 billion from Tata Projects in this space.

The first is for Tata Electronics’ semiconductor fabrication facility in Jagiroad, Assam. This is India’s first commercial semiconductor fab, a joint venture with Taiwan’s Powerchip Semiconductor Manufacturing Corporation. The facility will manufacture chips for automotive, computing, and communications applications. The second is for a lithium-ion battery cell manufacturing unit in Sanand, Gujarat for Agratas Energy Storage Solutions, a Tata Group company. This is a 40 GWh capacity facility.

The semiconductor client list shows Micron and Tata Electronics. Micron is building a ₹22,500 crore assembly and test facility in Gujarat. More fabs are expected as the government has approved proposals from multiple consortiums.

Electronics manufacturing more broadly continues to expand under the PLI schemes for mobile phones, IT hardware, and components. Foxconn, Pegatron, Wistron, and others are building and expanding facilities in India.

5. Data Center Construction Boom

Data center capacity in India is expanding rapidly. Current capacity stands at approximately 900 MW across major cities. This is expected to grow to over 2,000 MW by 2027.

Each MW of data center capacity requires approximately 10,000-12,000 square feet of built-up area. A 50 MW data center needs around 500,000 square feet of building space. The shell and structure for data centers increasingly use PEB given speed of construction and ability to accommodate the high floor loads and ceiling heights these facilities require.

Interarch has supplied PEB solutions for data center buildings, including a project in Navi Mumbai. The company’s experience with complex industrial structures translates well to data center requirements. Major data center operators like NTT, Equinix, STT GDC, CtrlS, Yotta, and Adani are all expanding capacity. Hyperscalers like AWS, Google Cloud, and Microsoft Azure are investing in India regions.

6. Rising PEB Penetration Across Segments

Current PEB penetration in India stands at 14% for industrial/manufacturing applications, 6% for infrastructure, and just 0.5% for buildings. Industry projections show penetration rising to 20% for industrial, 9% for infrastructure, and 1% for buildings by FY29. The penetration increase alone represents significant demand growth even without underlying sector expansion. If the industrial construction market remains flat but penetration rises from 14% to 20%, that’s a 43% increase in PEB demand from industrial alone.

PEB structures cost 20-40% less than RCC when accounting for faster construction time, lower labor costs, and reduced foundation requirements. The opportunity cost of delayed plant startup increasingly matters to manufacturers racing to capture market share. Infrastructure penetration is rising as more warehouses, cold storage facilities, and logistics parks choose PEB. Airport hangars, railway yards, and metro depots are increasingly using PEB.

Building segment penetration remains low but is growing from a tiny base. Multi-story commercial buildings, hospitals, and institutional structures are beginning to adopt steel construction. The JSPL partnership positions Interarch to capture this emerging opportunity.

7. Market Share Shift from Unorganized to Organized

The organized segment’s share of the PEB market has grown from 32% in FY18 to 44% in FY24. Unorganized players lost 12 percentage points of market share in six years. This shift accelerates during periods of high demand. When large industrial clients need reliable execution on tight timelines, they choose established players with proven track records. The cost of a delayed factory startup far exceeds any savings from using a cheaper unorganized supplier.

Quality requirements are also tightening. MNC clients demand certifications, quality management systems, and safety standards that unorganized players cannot provide. Insurance and compliance requirements favor organized players. Among organized players, the top seven have maintained 80-85% share consistently. Within this group, market share has been relatively stable, though Interarch and EPack Prefab have grown faster than Pennar and Everest in recent years.

Interarch’s 15% revenue CAGR from FY20-25 compares to 8% for Pennar and 6% for Everest. Faster growth at similar or better margins suggests Interarch is gaining share within the organized segment as well.

8. JSPL Partnership for Heavy Building Structures

Interarch has partnered with Jindal Steel and Power Limited to offer PEB solutions for multi-story buildings and heavy building structures. This expands capabilities beyond the traditional single-story industrial sheds.

Multi-story buildings require heavier steel sections and different engineering expertise. JSPL brings technical knowhow from its structural steel business and access to specialized steel grades. Interarch brings design engineering, fabrication, and project execution capabilities.

Applications include IT parks, commercial complexes, hospitals, educational institutions, and residential towers. A single multi-story project can be worth ₹500 million to ₹1 billion, significantly larger than typical industrial shed orders.

Key Risks

Steel price volatility: The company enters into fixed price contracts and holds inventory of ~2 months of raw material (steel). sharp volatility in prices of raw material can affect the financials of the company.

Slowdown in Capex Cycle: interarch’s order inflow is dependent on the private capex cycle. If there is a slowdown in the capex cycle it will result in a slowdown for the company.

Hiring right talent is the key: company relies on its internal design & engineering team for optimum & efficient designing of its project. Any alteration or loss of this talent may cause the company to lose market share and revenues.

Increased competitive intensity & pricing war: An increase in the competitive intensity by players will lead to a bidding war which will cause prices and in turn revenue and margins to drop. industry has low entry barriers with limited capital requirements which makes the risks to margin for interarch a key risk.

Valuations

This post has been provided solely for information purposes and does not constitute an offer or solicitation of an offer or any advice or recommendation to purchase any securities or other financial instruments and may not be construed as such. The author makes no representations as to the accuracy or completeness of any information in this post, Do your own diligence and consider this blog as just an educational piece.

Subscribe now

Subscribe now

BlueJet Healthcare is a pharmaceutical ingredients & intermediates manufacturer established in 1968 and produces specialty pharma, intermediates, and active pharmaceutical ingredients (APIs) targeted towards innovator and multi-national pharmaceutical companies. It operates three manufacturing facilities in Maharashtra, India and has a customer base of over 400 clients across 39 countries. Company manufactures a range of products, including the key starting and advanced intermediates & is highly backward integrated which allows the company to control the production process for consistent quality and cost effectiveness.

BlueJet has 3 business verticals - contrast media intermediates, high intensity sweeteners and pharma intermediate / Active pharma ingredients (PI/API). The company’s recent growth is primarily driven by its Pharma Intermediate and API (PI/API) business where it has a long term contract with Esperion Therapeutics for supplying a key intermediate for bempedoic acid. Company's revenue has grown at a CAGR of 26.2% from FY21 to FY25 with Pi/API business growing at the rate of 82.4% CAGR during same period.

History and milestones

The company was established as Jet Chemicals in Shahad (Unit-1) by Mr. BL Arora, starting with production of saccharine in 1970. It entered into the contrast media segment with building block (5-NIPA) in 2000, before stepping into the PI/API space in 2002. In 2003, it commenced operations in Ambernath facility (Unit-2) under Blue Circle Organics. In 2017, the company commissioned a semi-automated facility dedicated to manufacturing contrast media. Later, it acquired Mahad facility (Unit-3) in 2020, and another site in Ambernath (Unit-4) in 2021. Ahead of its IPO in 2022, the company merged Jet Chemicals and Blue Circle Organics to create BlueJet Healthcare.

Business Segments

BlueJet has 3 business segments: 1) Contrast media intermediates, 2) high-intensity sweeteners and 3) PI/APIs (CDMO)

Contrast media: Contrast media are agents used in medical imaging to enhance the visibility of body tissues under X-rays, CT scan, MRI or ultrasound. Bluejet supplies a critical building block and several advanced intermediates for iodine-based X-ray/CT contrast agents and gadolinium-based MRI contrast agents primarily to three of the largest contrast media manufacturers including GE Healthcare, Guerbet, and Bracco directly. The company maintains long-standing relationships with these manufacturers, spanning from four to 24 years.

Sweeteners: Bluejet is involved in the manufacture of saccharin and its salts. The product has high customer stickiness due to 1) consistency of taste, which is a key factor for its customers, including FMCG companies and oral care companies. Further, other essential factors are to maintain their product quality, consistency, taste and brand equity; and 2) given stringent regulations on the use of ingredients in food and beverages by regulatory agencies, customers prefer long-term stability in supply-chain operations. Bluejet supplied sweeteners to >300 customers and is among the select suppliers for several MNCs such as Colgate Palmolive, Unilever, Prinova, and others.

PI/APIs: Bluejet focuses on collaborating with large pharmaceutical companies (innovators/generic), supplying pharma intermediates that serve as building blocks for APIs in chronic therapeutic areas. The company engages with innovators early in the drug development process, which provides it with the opportunity to continue expanding its relationship with these customers as drug development progresses through the clinical phase and into commercial manufacturing. Bluejet has been a CDMO for certain products over the past two decades. The company has a pipeline of about 20 new opportunities out of which 6 are in late phase 3 or commercial phase.

Contrast Media Intermediates

Contrast media are specialized chemical agents designed to improve the visibility and contrast in various imaging modalities, such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. These agents are administered to patients prior to scans, where they are selectively absorbed or distributed in body tissues, enhancing image quality by altering signal intensity or density. This improved visualization aids in the accurate diagnosis of conditions like tumors, infections, blood clots, internal injuries, bleedings, and chronic diseases including cancer, cardiovascular disorders, and pulmonary ailments.

Global contrast media market is estimated to be $6.9B in 2023 which is expected to reach $13.9B by 2032 growing at 8.1% CAGR. Contrast media can be divided into three key segments based on the imaging modality for which they are used: (1) Iodine-based contrast media which are used as x-ray and CT scan contrast agents (2) Gadolinium based-contrast media used as MRI contrast agent and (3) Microbubble-based contrast media used in ultrasound contrast agent.

The iodine-based segment dominates due to its widespread use in high-volume CT procedures, which account for over 60% of global contrast-enhanced imaging. Gadolinium agents are critical for neurological and oncological MRIs, while microbubbles are niche agents used in cardiology and liver imaging.

Bluejet has been manufacturing contrast media intermediates for more than two decades. Global contrast media formulations industry is highly concentrated with four players accounting for ~75% of global sales of contrast media formulations. These four players are: Bayer, Bracco, GE Healthcare, and Guerbet. BlueJet supplies contrast media intermediates to 3 of the top 4 contrast media formulation manufacturers, with whom it has had long-term relationships (4-20+ years). The company currently has a commercialized portfolio of 19 contrast media intermediates, out of which 17 are in iodinated contrast media while 2 of them for gadolinium contrast media.

The largest product in Bluejet’s contrast media intermediate portfolio is ABA-Hcl. ABA HCl is used as an intermediate in the synthesis of iodinated contrast agents, including Iohexol, Ioversol, and Iodixanol. GE Healthcare procures ABA HCl from the company to manufacture Iohexol and Iodixanol, which collectively account for ~45% of the iodinebased contrast media market. Apart from that, the company also produces 5-NIPA (5-Nitroisophthalic Acid), NIPA-DME (5-Nitroisophthalic Acid Dimethyl Ester), and 3- Aminobenzoic Acid.

Forward integration into Iodinated HCl

The company started in the early 2000s by making relatively simple starting materials like 5-Nitroisophthalic Acid (5-NIPA) – a nitrated aromatic acid that is the foundational building block for many iodinated contrast agents. The company has, over the years, moved up the value chain by developing advanced intermediates (NIPA → NIPA DME/MME → ABA HCl → Iodinated ABA HCl).

BlueJet initiated the supply of validation batches of Iodinated ABA Hcl to one of its existing customer in 4Q FY25. The advanced intermediate has recently been validated by the customer and is expected to start contributing meaningfully to Blue Jet’s top line from 2Q FY26. This advanced iodinated intermediate will be used in the manufacture of Ioversol, a non-ionic CT contrast agent marketed as Optiray (initially by Mallinckrodt, now by Guerbet/Bracco) which has been approved in more than 65 countries. Ioversol has low viscosity which helps reduce infusion time and is also available in prefilled syringes that helps prevent microbiological contamination (particularly in the case of immunocompromised patients). iodinated ABA-HCl has four-times higher realisation than ABA-HCl and 16× higher than 5-NIPA. BlueJet’s iodinated ABA-HCl venture was in collaboration with Guerbet, aimed at Guerbet’s needs for Ioversol (Optiray) production.

Gadolinium based intermediates

Bluejet is expanding its presence in gadolinium contrast media where it has two products – 1,4,7,10-Tetraazacyclododecane (Cyclen) and Pentanedioic 2-Bromo,1,5- Dibutylester (BGB). BlueJet is supplying Guerbet (and its partner Bracco) with a specialized intermediate for the latest MRI contrast agent, Gadopiclenol. Gadopiclenol is a new high-relaxivity gadolinium-based agent co-developed by Guerbet and Bracco, recently approved in the US (Sep 2022) and EU (Dec 2023) under brand names Elucirem™ (Guerbet) and Vueway™ (Bracco). It provides similar image enhancement with only half the gadolinium dose compared to older agents. BlueJet produces Pentanedioic 2-bromo-1,5-dibutyl ester (BGB), an intermediate used in the synthesis of Gadopiclenol.

Bluejet plans to achieve growth in gadolinium contrast media intermediates, and it expects to move up the value chain as it has in iodinated contrast media. It has also succeeded in signing a contract to supply key intermediate for NCE in gadolinium contrast media showing promising prospects.

Backward integrating into APD

Bluejet's largest raw material is 3-Amino-1,2-propanediol (APD) which is required to produce ABA HCL. More than 70% of Bluejet's imports are purchase of APD, which it imports currently from Europe & China. BlueJet is building a continuous-process plant at Unit III to manufacture APD. The plant (capex ~₹300 cr) is on track to be commissioned in H2 FY26, with around ₹100 cr already spent. The upcoming capacity of APD is anticipated to be more than the company’s in-house requirement.

Contrast media has better margin profile compared to pharma intermediates and sweeteners. Reading management’s commentary, our base case suggests contrast media will be major growth driver in coming years. GE HealthCare announced a US$ 138 mn investment in Feb 2025 to build a new facility in Cork, Ireland; the site will add ~25 million additional doses of contrast media annually by 2027 and GE expects demand for iodine-based agents to double over the next decade.

High intensity sweeteners

Bluejet started manufacturing a high intensity sweetener namely saccharin in 1970. Global demand for saccharin is estimated to be around 37000-40,000MT per annum . High intensity sweeteners are compounds that are commonly used as substitute for sugar in food, beverages, oral health, and pharmaceutical products. End usage industries for sweeteners include beverages , confectionery products , oral care products , pharmaceutical products and animal feed. Company offers high intensity sweeteners to over 300 customers in customers in India, the US, Europe, Asia, and LATAM.

Growth in high intensity sweeteners is driven by: 1) Growing incidence of diabetes and obesity and corresponding need for low-calorie foods; 2) shifting consumer preference, 3) increase in investment in R&D by manufacturers of end-products; and 4) rising urbanisation and changing lifestyle, resulting in higher consumption of ready-toeat/processed foods.

Sweeteners division has two kinds of customers – 1) long-term customers who require steady growth; and 2) spot customers, or sales through distributors. Long-term customers are sticky & contracts are generally long term in nature. Spot customers are relatively less sensitive, and pricing is priority. Revenues from high intensity Sweeteners segment has been severely impacted with the rise in Chinese competition primarily in spot markets as company chose not to enter into pricing wars. Company has its focus on the FMCG customers which are sticky and have high quality requirements.

Globally, seven major high intensity sweeteners are popularly used. Aspartame and Sucralose together have >50% share in high intensity sweeteners. The next two large sweeteners are cyclamate and saccharin. Saccharin forms 12-14% (by value) and 17-19% (by volume) of high-intensity sweeteners market. saccharin is preferred due to its taste consistency , established safety profile , cost effectiveness and versatility.

Pharma Intermediates & API

Bluejet is primarily focused on the manufacturing of pharma intermediates used in the therapeutic areas of oncology, CNS and CVS and has over 40 customers in India and more than 15 customers globally across the US, Europe, and Asia. Company’s PI/API segement’s revenue has grown from 41cr in FY21 to 464cr in FY25 growing at a CAGR of 82.4% . This growth is driven primarily by multi-year supply agreement with Esperion for advanced intermediate which is used to produce bempedoic acid , a lipid lowering drug. Bluejet recently commercialised 120KL of new capacity owing to the demand for the intermediate.

Esperion therapeutics developed and now markets the first oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering drugs : NEXLETOL® (bempedoic acid) and NEXLIZET®(bempedoic acid + ezetimibe). These medications target patients at risk of cardiovascular disease who struggle with high LDL-C, especially those who cannot tolerate statins (due to side effects like muscle pain) or need additional LDL reduction beyond statins.The drugs act by inhibiting ATP citrate lyase (ACLY) in the liver, reducing cholesterol synthesis upstream of statins’ mechanism, but importantly they are inactive in muscle tissue – a key reason bempedoic acid avoids the muscle-related side effects that plague some statin users. Esperion recently achieved 1 million prescription milestone in US for nexletol and nexlizet.

Cholesterol is a waxy, fat-like substance that the body needs for cell membrane integrity, hormone synthesis and other functions. It is transported in the blood as lipoprotein particles. Low-density lipoprotein (LDL) particles deliver cholesterol to tissues and are considered the “bad” cholesterol, while high-density lipoprotein (HDL) particles carry cholesterol away from tissues and are considered the “good” cholesterol. Elevated LDL leads to atherosclerosis, where cholesterol deposits in arterial walls narrow the arteries and can precipitate heart attacks or strokes. Cardiovascular disease remains the leading cause of death globally, and lowering LDL cholesterol is a proven strategy to reduce cardiac event.

The global burden of elevated cholesterol has reached epidemic proportions, with LDL cholesterol-related disabilities increasing 37.3% over 25 years from 2.8% of global disease burden in 1997 to 3.8% by 2017. Currently, 32.8% of U.S. males and 36.2% of U.S. females have cholesterol levels exceeding 200 mg/dL, while cardiovascular diseases account for 35.5% of cholesterol management market revenue.

Statins

Statins are the dominant first-line treatment. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. HMG-CoA reductase catalyzes the rate-limiting step in hepatic cholesterol biosynthesis. By competitively inhibiting this enzyme, statins reduce hepatic cholesterol production, upregulate LDL-receptor expression and accelerate clearance of LDL particles from the blood. Statins (like atorvastatin, rosuvastatin) are inexpensive generics that lower LDL by ~30–50% and reduce risk of heart attacks and strokes by ~25–30% over several years in high-risk patients. Statins are widely prescribed to tens of millions of patients worldwide.

Currently, statins command 45.2% of the hyperlipidemia drugs market, with atorvastatin dominating 36-39% of statin market share. The total statin market ranges from $15.5-35.35 billion depending on scope, while generic penetration has driven 75% reductions in out-of-pocket costs and 28% overall expenditure savings despite increased utilization. Clinical efficacy data demonstrates 20-60% LDL cholesterol reduction depending on statin and dose, with 20-30% reduction in major adverse cardiovascular events. However, up to 20–30% of patients report muscle-related side effects or other issues that make them statin-intolerant.

Major non-statin cholesterol medications and mechanisms

Ezetimibe: A once-daily oral drug that inhibits cholesterol absorption in the intestine (Merck’s Zetia, now generic). It provides ~15–20% LDL reduction & serves as the firstline non statin therapy, selectively inhibiting cholesterol absorption at the intestinal brush border via Niemann-Pick C1-Like 1 (NPC1L1) protein blockade.

PCSK9 Inhibitors: High-potency LDL-lowering biologics (injectable monoclonal antibodies such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab)). They can slash LDL levels by ~50–60%. Clinical trials demonstrated ~15% reductions in cardiovascular events in secondary-prevention patients already on statins. These agents are very effective, but subcutaneous administration every 2 weeks to 6 months and annual costs of $5,800-9,750 limit accessibility despite 50- 60% LDL cholesterol reduction capabilities.

siRNA Therapy (Inclisiran): A next-generation, injectable LDL-lowering therapy that uses RNA interference to durably lower cholesterol with just two maintenance doses per year. Unlike monoclonal antibodies that bind to existing PCSK9 protein, Inclisiran works by preventing the protein from being made in the first place. It is a smallinterfering RNA (siRNA) that specifically targets and silences the messenger RNA (mRNA) responsible for producing PCSK9 within liver cells. This potent mechanism results in a sustained LDL cholesterol reduction of ~50%. Its primary advantage is its administration schedule; after two initial starter doses, it is given by a healthcare professional just once every 6 months, which dramatically improves convenience and ensures long-term adherence for high-risk patients needing significant LDL reduction on top of statins. The first-in-class drug is Novartis's Leqvio (inclisiran).

Bempedoic acid: Bempedoic acid is the first oral non-statin cholesterol-lowering therapy to demonstrate cardiovascular outcomes benefits and typically lowers LDL by ~20–25%. It offers moderate LDL reduction and proven risk reduction to patients who cannot tolerate statins (or need more LDL lowering despite statins), with the convenience of a pill rather than an injection. Additionally, bempedoic acid demonstrates 34% reduction in high-sensitivity C-reactive protein, suggesting antiinflammatory cardiovascular benefits beyond LDL cholesterol lowering.

Benefits of bempedoic acid

• Effective LDL-C reduction – Bempedoic acid provides 17–29 % LDL-C reduction as monotherapy and around 30 % when combined with ezetimibe

• Statin-free mechanism – ACLY inhibition occurs upstream of HMG-CoA reductase and is activated primarily in the liver. This liver-selective activation minimizes muscle exposure to the drug and reduces myalgia, making it suitable for statin-intolerant patients

• Cardiovascular outcome benefit – CLEAR Outcomes showed significant reductions in major cardiovascular events, including myocardial infarction and revascularisation

• Combination therapy – Bempedoic acid is most effective when combined with ezetimibe or used as part of triple therapy with statins. Its ability to augment lower-dose statins may allow some patients to achieve LDL targets without the adverse effects associated with high-dose statins

Arrangements & Partnerships

Esperion operates a lean commercial model in the U.S., directly marketing NEXLETOL and NEXLIZET with its own specialty sales force targeting cardiologists and primary care physicians.

Daiichi Sankyo Europe (DSE) holds exclusive rights (brand names NILEMDO for bempedoic acid and NUSTENDI® for the combo) and has launched the products across several EU countries.Esperion earns tiered royalties on DSE’s sales. In 2021, the partnership expanded to include Asia (ex-Japan), Middle East, and Latin America for an additional $30 M upfront plus up to $175 M in milestones and 5–20% royalties

Otsuka Pharmaceutical acquired exclusive development and commercialization rights in 2020 (a deal valued up to $510 M, including upfront and milestones). Otsuka ran local trials and filed a NDA in Japan in nov 2024. Approval and launch in Japan (with national insurance pricing) are expected in H2 2025, which could open a major new market.

In May 2025, Esperion partnered with HLS Therapeutics for exclusive Canadian rights. Terms include an upfront payment, up to ~$5 M in near-term milestones, and tiered royalties. Health Canada approval of NEXLETOL/NEXLIZET is anticipated by Q4 2025, targeting ~2.6 million Canadians living with diagnosed heart disease.

bempedoic acid prescriptions growing 15% quarter-over-quarter in the US market, with annual growth exceeding 50%. Esperion achieved over 1 million retail prescriptions in the US as of Q1 2025, with strong growth trajectory in European markets led by Germany.

CLEAR Outcomes Trial & Upcoming Triple Combination therapy

CLEAR Outcomes trial involved 13,970 patients, evaluating bempedoic acid (180 mg daily) against a placebo over a median follow-up of 40.7 months. The primary objective was to determine if bempedoic acid could reduce the incidence of major adverse cardiovascular events (MACE-4).

In patients with obesity, a subset of the trial, bempedoic acid led to placebo-corrected reductions of 22.5% in low-density lipoprotein cholesterol (LDL-C) and 23.2% in highsensitivity C-reactive protein (hs-CRP) at six months. Overall, bempedoic acid treatment resulted in a 23% reduction in MACE-4 compared to placebo (Hazard Ratio, 0.77; 95% CI, 0.67-0.89.

Bempedoic acid received a Level 1a recommendation in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline, strengthening its clinical positioning.

Esperion is also advancing investigations into triple combination therapies and new indications intended for the U.S. market and are being developed in parallel. company is building two fixed-dose, once-daily tablets that marry its ACL-inhibitor bempedoicacid (180mg) with ezetimibe (10mg) and a moderate-intensity statin—one version contains atorvastatin20mg, the other rosuvastatin 10mg.

In a 63-patient randomized Phase2 study, six weeks of the atorvastatin-based triple pill drove a -63.6% mean reduction in LDL-C versus placebo, pushed 90% of participants below the 70mg/dL LDL-C goal, and cut high-sensitivity CRP by about -48%. New-drug applications (NDAs) for both triple combinations are targeted for 2027, positioning a first U.S. launch late that year if approved.

Other PI/API molecules

Bluejet mentions a huge surge in RFPs for the CDMO business . Apart from bempedoic acid , company is building capacities on newer chemistries like peptides, intermediates for GLPs. Company is incurring capex of 40cr for building a R&D center in hyderabad and the pilot plant in unit 2 which will help it with upcoming RFPs. Company is currently tracking 20 new opportunities with 6 in late phrase 3 or commericial phrase.

Manufacturing Facilities & capex plans

In the last 4 years company has quadrupled its manufacturing capacity from 230KL to 1,021 KL in FY25 and plans to add another 1000KL capacity in next 2-3 years owing to strong demand across segments.

Unit I in Shahad (near Kalyan, Maharashtra) is Blue Jet’s oldest manufacturing facility. It has an installed reactor capacity of about 200 KL and is certified for WHO-GMP and ISO compliance. This plant primarily produces contrast media intermediates and highintensity sweeteners (e.g. saccharin), and also handles select pharma intermediates/APIs on a smaller scale.

Unit II at Ambernath is Blue Jet’s flagship plant and largest capacity site, with ~607 KL of installed reactor volume. It is a multi-purpose facility with USFDA, WHO-GMP, ISO, and OHSAS accreditations. Unit II manufactures the bulk of Blue Jet’s contrast media intermediates for global CT/MRI contrast agent makers, as well as high-intensity sweeteners and various pharmaceutical intermediates (including advanced drug intermediates). In FY2025 the company completed a two-phase expansion here, adding 157 KL of capacity via two new production blocks. One block was dedicated to a cardiovascular drug intermediate (the key intermediate for Bempedoic Acid), and another to a new gadolinium-based contrast media intermediate (an NCE launched in Q4 FY25). Unit II is running at about 60–65% utilization and has ample headroom to scale output further.

Unit III in Mahad (Maharashtra) is a facility being developed to strengthen Blue Jet’s supply chain and technology capabilities. It currently has ~213 KL installed capacity, and is undergoing a Capex of ₹300 Cr to build a continuous-process plant for backward integration. This Unit III expansion is a highly engineered flowchemistry facility designed to manufacture APD for Blue Jet’s contrast media intermediates in-house. The initial Mahad project is on track for commissioning by H2 FY26. As of Q4 FY25, about ₹100 Cr of the planned ₹300 Cr CapEx had been invested in Mahad, with the remainder to be spent by FY27 as the project progresses.

Unit IV in Ambernath is a greenfield site acquired in FY2021 to expand Blue Jet’s capacity for contract development and manufacturing (CDMO) work. The Unit IV facility is expected to have about ~71 KL of reactor capacity once built.

Key Risks

Potential change in the sourcing strategy following a transition in manufacturing of Bempedoic Acid to the innovator's partner: Under a supply agreement, the innovator currently supplies bulk tablets of Bempedoic Acid to its partner in Europe. As part of an amended agreement between the innovator and its European partner, the innovator's partner will gradually assume manufacturing and supply responsibilities in Europe and certain other geographies. Any change in the sourcing strategy, in terms of a change in the supplier of the intermediate, could have a material impact on our intermediate sales estimates

Customer and product concentration: Blue Jet's largest customer in CMI & Esperion in PI/API contributes more than 50% of FY25 revenues . Any change in partnership can be a risk going forward .

Fire incidents: The company faced two fire incidents in its manufacturing facilities in 2023 (Unit 2 in Jun-23, and Unit 3 in Nov-23).

Competitive Pressure in Sweeteners: In the artificial sweetener segment (saccharin), BlueJet faces intense competition from Chinese suppliers, including dumping of lowpriced material which has led to slow growth in this segment . Company chose not to enter into price wars by focusing on FMCG clients .

Regulatory & Compliance Uncertainties: company is involved in a tax dispute with authorities: it received income tax assessment orders disallowing depreciation on goodwill for FY2020–FY2023, resulting in demand notices (under appeal)

Growth Triggers

Developments in contrast media : In contrast media company has multiple growth triggers which might fuel growth in coming years (1) The company is moving up the value chain in iodinated contrast media which has 4x more realisation compared to its existing largest product ABL HCL (2) BlueJet’s new Unit-3 Mahad facility (a continuousprocess plant) is being established to manufacture a critical raw material for contrast media in-house. (3) secured a contract to supply a key intermediate for a novel (NCE) gadolinium-based contrast agent.

CDMO ramp up : The non-statin market is growing at 15-16% CAGR in the US. Bempedoic acid’s adoption is rising in US/EU with 60% prescription growth last year. BlueJet's 120 KL dedicated capacity for the cardiovascular intermediate is now operational and running optimally. Management indicated they can double capacity through debottlenecking if required, without adding new reactors, providing flexibility to meet growing demand. Patent protection for bempedoic acid extends to 2031 in the US and 2032 in Europe (due to patent term extensions and marketing exclusivity), providing significant runway for growth ahead.

R&D and New Opportunities: Company is setting up new R&D labs and doubling its scientific talent to pursue emerging opportunities in complex therapeutics. BlueJet is developing expertise in amino-acid derivative chemistry for GLP-1 drugs and creating dedicated CDMO labs for fast-turnaround projects for virtual biotech clients.

Capacity Expansion Plans: Bluejet is adding ~1,000 KL reactor capacity over next 2–3 years to support future volumes.

Subscribe now

Subscribe now

Astra microwave products is a manufacturer and designer of high performance Radio frequency (RF) and microwave modules, sub-systems and systems. It’s products find application in defense, space, meteorology, homeland security systems integration and unmanned ground vehicles and is steadily moving up from components/sub‑systems to full systems and solutions, especially in radars and weather applications.

What sets it apart?

Astra has over 30 years of deep domain expertise and DSIR-recognized research and development capabilities, with a team of more than 400 R&D staff with comprehensive in-house testing capabilities including MMIC (Monolithic Microwave Integrated Circuit), digital, PCB (Printed Circuit Board), mechanical, and environmental testing across 6 facilities located in Hyderabad and Bangalore. Astra is one of the few private sector players in India that has the capability to develop and supply GaN & GaAs MMIC products up to 40 GHz.

The company has established long-term relationships with DRDO laboratories, DPSUs, and ISRO and are an approved production partner for multiple foreign OEMs including Elta, Elbit, Rafael, and Thales. Astra execute both BTS (Build-to-Specification) projects, which are high value-added contracts, and BTP (Build-to-Print) projects, which serve as capacity fillers.

P.S - Read this deep dive in a better format here

History

Astra was incorporated in 1991 in Hyderabad by a team of DRDO‑trained scientists in RF/microwave and digital electronics. Although the founders had defense in mind, the company’s first break came from India’s early-1990s telecom boom, which helped seed product development and cash flows. By 1993, Astra’s first microwave components and sub-systems were finding their way into DRDO radar programs, alongside early telemetry and strategic electronics work. To fund infrastructure, people, and test capability, Astra went public early listing on Indian exchanges in 1995. In 1997, it recorded its first R&D deliveries into a DRDO surface-to-air missile telemetry program.

Through the 2000s Astra deepened in defence and stepped into space. ISRO began awarding the private sector space‑grade work in the early 2000s, and Astra became a recurring supplier of on‑board RF sub‑systems and ground satcom/telemetry gear. Inside the company, it built a fabless MMIC design team (GaAs/GaN) to de‑risk critical RF devices and to shrink/modernise transmit‑receive modules - capabilities that would later prove important for AESA radar programs. It also kept investing in labs: EMI/EMC, environmental test, and multiple SMT lines across expanding Hyderabad units.

From the late 2010s into the early 2020s, Astra moved up the value chain from sub‑systems to full systems and integration. It broadened radar offerings (ground surveillance, coastal, weather) and meteorology/hydrology instruments, while commissioning a near‑field antenna test range in Bengaluru to qualify active phased arrays. In meteorology, Astra delivered multiple X‑ and C‑band Doppler Weather Radars and automated weather networks for IMD, and built a steady presence in wind profilers and hydrology stations.

Today the company has three production units and two R&D units that also include an exclusive space qualified facility. Astra today has an array of assembly and test facilities that include 3 Automatic assembly lines for PCBA assembly, Seven Class 10K and one Class 100K clean rooms, functional test infrastructure that extends from 30MHz up to 40GHz, in-house Environmental Test facilities including EMI/EMC facility and a first for any Indian Private Industry - Near Field Antenna Test Range (NFTR).

business segments

Defense

Radar electronics

Radar electronics involve systems that use radio waves for detecting, tracking and navigating objects. Advanced technologies like Active Electronically Scanned Array radars enhance detection capabilities and operational efficiency. These systems are critical in defence, aerospace, automotive (for ADAS features like adaptive cruise control), and infrastructure sectors.

The Indian radar market was valued at USD 230.3 million in 2024 and is projected to grow at a CAGR of 20.62%, reaching nearly USD 1.4 billion by 2033. This growth is driven by increasing defense budgets, modernized airport infrastructure and the expansion of civil aviation, with over 500 million air travelers expected in India by 2030. The sector is expanding due to advancements in radar technology, rising demand for surveillance systems and government initiatives promoting indigenous manufacturing.

The company has established itself as India’s leading private sector radar house with capabilities spanning from MMIC chip design to complete system integration, positioning it to capitalize on the expanding domestic and export radar markets.

Some of the products in this segment -

• Active Antenna Array Unit (AAAU) - the first private company to deliver the Active Antenna Array Unit (AAAU) for India’s indigenous Uttam AESA radar used in the Tejas fighter jet and similar shipborne systems, enables detection, tracking, and missile/fire control.

• X-band AESA seeker - Advanced radar “eye” fitted in missiles to guide them precisely to moving or hidden targets.

• QRSAM subsystems - Vital electronic subsystems (like radar electronics and RF modules) for India’s mobile air-defense Quick Reaction Surface-to-Air Missile (QRSAM), enabling rapid detection and interception of aerial threats.

• counter UAS - anti-drone solution combining active radar detection, passive RF sensors, and multi-band jamming capabilities (including non-standard frequencies) with omni-directional coverage extending up to 5+ kilometers range.

• Shipborne Multi-Function Radars - Indigenous replacement for imported naval radar systems, providing 360-degree threat detection and tracking capability for Indian Navy vessels across different ship classes and operational requirements.

• Fire Control Radar Subsystems - Critical T/R modules, signal processing units, and RF front-ends for air defense fire control radars like ADFCR, enabling precise target acquisition and weapon guidance for Army air defense systems.

• Photonics Radar Subsystems - Next-generation radar technology utilizing photonics for enhanced bandwidth and performance characteristics, representing cutting-edge development in collaboration with DRDO for future radar architectures.

Electronic warfare

Electronic warfare (EW) involves the strategic use of the electromagnetic spectrum to detect, intercept, disrupt or deceive enemy systems while protecting friendly operations. It includes Electronic Attack (EA), Electronic Protection (EP) and Electronic Support (ES), with modern systems incorporating AI, jammers and directed energy weapons. EW is primarily used in defence (threat detection, secure communications), homeland security (counter-terrorism) and intelligence agencies (SIGINT/ELINT operations).

key products here:

• Wideband & Ultra-Wideband Subsystems (0.5-40 GHz) - Critical RF front-ends for EW systems covering multiple threat bands, enabling simultaneous detection and jamming across the electromagnetic spectrum for naval, airborne and ground platforms

• DIFM (Digital Instantaneous Frequency Measurement) Receivers - High-speed receivers that instantly identify and characterize enemy radar frequencies, forming the core of radar warning receivers (RWR) and electronic support measures (ESM) systems

• Compact Microwave Receiver System (0.5-40 GHz) - Recently delivered to DLRL/DRDO in 2025, this wideband receiver provides comprehensive spectrum coverage for electronic intelligence (ELINT) and signal intelligence (SIGINT) applications.

telemetry

Telemetry is a critical technology for remote measurement and real-time data transmission, widely used in defense, aerospace, healthcare, and environmental monitoring. In defense, it tracks missile and aircraft performance, while in healthcare, it enables continuous patient monitoring. Automotive industries use telemetry for vehicle diagnostics and environmental agencies rely on it for weather forecasting and disaster management. Astra supplies telemetry subsystems for platforms like the LCA Tejas and IJT aircraft.

Space

Astra Designs, develops and manufactures components and sub-systems used in ground-based modules and Slevel (on-board) modules. Astra have been among the key players for the development of sub-systems for India’s Radar Satellite & Geosynchronous Satellite program, Resourcesat, Megatropics and Cartosat for Indian space programs by ISRO. Astra has a order book of 239cr as of 1Q26 end from space sector. Opportunity size in this segment is close to 600crs till FY28.

key products here:

• Flight-qualified RF sub-systems (filters, amplifiers, receivers, antennas) flown on ISRO satellites (RISAT, GSAT, Cartosat, Resourcesat, Megha-Tropiques).

• SATCOM terminals and ground stations; 7.3m ground telemetry systems for ranges like ITR.

Astra has established a wholly owned subsidiary by name astra space technology private limited to focus on space sector in a bigger way and taken steps to recruit people and assembly rooms for assembly and integration of small-sized satellites. Astra has also formed a SPV with a leading leading defense PSU to bid for a specific space tender.

Active Programs & Recent Deliveries:

• Onboard digital signal processing system for satellite payloads (recently delivered - positions Astra to build complete payloads)

• Critical subsystems for DRDO/ISRO satellite programs: OTGR, Anvesha, SAMOOHA

• Multi-function pulse compression radar delivered to ISRO (site acceptance completed)

• Recent mission where Astra contributed 9% of payload value and 3% of overall satellite value

Meteorology & hydrology

Meteorology ensures precision measurement in manufacturing. Meteorological devices are essential tools for collecting and analyzing atmospheric data, crucial for weather forecasting, climate research and various industrial applications. These instruments measure temperature, atmospheric pressure, humidity, wind speed and direction and precipitation. Common devices include hygrometers, barometers, thermometers, anemometers, and rain gauges. In sectors like aerospace, defense, agriculture, and environment monitoring, the need for accurate, real-time weather data has grown substantially.

Hydrology on the other hand monitors water resources using sensors, GIS and real-time analytics. Astra’s components enable accurate data collection. The Company specializes in solutions for agriculture (irrigation planning), energy (hydroelectric dam management) and urban infrastructure (Smart water grids).

Products by the company in this segment:

• Doppler Weather Radars (DWR) - X/C-band - Astra has delivered 13 out of 14 DWRs currently operational across India for IMD.

• Wind Profiler Radars - Advanced atmospheric monitoring systems that measure wind speed and direction at multiple altitudes, crucial for aviation safety and weather prediction

• Water Level Measurement Systems - Advanced bubbler and radar-based sensors for accurate water level monitoring in rivers, reservoirs, and groundwater systems

Management expects an order book exceeding INR 400 to 500 crores from meteorology and hydrology segments within next 2 years with opportunities from MAUSUM program, Weather as a Service and some other programs.

Subsidiaries & JV

Joint ventures

Astra Rafael Comsys private Limited

Astra Rafael Comsys private Limited is 51:49 joint venture between Astra and Rafael Defense Systems Limited, Israel. Astra alone holds 50% in this venture. ARC is engaged in India in indigenous development, production, and integration of high-end digital communication systems which includes a wide range of technologies and products like SDR, ESM and Cognitive Radio technology.

key products:

For FY26, management guides to ~INR 350+ crores revenue with PBT of 10% and an order book already INR 400‑plus crores, with visibility to secure close to $100 million across three major contracts before March ’26 and potential aggregate inflows of 800 crores.

Subsidiaries

Bhavyabhanu Electronics Private Limited : This is the Company’s wholly owned subsidiary that possesses state-of-the-art manufacturing and testing facilities addressing global standards.

Aelius Semiconductors Pte. Ltd: This is a fabless MMIC design house in Singapore that specialises in designing GaAs and GaN MMIC products. The Company utilizes leading foundries worldwide for fabrication and utilizes cutting-edge facilities for testing and packaging products.

Astra Space Technologies Private Limited: This is the Company’s wholly owned subsidiary engaged to carry on the business of design, development, and integration of satellites, satellite pay loads, launching of satellites, and establishment of ground stations for satellite tracking. Management also noted that a leading defense PSU formed an SPV with Astra to bid a specific space tender.

What underpins my bullishness

Transition from a build‑to‑spec sub‑system supplier to a systems integrator/solutions provider

In the past when the company had no sectoral understanding, it focused on components and sub systems. In doing so, the Company gained an insight into building a sub-system from scratch; thereafter, it developed an insight into the manufacture of other sub-systems.
Now the focus of astra is to move from fabrication and assembly of sub-systems to complete systems. In FY25 company generated only 15% of its revenues from large and complex systems which it intends to increase to 50% in next three to five years, strengthening its margins and return ratios.

Strong Order Book & BTP vs BTS

There are fundamentally two types of orders for Astra micro:

Build-To-Spec (BTS): customer gives a performance specification and then astra designs, develops, qualifies, and then produces the subsystem/system. BTS has a higher value add and provides better margins to Astra. Company here works with systems integrators like DPSUs (Defence Public Sector Undertakings) and others for commercialization of the products.

Build-To-Print (BTP): design is usually provided by the OEMs itself, so astra manufacture, assemble, test to the customer’s drawings with not much value addition and lower margins compared to BTS orders. Astra works with many foreign OEMS for producing their products in India under this mode for meeting their offset requirements with key customers including Elta Systems Ltd, ELBIT, Rafael, Thales.

Order book for astra stands at Rs 1,891 cr as of 1QFY26 (standalone), with 90% + of orders being BTS (higher value-add/margins). New wins included AAAU for LCA Mk‑2 and Su‑30 and radar sub‑systems for Akash Prime and VL‑SRSAM, plus weather radars and agro‑AWS for IMD. Management guided FY26 order inflow of Rs 1,300–1,400 crore, revenue growth near 20%, and PBT margins around 18%, with systems (radar/EW, counter‑UAS) as the growth engines.

Key programs and TAM

Have they delivered in past?

Key Qualitative Promises vs. Delivery

Product Launch Track Record

risks

1. B2G risk: Revenue is dominated by Indian defense B2G programs where DRDO specs and L1 tendering drive awards. Delays in orders for subsystems remains a major risk factor

2. Working-capital intensity: company has a high working capital cycle; this can force higher borrowings or equity raise for further growth

3. Supply-chain risk: MMIC and mil-grade parts are long-lead / export-controlled; shortages can delay builds or force redesigns.

4. Execution/qualification risk: System-level programs carry higher integration risk.

Growth triggers for Astra microwave

• Strong order book of 1,891 crores providing visibility for coming quarters.

• QRSAM could be a very big optionality for astra, keep tracking whenever BEL gets the order (4Q26)

• Guidance of INR 1,300-1,400 crores order inflow for FY26, with INR 1,100 crores remaining to be booked.

• Participating in Project Mausam with INR 2,000+ crores allocation for weather radar deployment.

• Expected to book INR 400-500 crores orders from weather/meteorology segment in next 2 years.

• ARC JV targeting $100 million order book and expected to book additional INR 800 crores orders in FY26.

• Developing 3 new 100% Astra radars to be delivered within 12 months with massive global market potential.

• Space business order book at INR 239 crores with satellite assembly capabilities being established.

• MMIC chips portfolio targeting $50+ million sales globally over next 5 years.

• Anti-drone systems participating in 36+ programs with massive market potential.

• Virupaksha program development could result in business twice current turnover when productized.

• Ground penetrating radar targeting 100+ units annually replacing imports.

• Total business potential of INR 4,000-5,000 crores over next 5-6 years from just new initiatives.

• Revenue growth guidance of 18-20% year-on-year with maintained profit margins.

• Focus on build-to-spec orders providing higher value addition vs build-to-print.

• X-band seeker expecting 50-60 numbers in next 2-3 years time frame.

• Ship borne radar development nearing completion with Navy showing interest for more.
  
  

Founded in 1981 in Bangalore, Sansera started with a single order from an Indian auto OEM. Four decades later, it supplies to Bajaj, Honda, TVS, Royal Enfield, Yamaha, Hero, and Maruti Suzuki domestically. It exports to 27 countries. It operates 17 manufacturing facilities across India and one in Sweden.

The company now faces a fundamental question. Its core business depends on internal combustion engines. Electric vehicles need fewer mechanical parts. Sansera’s response has been to diversify into aerospace, defence, semiconductors, and EV components while protecting its profitable ICE franchise.

Business Segments: A Deep Dive

Automotive ICE Business (74% of Revenue)

This is Sansera’s bread and butter. The company makes engine and transmission components for vehicles powered by petrol and diesel. The segment breaks down into three sub-categories.

Two-Wheeler Motorcycles (37% of total revenue)

Motorcycles contribute more than a third of Sansera’s revenue. The company supplies connecting rods, crankshafts, and rocker arms to every major Indian two-wheeler manufacturer. Bajaj Auto, Honda, TVS Motor, Royal Enfield, Yamaha, and Hero all buy from Sansera. Some of these partnerships span over 20 years. This stickiness comes from the nature of the product. Engine components require extensive testing and validation before production begins. Once an OEM qualifies a supplier, switching costs are high.

The Indian motorcycle market is the largest in the world. Consumers are buying more expensive motorcycles with larger engines. A 350cc Royal Enfield uses more sophisticated components than a 100cc commuter bike. This premiumisation trend increases the content per vehicle.

For ICE motorcycles, Sansera’s kit value runs around Rs 2,000 per vehicle. For electric motorcycles, this could rise to Rs 10,000 per vehicle. The company can make aluminium forged parts for chassis, suspension, and other structural components that EVs still need.

Two-Wheeler Scooters (7% of total revenue)

Scooters are a smaller but stable segment. Urbanization and last-mile mobility needs drive demand. The market is shifting toward premium models with better features, which suits Sansera’s precision manufacturing capabilities.

The Indian scooter market is transitioning rapidly to electric. Sansera’s participation in EV scooter components remains limited but evolving. The focus remains on high-value drivetrain and precision components for electric two-wheelers in the motorcycle category.

Passenger Vehicles (19% of total revenue)

The PV segment serves both domestic and global OEMs. Products include rocker arms, connecting rods, and shifter forks. Maruti Suzuki is a key customer domestically. Global customers include manufacturers in Europe and North America. FY25 was difficult for this segment. The domestic market slowed. Export markets in Europe and the USA faced their own headwinds. Inventory buildup at customers led to order reductions.

The company sees recovery ahead. New model launches and fresh OEM order wins should support growth. Localisation efforts with global customers are deepening Sansera’s share of business across platforms.

Commercial Vehicles (10% of total revenue)

Sansera serves both medium and heavy commercial vehicles as well as light commercial vehicles. Products span engine parts (connecting rods, brackets, valve bridges), transmission parts (gear shifter forks, intermediate rings), and braking assembly components (crankshafts, guide bushes). The CV industry is cyclical. Domestic and global markets have seen pressure. Sansera has partially offset this through its diversified customer base and increased content per vehicle.

The 2017 acquisition of Mape in Sweden marked Sansera’s entry into heavy commercial vehicles in Europe. Mape specializes in connecting rods for diesel engines used in buses, trucks, boats, and industrial applications like generators and compressors.

Tech-Agnostic and xEV Business (15% of Revenue)

This is where Sansera is building its future. Tech-agnostic components work across ICE, hybrid, and electric vehicles. Chassis parts, steering components, braking systems, and suspension parts fall into this category. These products do not care what powers the vehicle. The xEV segment focuses specifically on electric and hybrid vehicles. Products include clutch assembly parts for battery EVs, transmission parts for hybrids (pinion differential drives, motor generator shafts, gear components), and drivetrain parts for electric two-wheelers.

Combined revenue from tech-agnostic and xEV grew 30% year-on-year in FY25. The order book for these segments stands at Rs 3.1 bn (17% of total order book) for xEV and Rs 1.5 bn (8% of total order book) for tech-agnostic.

Sansera has expanded its aluminium forging operations to serve this market. Aluminium is lighter than steel. Electric vehicles need lightweighting to maximize range. Global EV manufacturers in the US and Europe are key customers. The company secured orders from a new American xEV OEM that started production in the fourth quarter of FY24. Management targets 20% of revenue from xEV and tech-agnostic segments within three years, up from 15% today.

Non-Auto Business (12% of Revenue)

Sansera is building a non automotive business across four verticals.

Aerospace, Defence, and Semiconductor (4.4% of total revenue)

This is the most exciting part of Sansera’s diversification story. The segment has a strong order book of Rs 3.7 bn (20% of total order book). Revenue is expected to double in FY26 from the current Rs 1.3 bn.

In aerospace, Sansera manufactures aerostructure parts, cargo parts, lighting parts, seating parts, engine auxiliaries, and engine casings. The company recently won direct supply contracts from Airbus. This marks a milestone in its aerospace expansion. The company has invested Rs 1.2 bn in aerospace machining infrastructure. The target is Rs 6.0 to 6.5 bn in revenue from a gross block of Rs 3.0 bn, implying asset turns of around 2x.

Semiconductor equipment manufacturing is a newer but high-potential area. Sansera has secured a long-term letter of intent from a global leader in wafer fabrication equipment. The initial annual order is worth US$ 17 mn, expected to scale to US$ 30 mn over three years. To support this business, the company is setting up a Class 1000 Clean Room facility. Semiconductor equipment requires extremely high precision and specialized machining capabilities. This segment should deliver premium pricing and margin accretion.

Off-Road (3.4% of total revenue)

Sansera supplies connecting rods, crankshaft assemblies, balancer shafts, suspension parts, and transmission components for ATVs and off-road vehicles. Key markets include Europe and North America. The segment saw revenue decline in FY25 due to labor issues at a key customer’s facility in Europe. Orders dropped temporarily. Management expects recovery in coming quarters. The company recently added a large European off-road vehicle OEM to its customer base.

Agriculture (2.1% of total revenue)

Products include cam shafts, pump housings, common rail parts, and body flanges for tractors and agricultural machinery. Strong rural demand has supported this segment. Increasing mechanization in farming and expansion of precision agricultural technologies provide a stable revenue base.

Others (1.8% of total revenue)

This includes engineering and capital goods (connecting rods, valve bridges, integral cranks, hubs), power tools (hand tools for residential and industrial applications), and power transmission components (fuse caps).

Investment Thesis

1. Diversification to Non-Auto and EV Segments Reduces ICE Risk

Sansera derives 74% of revenue from ICE components. This creates vulnerability if electric vehicle adoption accelerates faster than expected. The company is addressing this head-on. The plan is to increase the combined share of xEV, tech-agnostic, and non-auto segments from 26% to 40% within three years. This would reduce ICE auto contribution from 74% to 60%.

Of the Rs 18.5 bn order book, 50% comes from ICE auto, 17% from xEV, 8% from tech-agnostic, and 20% from aerospace, defence, and semiconductor. New businesses are growing faster than the legacy business.

2. Two-Wheeler Premiumisation Drives Content Growth

India is the world’s largest two-wheeler market. Sansera has deep relationships with all major OEMs. The premiumisation trend benefits the company directly. Consumers are buying motorcycles with larger engines. A 350cc motorcycle uses more sophisticated and valuable components than a 100cc commuter. Higher displacement means higher content per vehicle.

Tax relief in recent budgets has increased disposable income. Rural demand is improving. Two-wheeler exports are recovering. All these factors support volume growth in Sansera’s largest segment.

3. Aerospace and Semiconductor Businesses Offer High Margins

The ADS segment commands higher margins than auto components. Aerospace and semiconductor customers pay premium prices for precision manufacturing. These industries have longer qualification cycles but stickier relationships once established. Sansera’s Rs 3.7 bn ADS order book provides revenue visibility. The Airbus supply win demonstrates credibility with global aerospace players. The semiconductor equipment order from a global leader validates capabilities in precision machining.

4. Global Footprint Captures Supply Chain Shifts

Sansera derives 32% of revenue from exports to 27 countries. The order book has 62% exposure to international markets. This positions the company to benefit from China Plus One and Europe Plus One strategies. Global OEMs are seeking alternative sourcing locations. Indian suppliers with proven track records are winning new business. Sansera’s presence in Europe through its Sweden subsidiary provides a local foothold.

The company targets 35% to 40% export revenue over three to five years. North America is a particular focus, with growing RFQs from global customers.

5. Strategic Investment in MMRFIC Opens New Markets

Sansera owns approximately 30% of MMRFIC Technology, a company specializing in advanced radars and millimeter-wave sensors. This investment provides exposure to defence, aerospace, telecom (5G), and automotive (autonomous driving) applications.

MMRFIC reported Rs 200 mn revenue in FY25 with 40% EBITDA margins. These margins are expected to increase with scale. The partnership gives Sansera access to advanced technologies and a strong R&D team. MMRFIC has received orders and grants from ISRO, DRDO, and the iDEX program. This validates the technology and provides a path to larger defence contracts.

Manufacturing Footprint and Capacity

Sansera operates 17 integrated manufacturing facilities. Ten facilities cluster in Bengaluru and Bidadi. Two are in Tumkur. One each in Chakan (Pune), Mehsana, Manesar, and Pantnagar. One facility operates in Sweden. The production lines are fungible. Capacity can shift between auto and non-auto products. This flexibility allows the company to respond to changing demand across segments.

The company signed an MoU with the Government of Karnataka and invested Rs 10 bn toward acquiring 55 acres of land. Construction is planned to start in FY27.

The Pantnagar facility spreads across more than 6 acres with built-up infrastructure. It will produce domestic two-wheeler components starting Q2FY26. The location serves low-cost manufacturing needs for mass production and legacy components. For the ADS business, gross block will reach approximately Rs 3.0 bn. The target is Rs 6.0 to 6.5 bn revenue, implying asset turns of around 2x.

Sweden Operations

Sansera acquired Mape Sweden AB in 2017 and renamed it Sansera Sweden AB. This acquisition provided entry into heavy commercial vehicles in Europe. The Swedish subsidiary manufactures precision-forged and machined components including connecting rods for diesel engines. Applications span buses, trucks, boats, generators, and compressors.

A new factory in Trollhättan consolidates operations into a modern facility. The subsidiary exports to 15+ countries and serves as a platform for European customer relationships. Management expects EBITDA margins to stabilize between 10% and 12% going forward. The European market faces its own challenges, limiting long-term growth rates to 15-20%. But the subsidiary plays a crucial role in Sansera’s international strategy.

MMRFIC Investment

Sansera committed Rs 200 mn in March 2023 to acquire approximately 21% of MMRFIC Technology. An additional Rs 100 mn investment during FY25 increased ownership to approximately 30%. The company has the option to increase its stake to 51% based on a predefined valuation formula. MMRFIC specializes in research, design, and manufacturing of sub-systems for next-generation radars and millimeter-wave sensors. Applications include defence, aerospace, telecom (5G networks), and automotive (autonomous driving subsystems).

The company has qualified technologies including millimeter-wave radar with the smallest RF payload and integrated RF gating switch, FMCW-based RF radar with digital beam forming and power over ethernet capability, wide-band AESA radar with 192 elements and one of the thinnest transmit-receive module planks, radio proximity sensors in the smallest form factor, and direct digital sampling radar processor cards up to C-band with one of the lowest form factors.

Government orders and grants come from ISRO for RF solutions development, DRDO for millimeter-wave RF radar solutions and systems, iDEX-DIO with Rs 20 crore for next-generation systems for defence and space communication, and DRDO-TDF with Rs 10 crore for secure solutions development. In June 2024, MMRFIC opened a new 14,000 square foot R&D facility in Bengaluru. The facility integrates semiconductor packaging, precision PCB assembly, and product testing. The US$ 4 mn investment enhances product development capabilities.

SWOT Analysis

Strengths

1. Sansera has cultivated relationships with major automakers over 20 years or more. Bajaj, Honda, Yamaha, and Maruti Suzuki provide repeat business built on trust and proven performance.

2. The company leads in ICE component manufacturing in India. Connecting rods, rocker arms, and gear shifter forks for two-wheelers and four-wheelers are core products with strong market positions.

3. Vertical integration from design to forging to machining controls the full value chain. This improves quality, delivery reliability, and cost competitiveness versus competitors who outsource parts of the process.

Weaknesses

1. The top 5 customers account for approximately 46% of revenue. Customer concentration has declined from 59% in FY21, but dependence on a handful of OEMs remains a risk.

2. With 74% of revenue from ICE components, rapid EV adoption could erode the core business faster than diversification can replace it. The transition requires flawless execution.

3. Expansion into aerospace, EVs, and defence demands heavy upfront investment in specialized infrastructure and precision tooling. Capital intensity is high, and payback periods are long.

Opportunities

1. New orders are shifting toward non-ICE segments. About 50% of new orders come from xEV, tech-agnostic, and non-auto verticals. The order book mix is already more diversified than the revenue mix.

2. The Sweden subsidiary provides a platform for European expansion. The MMRFIC investment opens doors to advanced technology markets. Exports to 27 countries can grow as global supply chains restructure.

3. The ADS segment has a Rs 3.7 bn order book and direct supply wins from Airbus. Revenue should double in FY26. A Rs 1.2 bn investment in machining capacity will support this growth.

Threats

1. The automotive sector is inherently cyclical. Slowdowns in overseas markets from trade tensions and tariff uncertainties can impact both volumes and margins.

2. Continued shift from ICE to EVs could reduce demand for traditional components faster than expected. Policy changes favoring EVs could accelerate this transition.

3. Non-automotive businesses involve longer development cycles. Customer validation and approvals take time before mass production begins. Delays in scaling up could impact returns on investment.

Growth Triggers

1. ADS segment revenue doubling in FY26 from Rs 1.3 bn, driven by strong order book and Airbus supply wins

2. Semiconductor equipment orders scaling from US$ 17 mn initial value to US$ 30 mn over three years

3. xEV component revenue growth of 30% annually, supported by new American OEM orders and aluminium forging capacity expansion

4. Two-wheeler premiumization increasing content per vehicle as consumers shift to higher displacement motorcycles

5. Sweden subsidiary margin improvement to 10-12% EBITDA levels following customer price support and capacity expansion

6. Export revenue expansion from 32% to 35-40% of total revenue as China Plus One and Europe Plus One strategies play out

7. Pantnagar facility commissioning in Q2FY26 for domestic two-wheeler component production at lower costs

8. Karnataka greenfield construction starting FY27 on 55 acres of land acquired with Rs 10 bn investment

Key Risks

1. EV disruption risk if electrification accelerates faster than expected, reducing demand for ICE components that constitute 74% of current revenue

2. Customer concentration risk with top 5 customers at 46% of revenue, exposing the company to OEM-specific volume swings

3. Automotive cyclicality risk from slowdowns in domestic or export markets affecting volume growth across segments

4. Execution risk in new segments given longer gestation periods in aerospace, defence, and semiconductor requiring customer validation before volume production

5. Currency and geopolitical risk with 32% export exposure to markets facing tariff uncertainties and demand slowdowns

6. Raw material fluctuation risk from steel and aluminium price volatility, though pass-through arrangements with lag provide partial protection.

Subscribe now

Acutaas’s business can be categorized into two broad categories: Pharma Intermediates (85% of FY25 revenues) and Specialty Chemicals (15%). The portfolio comprises 610+ products with a customer base of about 600 customers across 55 countries.

Management aims for 25% annual sales growth and targets revenues of ~Rs 1000 crore by FY28 in its pharma CDMO division. The strongest near term growth trigger will be its pharma CDMO contract with Fermion to supply intermediates for darolutamide, a fast growing blockbuster patented drug for prostate cancer.

Subscribe now

P.S - Read this deep dive in a better format here

Business Segments

Advanced pharma intermediates accounted for 85% of company’s overall revenues in FY25. The company develops, manufactures and commercialises intermediates used for manufacturing API and NCE in India and overseas markets in therapeutic areas such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer. Since inception, it has created over 550 pharmaceutical intermediates in 17 different therapeutic areas, which are supplied to over 160 customers.

Acutaas has positioned itself as a supplier capable of handling multiple chemistries such as nitration, diazotization, oxidation, esterification, ammoxidation, and is highly backward integrated for most of its intermediates. As a result company has gained dominant market share in many of its products.

As of FY24 the pharma intermediate business consists of 10% from CDMO, 40% from innovator and 50% from generic pharma intermediates. About 95% of the portfolio targets fast growing chronic therapy (anticancer, antiviral, CNS and cardiovascular segments). Company is usually first to market with different routes of synthesis and capabilities to supply intermediates from n-1 to n-12 stages. Once an intermediate supplier becomes a registered source in customer’s DMF, there is an entry barrier against new entrants. This becomes a source of moat and leads to limited competition and high market share in chosen molecules.

Acutaas has built strong relationships with customers like Fermion for which it started supplying intermediates since 2010. Company holds 15 process patents and has adopted newer technologies such as flow chemistry and distributed control systems to make production processes more efficient.

Key Growth Drivers in Non-CDMO Business

Apixaban: Apixaban (innovator brand name Eliquis) is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with non-valvular atrial fibrillation. The global market size of the drug is close to US$20 billion, although this will decrease after its patent expires in 2026. There are more than 70 manufacturers of the API. Acutaas has a sizeable market share for two intermediates used to produce the API: 1(4-aminophenyl)-3-morpholin-4-yl-5,6-dihydropyridine-2(1H)-one and ethylchloro acetate. Acutaas has already established a pipeline of 25-30 customers for the post-patent era.

Lumateperone tosylate: Lumateperone (innovator brand name Caplyta) is a medication used to manage and treat schizophrenia and other neuropsychiatric disorders. Its patent expiry is 2029. Acutaas holds a process patent for one of its intermediates: benzyl,3-methyl-2-oxo-2,3,9,10-tetrahydro-1H-pyrido[3’,4’:4,5]pyrrolo[1,2,3-de]-quinoxaline-8(7H)-carboxylate.

Rivaroxaban: Rivaroxaban (innovator brand name Xarelto) is an anticoagulant medication used to treat and prevent blood clots. The drug was initially developed by Bayer and marketed by Johnson & Johnson. Its patents are expiring by 2026, and Acutaas will supply four intermediates to generics suppliers.

Trazodone: Trazodone is the largest API in terms of revenues for the company and has been contributing Rs 100 crore+ of revenues for the past 2-3 years. Acutaas offers three intermediates used to make this API and claims to hold a dominant market share (80-90% in FY21) in these.

CDMO Business: Key Growth Driver

In its CDMO business Acutaas undertakes contract manufacturing for pharma companies under long term supply contracts. Company has commenced a 10 year contract with Fermion Oy of Finland to supply intermediates for darolutamide (brand name Nubeqa which has become a blockbuster for Bayer). This contract will be a major growth driver in coming years. Acutaas is currently supplying 5 intermediates for the molecule darolutamide. Bayer is selling Nubeqa as the end product. Acutaas is also working on several new CDMO contracts with other pharma innovators with multiple projects in pipeline to be commercialized by FY26.

Prostate Cancer Treatment Market

Prostate cancer is a condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (androgens) and ultimately blocks the action of androgen.

Antiandrogen drugs are medications that block androgens from binding with the androgen receptors that exist in prostate cancer cells. In its early stages, prostate cancer cells rely on androgens to feed their growth. By blocking the coupling of androgens with cancer cells, antiandrogens starve the cancer cells of the androgens they need to grow.

First-generation ARIs, like Bicalutamide, are the original, weaker drugs that partially block the androgen receptor. Second-generation ARIs (Nubeqa, Xtandi) are the modern standard, providing a much more potent and complete blockade of the receptor. Across the prostate cancer space, older androgen receptor inhibitors command the highest share. With newer ARi assets Erleada and Nubeqa, despite being third to market, Nubeqa now leads Erleada in every setting. This suggests physician preference for Nubeqa which could be due to the benign safety profile of the drug with similar or better efficacy.

About Darolutamide

Darolutamide (marketed by Bayer under the brand name Nubeqa) is a drug to combat prostate cancer. It was initially approved in 2019 to treat non-metastatic castration-resistant prostate cancer (nmCRPC), but subsequently in August 2022 also approved by the USFDA in fighting metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

Darolutamide was developed jointly by Bayer and Orion Pharma. Fermion (a fully-owned subsidiary of Orion) manufactures the darolutamide API, while Orion manufactures the formulations and Bayer holds the marketing and distribution rights.

Fermion manufactures the darolutamide API, upon which Orion manufactures the formulations and sells to Bayer at COGS; in exchange, Fermion/Orion receive a combination of royalties and milestone payments. The average annual royalty rate is currently above 20% including product sales to Bayer. As global sales increase, annual royalty rates will increase. If annual sales for darolutamide hits EUR 3 billion, Orion’s royalty rate will increase above 25%.

Efficacy of Darolutamide Versus Peer Drugs

Studies have shown that darolutamide offers certain advantages over other prostate cancer treatments, particularly in terms of efficacy and safety.

Minimal Blood-Brain Barrier Penetration: Its low penetration of the blood-brain barrier reduces central nervous system-related adverse events such as seizures, fatigue, dizziness, and mental impairment, making it better tolerated compared to other androgen receptor inhibitors.

Efficacy in Prolonging Metastasis-Free Survival: Clinical trials such as ARAMIS demonstrated that darolutamide significantly prolongs metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer, with a median metastasis-free survival of 40.4 months compared to 18.4 months with placebo.

Overall Survival Benefit: Darolutamide significantly reduces the risk of death by approximately 31% compared to placebo.

Favorable Safety Profile: Darolutamide is associated with a low incidence of adverse events, with rates similar to placebo for many side effects including fatigue, falls, fractures, seizures, cognitive disorders, and hypertension.

Better Tolerability: Indirect comparisons suggest darolutamide has a more favorable tolerability profile than apalutamide and enzalutamide, with fewer treatment-emergent adverse events like falls, fractures, rash, fatigue, and mental impairment.

Upcoming Clinical Trials

Orion is conducting two significant clinical trials for darolutamide:

ARASTEP (phase III, PSMA-positive biochemical recurrence): Evaluates darolutamide + ADT in men whose PSA is rising after local therapy but before overt metastasis. Success could shift Nubeqa into the early-recurrence setting and extend therapy duration per patient.

DASL-HiCaP (phase III, adjuvant high-risk localized PCa): Tests darolutamide as part of adjuvant ADT after surgery or radiotherapy in very-high-risk local disease. A positive read-out would move the drug even earlier in the treatment cascade, opening an entirely new adjuvant market.

Specialty Chemicals

Acutaas began to strategically diversify beyond advanced pharma intermediates in 2021, when it acquired two manufacturing sites (Ankleshwar and Jhagadia) from Gujarat Organics. In 2023, company acquired a 51% stake in Baba Fine Chemicals entering the niche of high-purity semiconductor chemicals. Company also has forayed into electrolyte additives where it will initially start with manufacturing Vinylene Carbonate and Fluoroethylene Carbonate.

Electrolyte Additives Business

Acutaas has forayed into battery chemicals by setting up production capacities for electrolyte additives under a wholly owned subsidiary named Ami Organics Electronics Private Limited. Company will have 2000 KTPA capacity each for Vinylene Carbonate and Fluoroethylene Carbonate and expects commissioning of plant by end of H1 FY26 and supplies starting from H2 of FY26. Acutaas has obtained an order from an OEM of a battery cell manufacturer which will take half of the capacity. These additives are used in small doses within Li-ion battery electrolyte formulations to improve cell life, safety, and performance.

Acutaas will be the first global manufacturer outside China to develop electrolyte additives for lithium-ion batteries. Initial capacity is 2,000 MT each and a pipeline of 9+ additives is under development. Company has also signed an MOU with the Gujarat Government for about Rs 300 crore investment to set up an electrolytes facility.

Gujarat Organics Business

Acutaas acquired 2 sites at Ankleshwar and Jhagadia from Gujarat Organics in 2021. Under this business Acutaas manufactures and supplies specialty chemicals and preservatives including paraben and paraben formulations, methyl salicylate and range of other specialty chemicals used in personal care, pharmaceuticals and agrochemical industries. However, this line of business is largely commoditized with modest margins. Rationale for this acquisition per management was to bag the manufacturing sites. Company does not have any major capex plans in this business and the unutilized land has been converted into a pharma CDMO unit.

Semiconductor Chemicals via Baba Fine Chemicals

This segment includes high-purity semiconductor chemicals via the Baba Fine Chemicals unit. Acutaas is the only manufacturer in India producing photoresist chemicals domestically. These chemicals are used in semiconductor fabrication in materials for photolithography such as photoresists, anti-reflective coatings, and photo acid generators, as well as precious-metal-based conductive inks (silver, copper, gold, platinum inks) for chip and PCB manufacturing.

Company acquired a majority stake in Baba Fine Chemicals in 2023. BFC was founded by three scientists in 2002. Before the acquisition by Acutaas, BFC was focused only on 1 single customer - Heraeus Epurio, a German company with operations worldwide. Volumes supplied had been very small and so business was very small at time of acquisition with revenues at Rs 40 crore in FY23 with EBITDA margins of 65-70%. Post acquisition, BFC revenues declined in FY24 and FY25 due to supply disruptions with demand weakness in semiconductor industry. Acutaas is actively in discussions with prominent semiconductor materials buyers in Korea and Japan and expects new orders to materialize by FY26 from these engagements, alongside a potential rebound from the original customer as the chip cycle improves.

India’s push to establish a domestic semiconductor ecosystem (new ATMP/OSAT facilities by Micron, government incentives for chip fabs) could create local demand for photoresist and ancillary chemicals in the coming years. Management guides that the semiconductor chemicals business could scale 2-3x its current sales over the next 2-3 years. It is a higher margin business, so margins for the company will expand as this line of business expands.

Manufacturing Facilities

Acutaas operates four manufacturing units in India, each supporting different segments of its business.

Unit I - Sachin (Surat, Gujarat): The flagship plant for advanced pharmaceutical intermediates. This facility has an installed reactor capacity of ~144 KL (with 13 production lines and 40 reactors) and is fully cGMP-compliant. Unit I also houses the main R&D center for the company, and it currently operates at around 70-80% capacity utilization.

Unit II - Ankleshwar (Gujarat): Inaugurated in December 2023. The company had acquired an older Ankleshwar facility in 2021 as part of the Gujarat Organics acquisition, but that aging unit was demolished and replaced with this state-of-the-art brownfield plant. The new Ankleshwar unit is spread over ~10,375 sq m and is equipped with ~90 reactors (~436-442 KL total capacity) along with modern automation (DCS and powder transfer systems). It is designed to cater pharma intermediates and CDMO contracts.

Unit III - Jhagadia (Gujarat): Focused on specialty chemicals production. This facility (acquired from Gujarat Organics in 2021) is much larger in land area (~56,998 sq m) with an installed capacity of about 512 KL. It manufactures products like preservatives and personal care specialty chemicals such as parabens, methyl salicylate and other specialty chemicals. This unit currently runs at roughly 60% utilization and a new electrolyte additives plant is under construction here as a brownfield expansion. Company has ample land here for further brownfield expansion.

Unit IV - Greater Noida (Uttar Pradesh): A small-scale facility operated via Acutaas’s subsidiary Baba Fine Chemicals (BFC) with installed capacity of ~1.8 KL of glass-lined reactor capacity geared towards semiconductor chemicals.

Key Growth Triggers

CDMO Ramp-up

Management targets Rs 1000 crore revenues from CDMO by FY28 as it ramps up production of intermediates for darolutamide. Company has a strong pipeline of molecules with many molecules in verification phase, which can be optionality.

Patent Expiry Wins

Several core pharmaceutical intermediates are expected to see volume uptick as major drug patents expire in 2025-2026, driving higher demand from generic manufacturers.

Ramp up of Specialty Chemicals

Semiconductor chemicals which are currently going through a down cycle - as demand comes back along with the company’s initiatives to expand customer base to Taiwan, Korea, Japan, can bring new orders as customer qualifications conclude. Battery electrolyte additives are a new growth driver. A dedicated plant (Jhagadia) will be operational by H2 FY26 to start contributing to revenues. Company is positioned as a non-China supplier for electrolyte additives. As specialty chemicals segment scales up, margins will expand owing to better mix.

Capacity and Efficiency

Major capacity expansion at Ankleshwar (4x reactor increase) completed, ensuring ample headroom for growth. A new pilot plant is being set up to accelerate scale-up of high-potency chemicals and CRAMS projects, enabling faster commercialization of new products. In-house solar power (10.8 MW commissioned) will reduce operating costs and support margin improvement as volumes grow.

Key Risks

Semiconductor Demand Slump

Prolonged weakness in legacy semiconductor markets could delay the recovery and scale-up of Acutaas’s photoresist chemicals business (Baba Fine Chemicals), keeping the specialty segment growth muted.

Regulatory Compliance

As a chemicals supplier to regulated pharma markets, any lapse in GMP quality standards or environmental/pollution norms could lead to production halts or export restrictions. The business environment is highly regulated, and non-compliance can severely disrupt operations.

Tariffs if Levied by the US on Pharma Imports

The US government has launched an investigation into pharma imports, which will likely culminate in tariffs within the next 6-12 months. This could impact demand for some of Acutaas’s customers, particularly those supplying generics to the US. It could also impact margins, as it may not be possible to fully pass on heavy tariffs to end-consumers.

Inability to Secure Customer Approvals for New Products

Regulatory approval processes can be lengthy and uncertain, potentially delaying revenue recognition from new product launches.

Seasonality and Lumpiness in Business

CDMO businesses are generally lumpy and cyclical in nature. For Acutaas H1 accounts for 40% of the topline and H2 with 60%. The nature of business is such where nothing happens for decades while months where decades happens. Company has been supplying intermediates to Fermion since 2010. Building relationships is a moat in this business. However if company fails to win new orders, sales might get impacted.

Nubeqa’s Growth Slowing Down

Any deceleration in Nubeqa’s market penetration or competitive pressure from other ARIs could impact Acutaas’s key CDMO revenues from darolutamide intermediates.

Subscribe now

Shaily Engineering Plastics is a precision plastic engineering company founded in 1987 by Mahendra (Mike) Sanghvi. The company started with two injection moulding machines in Halol, Gujarat. Today it operates seven manufacturing facilities in Gujarat with over 200 injection moulding machines and more than 2,000 employees.

Sanghvi studied chemical engineering at Wayne State University and completed an MBA from Toronto University. He worked in the North American plastics industry through the 1970s before returning to India. This background shaped Shaily’s focus on precision manufacturing and global customer standards.

The company specializes in high and ultra-high performance polymers including PA6/66/12, PES, PPS, PBT, LCP, PC, and PEEK. Shaily is the only company licensed to process Torlon in India. These materials serve demanding applications where regular plastics fail.

Exports account for 77% of revenue. Shaily serves customers across 35 countries. The business operates through three segments: Consumer (71% of FY25 revenue), Healthcare (21%), and Industrial (8%).

P.S - Read this deep dive in a better format here

Segments Deep Dive

Consumer Segment

The consumer segment generated Rs 5,608 million in FY25. It covers home furnishings, FMCG packaging, LED lights, carbon steel furniture, and toys.

Key customers include IKEA, Gillette, P&G, Hindustan Unilever, Corvi, Lidl, and Lowes. The IKEA relationship demonstrates Shaily’s manufacturing capabilities. IKEA follows its IWAY standard, a comprehensive assessment framework with on-site audits. Shaily has maintained compliance with these standards while scaling operations.

Beyond injection moulding, Shaily built secondary capabilities: ultrasonic welding, vacuum metalising, high-speed rotary pad printing, polymer painting, screen painting, hot stamping, and hot filing. These capabilities transform it from a component supplier to a solutions provider. A customer buying plastic components can also get finishing, assembly, and packaging from the same facility.

The consumer segment faces tariff-related challenges. Global clients compete India against other emerging economies that currently have more favorable duty rates. Any India-US trade deal with reduced tariffs would benefit this segment.

Healthcare Segment

The healthcare segment generated Rs 1,647 million in FY25 and represents Shaily’s primary growth opportunity. Products include platform devices, drug delivery devices, and pharma packaging.

Shaily entered pharma in 2007 when Wockhardt launched a reusable pen for insulin delivery. The company partnered with IDC UK to develop a pen and gained Sanofi as a customer after success with Wockhardt. This base expanded to include Dr. Reddy’s, Sun Pharma, Aurobindo Pharma, Alembic, Zydus, Alvogen, Cadila, Aspen, and others.

The segment holds key certifications. ISO 13485 covers quality management for medical device design and manufacturing. ISO 15378 addresses quality for primary packaging of medicinal products. MDSAP certification allows evaluation against quality requirements of Australia, Brazil, Canada, Japan, and the US through a single audit. The company also complies with FDA 21 CFR 820 Quality System Regulation and cGMP standards required for US market access.

In FY24, Shaily sold 11-12 million pens, primarily for insulin. The company has developed a platform of pens for GLP-1 drug delivery, which drives the growth outlook.

Industrial Segment

The industrial segment generated Rs 614 million in FY25. Products include automotive components, appliance casings, and high-performance engineering components.

Key customers are GE Appliances, Garrett Advancing Motion, MABE, Phoenix Mechano, Amvian, and Schaeffler. The segment carries IATF 16949 certification, a mandatory requirement for automotive industry suppliers.

The core strategy is metal-to-plastic conversion. High-performance polymers can replace metal components with lower weight and cost while maintaining strength and heat resistance. This positions Shaily for automotive lightweighting trends.

The GLP-1 Opportunity

GLP-1 drugs treat diabetes and enable weight loss. The drug class gained momentum after Novo Nordisk’s semaglutide showed 15-20% body weight loss in clinical trials. FDA approved Wegovy (semaglutide) for weight loss in 2021. Eli Lilly’s tirzepatide followed with even stronger efficacy.

In 2024, semaglutide generated US$54 billion in sales from 56 million doses. Tirzepatide generated US$32 billion from 32 million doses. These two molecules drive GLP-1 penetration in the US.

The semaglutide patent expires in 2026 in India, Canada, Brazil, China, and Turkey. These countries account for about 33% of the world’s obese population. Generic manufacturers are preparing to launch at patent expiry.

Shaily developed pen platforms for GLP-1 delivery:

Shaily Toby Auto-Injector: A two-step auto-injector for semaglutide delivery.

Shaily Tristan Auto-Injector: A three-step auto-injector with automatic needle insertion for dulaglutide and tirzepatide.

ShailyPen Neo: A spring-driven pen injector in variable and fixed dose formats for GLP-1.

ShailyPen Axiom: Handles multiple therapies including human growth hormone, follicle stimulating hormone, parathyroid hormone, and GLP-1.

ShailyPen Protean: A versatile 0-60 IU insulin pen adaptable for alternate therapies including triple-dose and single-dose peptide delivery.

ShailyPen Maxim: A 0-80 IU insulin pen for single-dose administration.

Management indicates Shaily has tied up with 23-24 global pharma companies for generic GLP-1 launch. This represents 50-60% of companies that have filed in Canada for generic semaglutide approval.

Patent Expiry Timeline

Generic Filings by Market

Canada: Eight companies have filed for approval as of the latest data. Two more (Biocon and Emcure) plan to file by end of FY26. Dr. Reddy’s was among the early filers and received a non-compliance notice seeking additional information, which may delay its launch.

India: At least eight domestic pharmaceutical manufacturers are conducting trials or preparing first-wave launches. These include Dr. Reddy’s, Biocon, Sun Pharma, Emcure, Alkem, Torrent, Cipla, and Natco. Eli Lilly launched Mounjaro (tirzepatide) in India in March 2025. Novo Nordisk launched Wegovy in June 2025.

Brazil: At least four companies plan generic launches. Three are Indian (Dr. Reddy’s, Biocon via tie-up with Biomm S.A., Torrent) and one is local (Hypera).

Addressable Market

The three key markets for Shaily represent substantial opportunity by 2030:

The calculations assume GLP-1 penetration reaches 25% in Canada and 15% in India and Brazil by 2030. Lower penetration in India and Brazil reflects affordability constraints and urban population concentration.

Injectable vs Oral

One debate is whether oral GLP-1 will reduce demand for injectables. The injectable form shows better efficacy. Semaglutide enters the bloodstream directly when injected, producing higher and more consistent drug levels. Only about 1% of oral semaglutide reaches the bloodstream due to stomach absorption limitations.

At the 14mg approved dose, oral semaglutide produces modest weight loss of about 5 pounds versus 15% body weight loss with injectable Wegovy at 2.4mg. A 50mg oral dose under regulatory review achieved 15.1% weight loss matching the injectable, but this requires higher drug quantities per dose.

Survey data shows 59% of GLP-1 users take injectable semaglutide (45% Ozempic, 14% Wegovy). Only 2% use Rybelsus, the oral version. Users show minimal hesitation about injections. 87% prefer single-use or multi-use pens versus vials and syringes.

Single-Use vs Multi-Use Pens

Both semaglutide drugs (Ozempic, Wegovy) and both tirzepatide drugs (Mounjaro, Zepbound) use single-use pens. Zepbound offers a vial and syringe option, but convenience favors single-use pens. Multi-use pens cost less but require complex dose management.

Competitive Landscape

Shaily competes with few global firms in healthcare devices:

Ypsomed AG (Switzerland): The leading developer and manufacturer of injection systems for self-administered medication. Revenue of US$630 million from delivery systems in FY25. Capacity around 350 million units annually with a target of 1 billion by 2031. Supplies Novo Nordisk for GLP-1. Opening a North America facility in 2027.

Becton Dickinson (US): Global medical technology company with US$4.4 billion medical segment revenue in CY24. Manufactures devices, instrument systems, and reagents.

Gerresheimer (Germany): Primary packaging and drug delivery devices with US$1.3 billion revenue from plastics and devices in CY24. Manufacturing in Europe, Americas, and Asia.

SHL Medical (Switzerland): Private company with indicated revenue around US$2.1 billion. Designs and manufactures autoinjectors, pen injectors, and specialty delivery systems for large-volume and high-viscosity formulations.

Ypsomed and Becton Dickinson work with innovators (Novo Nordisk, Eli Lilly), leaving limited capacity for generic manufacturers. Shaily positions as the primary option for generics in markets going off-patent in 2026.

Barriers to Entry

Three factors limit competition in GLP-1 pen manufacturing:

High switching costs: Drug filings mention the pen vendor. Pharma companies cannot switch vendors without refiling with regulatory authorities. Once a generic manufacturer commits to Shaily for a filing, that relationship locks in.

Limited capacity: Few companies globally manufacture GLP-1 pens. Long gestation periods for regulatory approvals apply to pen manufacturers too. Building capability to manufacture without infringing patents requires substantial investment and time.

India’s generic manufacturing base: Many domestic generic manufacturers launching semaglutide globally are Indian companies. Shaily has existing relationships with these customers from insulin pen supply.

Certifications as Moat

Shaily’s certifications create barriers competitors must clear:

ISO 13485: Quality management for medical device design and manufacture. Mandatory for manufacturers and suppliers selling internationally.

ISO 15378: Quality management for primary packaging of medicinal products. Required for materials in direct contact with medication.

MDSAP: Single audit program accepted by Australia, Brazil, Canada, Japan, and US. Involves documentation review, on-site audits, and annual compliance checks.

FDA 21 CFR 820: Comprehensive US regulations for medical device manufacturers. FDA inspects facilities for compliance. Mandatory for US market access.

IATF 16949: Automotive quality management standard. Prerequisite for business with major automotive manufacturers.

Beyond certifications, long-term relationships with demanding customers validate capabilities. IKEA’s supplier standards involve comprehensive assessments across 10 principles for responsible procurement. Consistent compliance while scaling shows operational discipline.

Company Evolution

1987-1994: Setup initial facility at Halol. Won first contract for precision gear components for a Japanese watch manufacturer. Built reputation for precision manufacturing to global standards.

1994-2007: Became the only licensed Torlon processor in India. Specialized in high-performance polymers. Built post-molding capabilities moving from component supplier to solutions provider. Onboarded IKEA, Gillette, P&G, GE Appliances, and Schaeffler.

2007-2015: Pivot to pharmaceutical through Wockhardt insulin pen. Partnered with IDC UK for pen development. Added Sanofi as customer. Built capacity for pharmaceutical bottles with necessary certifications.

2015-2021: Greater focus on pen device manufacturing. Executed projects including Vicks container redesign for leak-proof performance in extreme conditions, tamper-evident cap for Pepsi Aquafina, and low-voltage switchgears for ABB. Opened sheet metal furniture facility in 2019.

2021-Present: Aligned focus on GLP-1 pen development. Expanded offerings to gain wallet share from existing customers. Tied up with 23-24 pharma companies for generic GLP-1 launch.

Future Optionalities

Semiconductor and Consumer Electronics

Management has highlighted exploration of semiconductor and consumer electronics opportunities. Details remain unclear, but Shaily’s polymer expertise maps to potential applications:

India’s semiconductor capex is underway with fab announcements from Tata, Micron, and others. Shaily’s existing capabilities in precision plastic components position it for this value chain if customer relationships develop.

Expanding Therapy Coverage

Beyond insulin and GLP-1, Shaily manufactures devices for parathyroid hormone treatment and migraine medications. The pen platform can adapt to multiple therapies as global peers demonstrate. Ypsomed covers diabetes, fertility, growth disorders, obesity, osteoporosis, Parkinson’s, multiple sclerosis, oncology, and more.

Growth Triggers

Generic GLP-1 launch in 2026: Patent expiry in Canada (January 2026) and India/Brazil (March 2026) triggers generic launches. With 23-24 pharma customers committed, Shaily captures first-wave volume.

Market expansion as generics reduce cost: Current semaglutide costs limit adoption. Generic launches at a fraction of innovator pricing expand the addressable market significantly. Survey data shows 30% of past GLP-1 users stopped due to expense. Lower prices convert these users back.

Capacity utilization improvement: Consumer and industrial segments have unutilized capacity. New customer wins improve absorption. Q2 FY26 saw five new projects signed with three home furnishing customers.

Tariff normalization: Any India-US trade deal reducing tariffs versus competing manufacturing countries benefits the consumer segment. India currently faces unfavorable rates compared to some emerging economies.

Therapy expansion: Success in GLP-1 opens doors to other injectable therapies where pen delivery applies. Platform approach allows adaptation without starting from scratch.

Risks

Competition in GLP-1 pens: Additional global capacity could emerge. Ypsomed plans 1 billion pens by 2031. New entrants could pressure pricing and share.

Slower generic semaglutide adoption: If efficacy concerns, side effects, or regulatory delays slow uptake, volume projections miss. Oral alternatives gaining ground could reduce injectable demand.

Launch delays: Regulatory processes can extend beyond expected timelines. Dr. Reddy’s non-compliance notice in Canada illustrates this risk. Delays push volume ramp into future periods.

Customer concentration: With 50-60% share of Canada filings, outcomes depend on those customers executing successfully. A major customer facing issues would impact Shaily.

Forex exposure: 77% of revenue comes from exports. Currency movements affect realized value.

Consumer segment recovery uncertain: Tariff relief depends on trade deal negotiations outside company control. Without favorable policy changes, the segment faces continued headwinds.

Subscribe now